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Mucosal drug delivery is often limited by the presence of several barriers including mucus, 
the harsh pH and enzymatic activity on the mucosal surfaces. Nanoparticles have shown 
some potential to overcome these barriers. The aim of this thesis was to investigative how 
functionalisation of nanoparticles with non-ionic hydrophilic polymers (polyethylene glycol 
(PEG), polyhydroxyethyl acrylate (PHEA), poly-2-ethyl-2-oxazoline (POZ) and polyvinyl 
pyrrolidone (PVP)) affects their physicochemical and mucoadhesive properties, diffusion in 
mucin solution as well as ability to penetrate into mucosal tissues. Silica and chitosan 
nanoparticles were chosen. Thiolated silica nanoparticles were functionalised with PEG and 
POZ and therefore three types of silica nanoparticles were obtained; thiolated, PEGylated 
and POZylated. After the synthesis, the effect of the pH on the size of the silica nanoparticles 
was studied. No significant change in the size of PEGylated silica nanoparticles over the pH 
range of 1.5–9 was observed. A significant increase in the size of thiolated and POZylated 
silica nanoparticles at pH  ≤ 2 was observed. Fluorescently labelled thiolated, PEGylated and 
POZylated silica nanoparticles were incubated with freshly excised rat intestinal mucosae. 
Then, the mucosae with the nanoparticles were washed with phosphate buffer solution for 
several cycles and their fluorescent images were taken. It was found that PEGylated and 
POZylated silica nanoparticles were less mucoadhesive compared to the thiolated 
counterpart. This was evident by the lower fluorescence signal of the PEGylated and 
POZylated silica nanoparticles compared to the thiolated counterpart.  
Four chitosan derivatives (PEG-, PHEA-, POZ- and PVP-chitosan) were synthesised, which 
showed complete solubility over a broad pH range (3-9). Unmodified and modified chitosan 
nanoparticles were prepared using ionic gelation with sodium tripolyphosphate. Modified 
chitosan nanoparticles diffused faster in bovine submaxillary mucin solution measured by 
nanoparticle tracking analysis. The penetration of chitosan nanoparticles was evaluated 
using fluorescence microscopy and demonstrated that modified chitosan nanoparticles 
penetrated deeper into sheep nasal mucosa compared to unmodified chitosan nanoparticles. 
The possibilities of incorporating psychoactive drugs (haloperidol and phenobarbital) into 
unmodified and PVP-chitosan nanoparticles were investigated. Haloperidol-unmodified 
chitosan nanoparticles showed a relatively low loading capacity. However, phenobarbital-
unmodified and PVP-chitosan nanoparticles showed a high loading capacity and provided a 
sustained drug release. 
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These findings illustrate how the functionalisation of nanoparticles affect their 
physicochemical properties, which in turn determine their mucoadhesive properties and 
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Mucoadhesive drug delivery systems are desirable as they can increase the residence time 
of drugs at the site of absorption/action, provide sustained drug release and minimize the 
degradation of drugs in various body sites. Chitosan is a cationic polysaccharide that exhibits 
mucoadhesive properties and it has been widely used in the design of mucoadhesive dosage 
forms. However, its limited mucoadhesive strength and limited water-solubility at neutral 
and basic pH are considered as two major drawbacks of its use. Chemical modification of 
chitosan has been exploited to tackle these two issues. In this review, we highlight the up-
to-date studies involving the synthetic approaches and description of mucoadhesive 
properties of chitosan and chitosan derivatives. These derivatives include trimethyl chitosan, 
carboxymethyl chitosan, thiolated chitosan, chitosan-enzyme inhibitors, chitosan-
ethylenediaminetetraacetic acid (chitosan-EDTA), half-acetylated chitosan, acrylated 
chitosan, glycol chitosan, chitosan-catechol, methyl pyrrolidinone-chitosan, cyclodextrin-
chitosan and oleoyl-quaternised chitosan. We have particularly focused on the effect of 
chemical derivatization on the mucoadhesive properties of chitosan. Additionally, other 
important properties including water-solubility, stability, controlled release, permeation 








Mucus is a viscoelastic gel lining the mucosal tissues exposed to the external environment 
including gastrointestinal, respiratory, and reproductive tracts and the eyes (Lai et al., 2009a; 
Khutoryanskiy, 2011). It is mainly composed of water (~ 90-98% w/w), mucins (0.2-5% 
w/v), salts (~ 0.5-1.0% w/w), proteins (~ 0.5% w/v), cells and cellular debris, DNA, bacteria 
and lipids (Peppas & Huang, 2004; Bansil & Turner, 2006; Lai et al., 2009a; Lai et al., 
2009b; Khutoryanskiy, 2011; Boegh & Nielsen, 2015; Leal et al., 2017). Mucins are the 
main component of the mucus, which are glycoproteins responsible for its gel-like 
characteristics. These glycoproteins are made of protein core to which carbohydrate side 
chains are covalently attached via O-glycosidic linkages (Peppas & Buri, 1985; Serra et al., 
2009). 
Conventional (non-mucoadhesive) formulations lack the ability to withstand the strong 
involuntary muscular movement as well as the extensive washing effect by certain body 
fluids available, e.g., in the gastrointestinal lumen, ocular surface, urinary bladder and other 
mucosal surfaces. This limitation leads to the loss of a substantial amount of the administered 
drugs at the site of application/absorption. This may not only result in the overall increased 
cost of the treatment courses; it can also lead to the failure of therapy as effective drug 
concentration cannot be reached. This is especially more important in case of drugs such as 
antibiotics as amount lower than minimum inhibitory concentration probably leads to 
intractable complications including bacterial resistance. Mucoadhesive drug delivery 
systems are advantageous as they can adhere to the mucus layer of the mucous membrane. 
The adhesion of the delivery systems to mucosa (defined as mucoadhesion) increases the 
residence time of drugs, increases the concentration gradient, and protects the vulnerable 
small molecular weight drugs as well as peptide-based drugs. The overall effects could lead 
to controlled drug release, prolongation of therapeutic effects, enhancement in the 
bioavailability, cost-effective treatment, and improved patient compliance (Serra et al., 
2009; Gullberg et al., 2011; Khutoryanskiy, 2011; Lee et al., 2013; Date et al., 2016). 
However, transmucosal drug delivery systems often have poor residence on mucosal 
surfaces, which justifies the need for novel mucoadhesive materials.  
Various polymers have been used in the formulation of mucoadhesive delivery systems. 
Among them, chitosan and its derivatives are listed at the top (Bernkop-Schnürch et al., 
1997; Bernkop-Schnürch et al., 2004b; Peppas & Huang, 2004; Sogias et al., 2008; 





acetyl-D-glucosamine and D-glucosamine and its units linked by 1-4-β-glycosidic bonds 
(Figure 1.1). It can be prepared by deacetylation of chitin in basic media (Hejazi & Amiji, 
2003; Sogias et al., 2010). Chitin is the second most abundant polysaccharide in nature, 
while cellulose is the most abundant (Hejazi & Amiji, 2003). Crustaceans produce chitin in 
their shells and plants produce cellulose in their cell walls. Therefore, these two 
polysaccharides impart structural integrity and protection to animals and plants (Pillai et al., 
2009). 
 
Figure 1.1 Chemical structure of chitosan. 
 
Chitosan has –OH and –NH2 groups leading to the capability of forming hydrogen and 
covalent bonding. This characteristic results in the possibilities of various chitosan chemical 
derivatization. These functional groups also play an essential role in the solubility character 
of chitosan macromolecules. At low pH, the amino groups undergo protonation, which 
makes chitosan macromolecules positively charged. This cationic nature provides strong 
electrostatic interaction with negatively charged components of mucus including sialic acid 
as well as epithelial surfaces (Smart et al., 1984; Peppas & Buri, 1985; Robinson et al., 1987; 
Robinson & Mlynek, 1995; Sogias et al., 2008; Khutoryanskiy, 2011; Casettari et al., 2012). 
Hydrogen bonding and hydrophobic interaction also play important role in the 
mucoadhesion of chitosan (Sogias et al., 2008). 
The derivatization of chitosan to improve its mucoadhesive properties has been considered 
in several publications (Figure 1.2). Some chitosan and its derivatives have shown potential 
in preclinical and clinical investigations for applications in transmucosal drug delivery (e.g., 
ChiSys® as a platform for nasal vaccination (Watts et al., 2014) and Lacrimera® eye drops 
(Bonengel & Bernkop-Schnürch, 2014)). However, there is still lack of review articles 
analyzing recent studies on the mucoadhesive applications of chitosan derivatives. In this 





materials. This review, however, does not consider any physical mixtures of chitosan or salt 
forms, which are discussed in several previous publications (Ganguly & Dash, 2004; 
Bonferoni et al., 2009). 
 
Figure 1.2 Number of publications related to mucoadhesive properties of chitosan and 
chitosan derivatives, source: SciFinder, keywords: chitosan or chitosan derivatives 
and mucoadhesion, retrieved on 24 November 2017. 
 
1.2 Chitosan as a mucoadhesive material 
Chitosan has been widely used in various biomedical and drug delivery areas because of its 
low toxicity, biocompatibility, antimicrobial activity, mucoadhesive properties and 
permeation enhancing effects (Illum et al., 1994; Illum et al., 2001; Hejazi & Amiji, 2003; 
Rabea et al., 2003; Agnihotri et al., 2004; Peppas & Huang, 2004; Issa et al., 2005; Sogias 
et al., 2008). It has been extensively studied as a potential excipient for the oral delivery of 
peptides (Bernkop-Schnürch et al., 2000). Alonso and co-workers found that chitosan 
nanocapsules enhanced and prolonged intestinal absorption of salmon calcitonin because of 
their mucoadhesive properties and strong interactions with the intestinal barrier (Prego et al., 
2006). 
Our group has demonstrated the mucoadhesive character of chitosan in several studies. We 
have used a range of techniques including mucin-particle interaction (Sogias et al., 2008), 
tensile strength (Sogias et al., 2012) and most recently flow-through technique coupled with 







































































































































fluorescein isothiocyanate-chitosan (FITC-chitosan) was used as a positive control and 
compared to other materials as well as FITC-dextran (non-mucoadhesive or negative 
control). Fluorescent samples were deposited onto ex vivo mucosal tissues (e.g., porcine 
urinary bladder or bovine eyes) and washed with bio-relevant fluids. Fluorescence images 
were taken after several wash cycles and the fluorescence intensity was used to compare the 
retention of each material on the mucosal tissues. We observed excellent mucoadhesive 
properties of chitosan in all cases, although some differences in the extent of its 
mucoadhesive potential in different mucosal tissues were noticed (Mun et al., 2016; 
Tonglairoum et al., 2016; Kaldybekov et al., 2018). Figure 1.3 shows the result of 
mucoadhesion study of different silica nanoparticles in porcine urinary bladder ex vivo. The 
fluorescence signal of chitosan after washing was more intense compared to other materials 
and this indicated its excellent mucoadhesive properties. The rank of retention of materials 
was as follows: FITC-chitosan > thiolated silica nanoparticles > PEGylated (polyethylene 
glycol, 750 Da) silica nanoparticles > PEGylated (5000 Da) silica nanoparticles > FITC-
dextran (Mun et al., 2016). 
 
Figure 1.3 Representative microscopic fluorescence images of ex vivo porcine urinary 
bladder mucosa incubated with FITC-chitosan, thiolated silica, PEGylated silica 
(750 Da), PEGylated silica (5000 Da) and FITC-dextran and washed with different 
volumes of artificial urine solution. Scale bars are 200 µm. (Mun et al., 2016). 
 
Behrens et al. (2002) studied interactions of polystyrene, chitosan and polylactide (PLA)-





and mucus-secreting MTX-E12 cells. They revealed that the nanoparticles associated with 
Caco2 cells in the following order: polystyrene > chitosan > PEG-PLA. On the other hand, 
chitosan nanoparticles strongly bound to the mucus secreting cells and the binding of 
polystyrene nanoparticles was significantly decreased. PEG-PLA did not show any 
association with the mucus secreting cells. Intraduodenal administration of chitosan 
nanoparticles demonstrated that they could be internalized in both epithelial cells and 
Peyer’s patches. The mechanism of the transport of chitosan and polystyrene nanoparticles 
was studied using Caco2 cells. It was found that chitosan nanoparticles were internalized by 
adsorptive endocytosis, whereas non-adsorptive endocytosis could be involved with 
polystyrene nanoparticles. Decreasing the temperature of incubation (4 °C) significantly 
decreased the transport of both types of nanoparticles. Addition of 1 mM protamine sulfate 
(inhibitor of active transport process) and pre-treatment of the cells with 10 U/mL heparinase 
II or 35 mM sodium chlorate (led to de-sulfation and the removal of anionic sites of mucus 
and cell membranes) significantly reduced the cellular transport of chitosan nanoparticles. 
However, the transport of polystyrene nanoparticles did not change with these factors. 
Chitosan endocytosis was saturable, i.e., cellular association increased linearly with 
concentration (31.25–1000 µg/mL) and reached a steady state at some point. Other studies 
have also reported the cellular uptake enhancing effect of chitosan, which could occur by 
adsorptive endocytosis, where a positively-charged coated nanoparticles adhere strongly to 
the negatively charged components of the cell membranes (Kim et al., 2008).  
Thongborisute et al. (2006) investigated the mucoadhesion and muco-penetration of chitosan 
solution, liposomes and chitosan-coated liposomes in rat small intestine in ex vivo and in 
vivo models. The systems were fluorescently labelled with FITC and administered orally to 
male Wistar rats or in the ex vivo model rats were sacrificed and the samples were incubated 
to interact with the mucosal tissues for 1 h at 37 °C. To visualize the penetration of these 
materials, cross-sections of 3 different regions of the small intestine (duodenum, jejunum, 
and ileum) were obtained and examined with confocal laser scanning microscopy (CLSM). 
They showed that chitosan, non-coated liposomes, and chitosan-coated liposomes could 
adhere and penetrate the mucosal tissues. However, the extent of adhesion and penetration 
of chitosan-coated liposomes was greater than for non-coated liposomes. The authors related 
this behaviour to firstly, the mucoadhesive properties of chitosan. Secondly, the presence of 
chitosan on the surface of liposomes could result in the formation of large aggregates due to 





liposomes adhering to the mucus layer. This phenomenon is not observed in the case of non-
coated liposomes and only individual particles disperse in the suspension. Interestingly, 
although the authors did not discriminate the mucoadhesion and the mucosal penetration, 
they observed more mucosal penetration in the ileum region compared to both duodenum 
and jejunum, which they believe was due to the thicker nature of the ileum, which is also 
supported by other studies (Atuma et al., 2001; Varum et al., 2010, 2012). Deacona et al. 
(1999) also revealed the difference in the mucoadhesive interactions of chitosan in different 
regions of porcine stomach by sedimentation velocity technique using analytical 
ultracentrifuge equipped with conventional Philpott-Svensson Schlieren optical systems and 
coupled on-line to a charge-coupled device (CCD) camera. The cardiac region displayed the 
strongest interaction with chitosan compared to corpus and antrum.  
1.3 Problems of chitosan in mucosal drug delivery 
Being a basic polymer, chitosan is mucoadhesive only at limited pH and is only soluble at 
acidic pH (pH < 6) (Caramella et al., 2010; Sogias et al., 2010). The requirement of 
decreasing the pH of chitosan vehicles limits its applications in drug and gene delivery as 
many biomolecules including DNA, proteins and peptide-based drugs are not stable at low 
pH (Jeong et al., 2008). Additionally, even acidic chitosan formulations will encounter 
neutral to basic pH once they administered into the human body either topically or 
systemically. High pH environment results in the precipitation of chitosan and can affect the 
performance of the carrier systems (Sogias et al., 2010). 
Chitosan-based mucosal drug delivery systems have been investigated to increase the 
residence time of drugs on the application/absorption sites (Illum et al., 1994; Bernkop-
Schnürch et al., 2000; Sogias et al., 2012). The increase in the residence time is advantageous 
as it may prolong the action of drugs and provides sustained drug release. However, with 
unmodified chitosan, this is only possible to a certain degree. Therefore, there is an obvious 
need for further controlled drug release with subsequent prolongation of drug action 
(Bernkop-Schnürch, 2000). 
Several modifications of chitosan have been investigated to enhance its mucoadhesive 
properties. In the next sections, we will discuss various chitosan derivatives with potential 






1.4 Mucoadhesive chitosan derivatives 
1.4.1 Trimethyl chitosan (TMC) 
TMC is a chitosan derivative which is always positively charged. This persistent cationic 
nature makes it one of the strongest mucoadhesive polymers. It has a much wider pH 
solubility range than unmodified chitosan due the presence of protonated groups (–
N+(CH3)3) (Kulkarni et al., 2017). TMC can be synthesized by three general methods: 
indirect trimethylation (Muzzarelli & Tanfani, 1985; Verheul et al., 2008), direct 
trimethylation (Sieval et al., 1998; de Britto & Assis, 2007) and protection of chitosan 
hydroxyl groups (at C-3 and C-6 positions) by O-silylation (Benediktsdóttir et al., 2011). 
The first method is usually a two-step process including the formation of an intermediate 
product (N,N-dimethyl chitosan) and can be conducted using two different reaction 
conditions. Whereas, the second method is a one-step process and does not contain any 
intermediate product, but it can also be conducted using two different reaction conditions. 
Using either indirect or direct trimethylation can often result in the formation of O-
methylated TMC. However, using hydroxyl protection method by O-silylation, e.g., by 
employing tert-butyldimethylsilyl chloride, O-methylation can be avoided (Muzzarelli & 
Tanfani, 1985; Sieval et al., 1998; de Britto & Assis, 2007; Verheul et al., 2008; 
Benediktsdóttir et al., 2011; Wu et al., 2016; Kulkarni et al., 2017). Verheul et al. (2008) 
also claimed that their synthetic approach can result in O-methyl free TMC. The synthetic 
pathway for each method is illustrated in Figure 1.4, Figure 1.5 and Figure 1.6. For the details 
of the experimental methods of TMC synthesis, readers are referred to two recent reviews 






Figure 1.4 Synthetic pathway for preparation of TMC using indirect trimethylation approach 
according to (1) Muzzarelli and Tanfani (1985), ACN = acetonitrile and (2) Verheul 






Figure 1.5 Synthetic pathway for preparation of TMC using direct trimethylation approach 
according to (1) Sieval et al. (1998), NMP = N-methyl-2-pyrrolidinone and (2) de 
Britto and Assis (2007), DMS = dimethyl sulfate. 
 
Figure 1.6 Synthetic pathway for preparation of TMC using hydroxyl groups protection 
approach by O-silylation according to Benediktsdóttir et al. (2011). 
 
TMC has been synthesized so as to enhance the water-solubility of chitosan with wider 





the effect of a few variables including the number of reaction steps, the duration of each 
reaction step and the amount of methyl iodide as a reagent. It was found that 2-step reaction 
resulted in products with high degree of substitution (40–80%). However, 3-step reaction 
led to even greater degree of substitution but at the same time water-solubility of the resulting 
product decreased.  
Jintapattanakit et al. (2009) synthesized TMC by reductive methylation of chitosan. TMC 
was then PEGylated. Both polymers were then fluorescently labelled using tetramethyl-
rhodamine isothiocyanate (TRITC) and Oregon Green carboxylic acid succinimidyl ester 
(Oregon Green 448). The insulin-loaded nanoparticles were synthesized using self-assembly 
technique. The influence of TMC PEGylation and its positive charge density on 
mucoadhesive properties were assessed using a mucin assay and mucus-secreting HT29-
MTX-E12 (E12) monolayers. It was found that introduction of PEG improved the 
mucoadhesive effect of TMC. This could be due to the interpenetration of PEG with mucus. 
In some other studies, PEGylation of chitosan also shown reduced toxicity and significantly 
increased the cellular permeation of hydrophilic macromolecules including FITC-dextran 
(Casettari et al., 2010; Casettari et al., 2012). 
Hauptstein et al. (2014) also studied the effect of PEGylation as well as thiolation (will be 
discussed in the next section) on adhesion of chitosan’s compressed discs to porcine 
intestinal mucosa. They synthesized PEG-bearing thiolated chitosan by conjugating thiol-
bearing polyoxyethylene ligand [O-(3-carboxylpropyl)-O′-[2- [3-
mercaptopropionylamino)ethyl]-polyethyleneglycol] to amino groups of chitosan. The 
reaction was mediated by 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride 
(EDAC)/N-hydroxysuccinimide (NHS). In addition to its solubility in basic media, PEG-
bearing thiolated chitosan showed greater mucoadhesive strength compared to unmodified 
chitosan. However, it was equally mucoadhesive as thiolated chitosan. Moreover, PEG-
bearing thiolated chitosan enhanced the permeation of FITC-dextran through rat intestinal 
mucosa and Caco2 cells monolayer. The enhancement in mucoadhesion is based on the 
formation of disulfide bridges with mucus glycoproteins. The permeation enhancing effect 
could be due to the interaction of thiol groups of the thiolated chitosans with protein tyrosine 






Sayın et al. (2009) demonstrated a novel approach for formation of nanoparticles via 
complexation between cationic TMC and polyampholytic N-carboxymethylchitosan without 
a crosslinker. The nanoparticles were loaded with FITC-BSA (bovine serum albumin) and 
their cellular uptake was studied. A significant number of the nanoparticles was taken up by 
murine macrophage J774A.1 within 30 min of incubation. The authors believed that the 
mucoadhesive effect of TMC plays a major role in the enhancement of the cellular uptake. 
The nasal administration of tetanium toxiod-loaded 283 nm nanoparticles in mice, induced 
the mucosal and systemic immune responses.  
Sajomsang et al. (2009) synthesized two methylated N-aryl chitosan derivatives, methylated 
N-(4-N,N-dimethylaminocinnamyl) chitosan chloride and methylated N-(4-pyridylmethyl) 
chitosan chloride by reductive amination and methylation of chitosan. It was found that 
increasing the degree of quaternization led to a stronger mucin-particle interaction. 
Moreover, the cytotoxicity was dependent on the polymer structure, the location of the 
positive charge and the molecular weight after methylation. 
On the other hand, some studies showed that TMC has greater potential to adhere to the 
epithelial tissue than to the mucin. For instance, Keely et al. (2005) evaluated the adhesion 
of coumarin-labelled-poly(2-dimethylaminoethyl) methacrylate (pDMAEMA) with 
different levels of quaternization (0, 10, 24 and 32%) and TMC to human mucus-secreting 
and non-mucus-secreting intestinal cell monolayers (E12 and HT29, respectively) as well as 
freshly excised rat intestinal mucosa using non-everted intestinal sacs model. CLSM, light 
and fluorescence microscopy were used to quantify either mucoadhesion (adhesion to the 
mucus layer) or bioadhesion (adhesion to the epithelial tissue rather than mucosal surface). 
It was found that pDMAEMA, regardless of the degree of quaternization, was more 
mucoadhesive than bioadhesive, whereas TMC was found to be more bioadhesive and as 
mucoadhesive as unquaternized pDMAEMA and 24% quaternized pDMAEMA. When E12 
cells and intestinal sacs were treated with mucolytic agent, N-acetylcysteine, for 15 min, the 
mucoadhesion of pDMAEMA polymers was significantly decreased, while the bioadhesion 
of TMC had not changed following this treatment. Additionally, the permeability of FITC-
dextran through both E12 cells monolayer and intestinal sacs was significantly decreased in 
the presence of pDMAEMA, whereas the use of TMC led to a significant increase in the 
permeability. Although they did not study the interactions between the polymers and the 
mucus, the authors claimed that pDMAEMA perhaps increased the viscosity of the mucus 





However, chitosan and its derivatives can open the tight junctions (Jonker et al., 2002; 
Hamman et al., 2003; Smith et al., 2004) that could enhance the paracellular diffusion of 
FITC-dextran. 
Liu et al. (2016) developed core-shell nanoparticles based on TMC. The nanoparticles were 
coated with dissociable layer of N-(2-hydroxypropyl) methacrylamide copolymer 
(pHPMA). The diffusion of coated and uncoated nanoparticles in human cervicovaginal 
mucus was evaluated using multiple particle tracking technique and Ussing chamber. 
Cellular internalization and transport were evaluated using E12 cells. It was found that 
pHPMA coating could enhance the diffusion of TMC nanoparticles through both mucus and 
epithelial layer. Non-coated TMC nanoparticles were found to be less diffusive in both 
mucus and the cells. Liu et al. (2016) indirectly demonstrated the mucoadhesive properties 
of TMC.  
Generally, mucoadhesive properties of chitosan could be affected by both the degree of 
quaternization and its molecular weight. Nazar et al. (2011) prepared TMC thermosensitive 
nasal gel from low, medium, and high molecular weight chitosan with quaternization of 25.6 
to 61.3%. It was found that gels made from lower quaternization and medium molecular 
weight TMC had the greatest work of adhesion (252 ± 14 μJ) and the shortest sol-gel 
transition time (7 min) at 32.5 °C. This could be due to their great capacity to hydrate and 
absorb large amounts of water. Partially quaternized TMC has the advantage of having a 
better water solubility profile in neutral and basic environment than the native chitosan (van 
der Merwe et al., 2004). This is important since absorption of most drugs happens at slightly 
basic or neutral part of the gastrointestinal tract (DeSesso & Jacobson, 2001).  
TMC has been used as an absorption enhancer for the delivery of buserelin and insulin across 
Caco-2 cells monolayers. Although at low concentrations TMC is a less active absorption 
enhancer than both chitosan hydrochloride and chitosan glutamate, increasing its 
concentration could increase its activity. Since it is more soluble than both chitosan salts, 
increasing TMC concentration is very unlikely to cause precipitation, however, it resulted in 
an increase in the transport rate of both buserelin and insulin across Caco-2 cell monolayers, 
which might be due to the decrease in transepithelial electrical resistance (TEER) (Kotzé et 
al., 1997). TEER is a parameter, which determines the intercellular ion flux and indicates 





1.4.2 Carboxymethyl chitosans 
Carboxymethyl chitosan is another derivative of chitosan with amphoteric properties, acting 
as both acid and base depending on the pH of its solution. The amphoteric properties 
originate from the presence of both amino (basic) and carboxylic (acidic) groups in its 
chemical structure (Jayakumar et al., 2010; Upadhyaya et al., 2014; Thanou et al., 2001). 
The amino groups undergo protonation in acidic media and make carboxymethyl chitosan 
positively charged. On the other hand, in basic media carboxylic groups dissociate and 
impart carboxymethyl chitosan negative charged.  
Chen and Park (2003) studied the pH-solubility profile of various O-carboxymethyl 
chitosans synthesized at different reaction conditions (temperature and ratio of 
water/isopropanol). The resultant chitosans showed a pH-dependent water-solubility 
character. Based on the degree of substitution, carboxymethyl chitosans (0.2 mg/mL) were 
insoluble at pH ranges close to neutral. However, at highly acidic and basic pHs, they 
demonstrated complete water-solubility. It was found that using low temperature (0 and 10 
°C, during the synthesis) resulted in completely water-soluble products but with low yield. 
Increasing the temperature and decreasing the water/isopropanol ratio resulted in more 
carboxymethylation, which subsequently shifted the region of insolubility towards the lower 
pH (~3). Vikhoreva and Gal’braikh (1997) also reported that carboxymethyl chitosan was 
insoluble at pH range of 3.5–6.5, whereas it showed complete solubility at pH < 3.5 and > 
6.5. The insolubility at those pH ranges could be due to the fact that the isoelectric point of 
carboxymethyl chitosan is 4.1 and therefore when the pH of the solution is near the 
isoelectric point, precipitation and aggregation could happen (Thanou et al., 2001). 
Generally, carboxymethyl chitosans can be prepared using two different approaches, which 
are reductive alkylation and direct alkylation. In case of reductive alkylation, the amino 
groups of chitosan react with aldehyde groups of glyoxylic acid to form an intermediate 
imine product, which then is hydrogenated using sodium borohydride or sodium 
cyanoborohydride. The ratio of glyoxylic acid to chitosan is important in determining 
whether mono- or di-carboxymethyl chitosan is formed. Direct alkylation can be performed 
by reacting chitosan with some alkyl halides, such as monochloroacetic acid, in the presence 
of inorganic bases including sodium bicarbonate and sodium carbonate to raise the pH to 
8.0–8.5. The pH of the reaction mixture is considered to be one of the important factors in 
determining whether O-, N- or O, N-substitution takes place (An et al., 2008; An et al., 2009; 





(Ge & Luo, 2005). Figure 1.7 shows the pathways for the synthesis of carboxymethyl 
chitosans. 
 
Figure 1.7 Schematic representation of the synthesis of carboxymethyl chitosans using 
reductive (1) (Thanou et al., 2001) and direct (2) alkylation (An et al., 2009) 
methods. 
 
Di Colo et al. (2004) studied the effect of chitosan and N-carboxymethyl chitosan on the 
ocular pharmacokinetics of ofloxacin in rabbits. Chitosan enhanced the penetration of the 
drug through the ocular tissue and its maximum concentration (Cmax) in the aqueous humor 
was greater than in the case when conventional eye drops (Exocin® eye drops) and reference 
formulation (polyvinyl alcohol-based ofloxacin solution) were used. This may be due to the 
tight junction opening effect of chitosan. N-carboxymethyl chitosan did not significantly 
enhance the Cmax of the drug in the aqueous humor. However, it resulted in a steady state 
drug concentration from 30–150 min post-ocular administration. The authors measured the 
viscosity of the three formulations and found that they were approximately similar. 
However, they still claimed that the viscosity enhancement is one of the reasons for the 
enhancement of pre-ocular drug residence time compared to the reference formulation. The 
binding of ofloxacin to N-carboxymethyl chitosan due to hydrogen bonding between amino 
groups of the drug and hydroxyl groups of the polymer, is also a reason for both the decrease 
in the ocular drug penetration and the increase in the residence time (Di Colo et al., 2004). 
Although they did not evaluate the mucoadhesive properties of these polymers, they 
hypothesized that it could have an impact on the increased residence time in the ocular 
tissues. Clearly, the residence time of a formulation on the ocular tissues will be related to 






N-carboxymethyl chitosan has also been used as an intestinal absorption enhancer and 
proved to increase the in vitro and in vivo transmucosal absorption of low molecular weight 
heparin (Thanou et al., 2001). It has also showed potential in the oral delivery of small 
molecules. Prabaharan and Gong (2008) synthesized thiolated carboxymethyl chitosan-g-β-
cyclodextrin and showed its potential for the oral delivery of lipophilic drug ketoprofen. The 
modified chitosan resulted in 5-fold improvement in the adhesion to mouse intestinal mucosa 
and slower drug release. 
1.4.3 Thiolated chitosans 
Thiolation is one of the techniques used to functionalize various polymers including chitosan 
using thiolating agents bearing thiol groups. These include cysteine (Bernkop-Schnürch et 
al., 1999a), thioglycolic acid (TGA) (Kast et al., 2003), 2-iminothiolane or 4-
thiobutylamidine (TBA) (Bernkop-Schnürch et al., 2003), N-acetyl cysteine (Schmitz et al., 
2008), isopropyl-S-acetylthioacetimidate (Kafedjiiski et al., 2005b) and glutathione 
(Kafedjiiski et al., 2005a). This technique has been pioneered by Bernkop-Schnürch and co-
workers (Bernkop-Schnürch et al., 1999b) to enhance the mucoadhesion of polymers for 
pharmaceutical and biomedical applications. Thiolated chitosans are now one of the 
extensively studied mucoadhesive materials. In addition to their superior mucoadhesive 
properties, they also have some permeation enhancing effects, ability to inhibit efflux pumps 
and in situ gelling properties (Bonengel & Bernkop-Schnürch, 2014). Figure 1.8 shows the 






Figure 1.8 Synthetic pathways to different thiolated chitosan derivatives (Bernkop-Schnürch 
et al., 1999a; Bernkop-Schnürch et al., 2003; Kast et al., 2003; Bernkop-Schnürch 
et al., 2004b; Kafedjiiski et al., 2005a; Kafedjiiski et al., 2005b; Schmitz et al., 
2008; Li et al., 2013). 
 
1.4.3.1 Chitosan-cysteine 
In 1999, Bernkop-Schnürch et al. (1999a) synthesized chitosan-cysteine conjugate by 
covalent attachment of cysteine to chitosan mediated by carbodiimide, where the amount of 
bound-cysteine was increased with an increase in the amount of the mediator reaching 1.2%. 
Subsequent mucoadhesion study revealed no significant difference between chitosan and 
thiolated chitosan. However, thiolated chitosan tablets showed superior cohesion over the 
chitosan tablets which could be due to the formation of intra/intermolecular disulfide bonds 
as a result of the oxidation of the thiol groups in thiolated chitosan. This improved cohesion 
is desirable not only for the mucoadhesion but also for the design of controlled release 






TMC has also been thiolated by reacting with cysteine mediated with EDAC/NHS. Insulin-
loaded nanoparticles were prepared using polyelectrolyte complexation method. The 
resultant TMC-cysteine showed significantly greater mucoadhesion capacity compared to 
unmodified TMC in both rat ileal loop and mucin adsorption models. This might be due 
firstly to the electrostatic interaction between positively charged chitosan and negatively 
charged sialic acid of mucin glycoproteins leads to the interpenetration of the polymer and 
mucin. Secondly, at neutral pH (pH of small intestine) the thiol groups of TMC-cysteine 
could be oxidized by reacting with cysteine-rich domains of mucin leads to the formation of 
disulfide bonds, which finally may immobilize more thiolated polymeric particles in the 
mucus layer than the unmodified polymer (Yin et al., 2009). TMC-cysteine nanoparticles 
also showed greater permeability enhancement effect compared to unmodified TMC, which 
can be linked to the inhibition of protein tyrosine phosphatase which facilitates opening of 
tight junctions (Bernkop-Schnürch et al., 2004b). It might also be due to the greater 
mucoadhesion of TMC-cysteine than the native chitosan. Third possible reason is the 
inhibition of protease activities on insulin via shielding of enzymatic cutting sites after 
formation of self-assembled nanoparticles (Yin et al., 2009). 
1.4.3.2 Chitosan-N-acetyl-cysteine 
Schmitz et al. (2008) synthesized chitosan-N-acetyl-cysteine conjugate via covalent 
attachment of N-acetyl-cysteine to chitosan using two different concentrations of EDAC as 
a mediator. They observed that this modification resulted in 50-fold increase in the retention 
of chitosan compressed discs on ex vivo porcine intestinal mucosa. The total work of 
adhesion required to detach the chitosan-N-acetyl-cysteine discs from the intestinal mucosa 
was 8.3-fold greater than unmodified chitosan. This may be due to the increase in the number 
of disulfide bonds between the polymers and the cysteine-rich domains of mucosa. They 
also revealed that increasing the concentration of EDAC resulted in products with greater 
amount of thiol groups. This is due to the activation of carboxylic groups of N-acetyl-
cysteine, which resulted in immobilization of more thiol groups on the polymer. This 







1.4.3.3 Chitosan-thioglycolic acid (Chitosan-TGA) 
Chitosan-TGA has been synthesized by introducing TGA to chitosan using EDAC as a 
mediator. The resulting thiolated chitosan showed 4.3-fold increase in the viscosity, which 
is desirable for mucosal drug and gene delivery and scaffold materials in tissue engineering. 
This improvement in the viscosity may be related to the formation of disulfide bonds within 
the polymeric matrix (Kast et al., 2003). The viscosity of this thiolated chitosan can be 
further improved by using different oxidizing agents including hydrogen peroxide, sodium 
periodate, ammonium persulfate and sodium hypochlorite. These agents accelerated the sol-
gel transition to take place only within few min, while without them this transition requires 
40 min. 25 nmol/L hydrogen peroxide has increased the dynamic viscosity of 1% chitosan-
TGA solution by up to 16,500-fold. This may be due to the formation of more inter- and 
intra-chain disulfide bonds (Sakloetsakun et al., 2009). To assess the potential of chitosan-
TGA for non-viral oral gene delivery, 100–200 nm nanoparticles with zeta potential of 5-6 
mV have been formed by complex coacervation of plasmid DNA and the thiolated chitosan. 
These particles showed acceptable stability toward DNase and thus resulted in a 5-fold 
increase in the rate of transfection (Martien et al., 2007) . 
In another study, Barthelmes et al. (2011) synthesized mucoadhesive nanoparticles based on 
chitosan-TGA using ionic gelation with sodium tripolyphosphate (TPP) for intravesical drug 
delivery. Two types of partially oxidized (different in their disulfide content, -SH groups 
oxidized to form -S-S- bonds) chitosan-TGA-TPP nanoparticles were also synthesized by 
the addition of H2O2 solution (0.5% v/v) to chitosan-TGA-TPP nanoparticles. Either 
fluorescein diacetate or trimethoprim were then loaded into the nanoparticles. Then, using a 
flow through technique, the amount of fluorescein diacetate adhered to the bladder mucosa 
was quantified using fluorescence spectrophotometry. It was found that using chitosan-
TGA-TPP nanoparticles, 14.2 ± 7.2% of fluorescein diacetate remained on the surface of the 
mucosal tissues but in the case of unmodified chitosan-TPP nanoparticles, only 1.1 ± 0.1% 
fluorescein diacetate remained after washing with simulated artificial urine for 3 h with a 
flow rate of 2 mL/min. This improvement in the mucoadhesion was due to the covalent 
bonds formed between the thiol groups of the polymers and the cysteine-rich domains of the 
glycosaminoglycan layer of the mucus which is composed of proteoglycans and 
glycoproteins as in the case of adhesion to the intestinal mucosa (Soler et al., 2008; 
Barthelmes et al., 2011). To prove the concept, a quantitative analysis of free thiol groups of 





between the thiol contents of the two mucosal tissues. Interestingly, release study using 
artificial urine as a dissolution media shown that covalently crosslinked chitosan-TGA-TPP 
nanoparticles resulted in a slower and more controlled release of trimethoprim compared to 
ionically crosslinked chitosan-TGA-TPP and unmodified chitosan-TPP nanoparticles. The 
nanoparticles with greater content of disulfide bonds released the drug significantly slower 
than the nanoparticles with fewer disulfide bonds. The authors suggested that covalent 
crosslinking resulted in harder nanoparticles due to the formation of disulfide bridges within 
the matrix of the nanoparticles. This then increased the mechanical strength of the 
nanoparticles and thus made the artificial urine diffuse slowly into the nanoparticles. 
Consequently the dissolution of trimethoprim decreased and the nanoparticles released the 
drug slowly (Barthelmes et al., 2011). 
1.4.3.4 Chitosan-4-thiobutylamidine 
Chitosan-4-thiobutylamidine (chitosan-TBA) is another type of thiolated chitosan with 
mucoadhesive properties (Grabovac et al., 2005). It remained on porcine small intestinal 
mucosa for 161 ± 7 h when tested using rotating cylinder method. In addition, the total work 
of adhesion was 740 ± 147 µJ. It has been reported that the mucoadhesive property of 
thiolated chitosans is pH dependent, and this point should be considered in the design of 
thiolated chitosan-based mucosal drug delivery systems (Grabovac et al., 2005). 
Langoth et al. (2006) designed mucoadhesive buccal delivery system of pituitary adenylate 
cyclase-activating polypeptide using chitosan-TBA as a promising treatment for type-2 
diabetes mellitus. The in vivo buccal administration through porcine buccal mucosa resulted 
in a continuous rise in the plasma level of the enzyme over 6 h.  
Dünnhaupt et al. (2011) synthesized fluorescently-labelled nanoparticles of chitosan-TBA 
and polyacrylic acid-cysteine conjugate using ionotropic gelation technique. For the 
mucoadhesion study, fresh jejunum of rats was cut into 2 cm segments and filled with 0.1 
mL nanoparticles. After fixation, the mucosal tissues were examined by fluorescence 
microscopy. The penetration study was performed using fresh “mucus-filled silicon tube” 
technique. It was found that nanoparticles of both modified chitosan (Figure 1.9) and 
polyacrylic acid exhibit greater mucoadhesive strength than unmodified nanoparticles. 
Chitosan particles showed 2-fold greater mucoadhesive property than polyacrylic acid 
particles. On the contrary, the muco-penetration ability of unmodified nanoparticles was 






Figure 1.9 Fluorescent images of rat intestinal tissues after 2 h incubation with 100 µL 0.5% 
w/v (a) chitosan and (b) chitosan-TBA nanoparticles labelled with Alexa Fluor 488, 
(a1 and b1,40×; a2 and b2, 100× magnification). The scale bars are 100 µm. 
Reprinted from (Dünnhaupt et al., 2011) with permission of Elsevier. 
 
The combination of chitosan-TBA and chitosan-Bowman-Birk inhibitor in the design of 2 
mg enteric coated microtablets showed a significant enhancement in the effect of oral salmon 
calcitonin on the level of plasma calcium when tested in rats (Guggi et al., 2003). The 
derivatization of chitosan with enzyme inhibitors will be discussed in a separate section. 
1.4.3.5 Chitosan-thioethylamidine 
The use of 2-iminothiolane to synthesize thiolated chitosan resulted in a marked increase in 
the mucoadhesion. However, the resultant thiolated chitosan lacks sufficient stability leading 
to the reduction in the number of free thiol groups. One of the reasons for the instability 
could be the formation of N-chitosanyl-substituted 2-iminothiolane structures, which 
happens after modification of some amines using 2-iminothiolane. This intermediate product 





To avoid this side reaction, Kafedjiiski et al. (2005b) synthesized thiolated chitosan using 
isopropyl-S-acetylthioacetimidate as a thiolating agent and an alternative to 2-iminothiolane. 
In contrast to chitosan-TBA (higher than unmodified chitosan) (Krauland et al., 2006), the 
swelling property of chitosan-thioethylamidine was not significantly different from 
unmodified chitosan. However, the mucoadhesion was significantly improved. Using 
chitosan-thioethylamidine, the release of FITC-dextran was sustained over 3 h, which could 
be due to the presence of disulfide bonds in the structure of chitosan, which can slow the 
diffusion of FITC-dextran macromolecules down. 
1.4.3.6 Chitosan-glutathione 
Several studies reported the use of glutathione for the synthesis of chitosan-glutathione 
conjugates (Kafedjiiski et al., 2005a; Moghaddam et al., 2009; Koo et al., 2011; Li et al., 
2013). Due to its permeation-enhancing effect, redox potential and safe toxicological profile, 
glutathione is a suitable thiolating agent for biomedical applications. Due to the presence of 
thiol groups in the cysteine part of glutathione, it has strong electron donating property, 
acting as a reducing agent. Additionally, the stability of glutathione against cellular 
aminopeptidase is provided by the presence of ɤ-peptidic bond between glutamic acid and 
cysteine. Also, its conformational flexibility, makes glutathione a highly reactive ligand 
(Kafedjiiski et al., 2005a).  
Similar to other thiolated chitosans, the synthetic approach is based on the formation of 
amide bonds between glycine carboxylic acid groups of glutathione and amino groups of 
chitosan. The reaction can be mediated by EDAC/NHS. The method was developed by 
Kafedjiiski et al. (2005a). The resultant chitosan-glutathione exhibited acceptable cohesive 
properties and did not disintegrate in physiological solution (0.1 M phosphate buffer solution 
pH 6.8) for 48 h. However, unmodified chitosan was only stable for 9 h. Interestingly, both 
polymers showed the same swelling behaviour, whereas chitosan glutathione had greater 
mucoadhesive properties (expressed as the total work of adhesion and tablets-porcine 
intestinal detachment time) than unmodified chitosan. The apparent permeability of 
rhodamine 123 across rat duodenum using chitosan-glutathione and unmodified chitosan 
were 2.06 × 10−7, and 0.66 × 10−7 cm/s, respectively. 
Jin et al. (2011) demonstrated the application of chitosan-glutathione in the oral delivery of 
thymopentin (a synthetic pentapeptide with immune-regulatory action). They synthesized 





technique. The particles were subsequently coated with either chitosan or chitosan-
glutathione and orally administered to immunosuppressed rats. It was found that chitosan-
glutathione-coated nanoparticles were able to normalize the immune function of rats, which 
is probably due to the enhanced mucoadhesive properties of chitosan-glutathione. 
Chitosan-glutathione hydrogel was also found to be more effective in the reduction of 
oxidative stress in neonatal rat cardiomyocytes than unmodified chitosan hydrogel. The 
action possibly related to better cellular adhesion potential of chitosan-glutathione compared 
to unmodified chitosan as a result of the availability of the biocompatible glutathione 
promoting the cells survival (Li et al., 2013). 
1.4.3.7 Comparison of chitosan, trimethyl chitosan and thiolated chitosan 
In a comparative study, Mei et al. (2008) investigated the mucoadhesion as well as the nasal 
absorption enhancing effect of chitosan, thiolated chitosan and trimethyl chitosan. Chitosans 
of different molecular weights were synthesized by depolymerization then the 
depolymerized samples were either trimethylated as reported in (Mao et al., 2005) or 
thiolated by reacting with cysteine using EDAC/NHS chemistry according to Bernkop-
Schnürch and Steininger (2000) with slight modification. The mucoadhesion of chitosan and 
thiolated chitosan was evaluated and the detachment time of 5 mm discs of the polymers 
from freshly excised porcine intestinal mucosa was evaluated. Discs of thiolated chitosan 
with greater degree of substitution (152 µmol/g) detached in a significantly longer time 
(about 12 h) than unmodified chitosan. The bioavailability of 2,3,5,6-tetramethylpyrazine 
phosphate through nasal route after its formulation with different chitosans was investigated. 
It was found that the use of any type of chitosan (unmodified, thiolated and trimethyl 
chitosan) resulted in a significantly improved absorption of 2,3,5,6-tetramethylpyrazine, 
however, no significant difference between thiolated chitosans (two different degrees of 
substitution) with unmodified chitosan was observed. The authors claimed that the 
permeation-enhancing effect is dose- and molecular weight-dependent and 100 kDa resulted 
in maximal absorption enhancement. On the other hand, trimethyl chitosan led to a 
significant enhancement in the nasal absorption of the drug. These results contradict those 
studies reporting the absorption enhancing effect of thiolated chitosan through intestinal 
mucosa. For example, Krauland et al. (2004; 2006) demonstrated that chitosan-4-
thiobulyamidine resulted in an increase in the oral and nasal absorption of insulin compared 





could also be due to the inhibition of protein tyrosinase and P-glycoprotein efflux pump in 
the mucosal membranes (Föger et al., 2006; Krauland et al., 2006). 
1.4.3.8 Pre-activated (S-protected) thiolated chitosans 
Vulnerability of thiolated chitosans to oxidation can be considered as one of the major 
limitations of their use as mucoadhesive polymers. Thiolated chitosans are generally stable 
in dry state. However, in solutions, they undergo rapid oxidation especially in the presence 
of oxidants such as oxygen and particularly at pH ˃ 5 (Bernkop-Schnürch et al., 2003). This, 
will not only lead to the formation of intra- and inter-molecular disulfide bonds, but also 
results in the reduction of the free thiol groups necessary for the formation of disulfide 
bridges with the cysteine-rich domains of the mucin. This will then lead to a significant 
reduction in the mucoadhesive potential of thiolated chitosans under physiological 
conditions of the gastrointestinal tract (Bernkop-Schnürch et al., 2003). To prevent the 
unwanted oxidation of thiolated chitosans, pre-activated or S-protected thiolated chitosans 
have been developed by Bernkop-Schnürch and co-workers.  
Generally, pre-activated thiolated chitosan can be synthesized by two steps. Firstly, thiolated 
chitosan is prepared using a thiolating agent and secondly thiol groups are protected by 
disulfide bond formation using ligands with mercaptopyridine substructure including 
mercaptonicotinamide, mercaptonicotinic acid and mercaptopyridine. Due to its toxicity 
profile mercaptopyridine is less commonly used (Bonengel & Bernkop-Schnürch, 2014). 
Despite improvement of mucoadhesive properties, S-protection can also enhance the 
intestinal permeability of hydrophilic molecules such as FITC-dextran. In addition, S-
protected thiolated chitosans have shown less cellular toxicity than the unprotected chitosans 
(Dünnhaupt et al., 2012b).  
Dünnhaupt et al. (2012c) synthesized S-protected thiolated chitosan using a two-steps 
approach (Figure 1.10). First, thioglycolic acid was covalently attached to chitosan and 
resulted in the formation of amide bonds between the amino groups of chitosan and the 
carboxylic groups of thioglycolic acid. Secondly, aromatic ligand 6-mercaptonicotinamide 
(6-MNA) was synthesized by reacting 6-chloro-nicotinamide with thiourea, which was then 
oxidized using hydrogen peroxide to form 6, 6′-dithionicotinamide (6, 6′-DTNA). Both 6-
MNA and 6, 6′-DTNA were then reacted with thiolated chitosan to obtain S-protected 
thiolated chitosan. Tablets of unmodified, thiolated and S-protected thiolated chitosans were 





with 660 µmol/g thiol groups remained attached to the intestinal mucosa for 90 h, whereas 
unprotected thiolated chitosan were only attached for 45 h. However, it seemed there was no 
significant difference between unprotected and S-protected thiolated chitosan with more 
thiol groups (980 µmol/g). Unmodified chitosan detached after only 10 h. Rheological 
studies also indicated that mixing S-protected thiolated chitosan with mucin resulted in a 
significant increase in the apparent viscosity of the mixture compared to both unmodified 
and unprotected thiolated chitosan. The authors believed that S-protected thiolated chitosan 
interacts more rapidly and quantitatively with mucus by thiol-disulfide exchange reaction 
between the thiol groups of mucus-cysteine and the pyridyl-thiol moiety of the S-protected 
thiolated chitosan. In the mucus, the amount of free thiol groups (-SH) is approximately two 
times greater than their oxidized form (-S-S-) (Barthelmes et al., 2011) and this is in favour 
of thiol-disulfide exchange. Thus, more bonding between S-protected thiolated chitosan and 
the mucus can be achieved compared to unprotected thiolated chitosan (Dünnhaupt et al., 
2012c). 
 







In another study, Dünnhaupt et al. (2012a) demonstrated the application of S-protected 
chitosan-TGA (chitosan-TGA-MNA) in the oral delivery of antide as tablets dosages forms. 
It was shown that hardness of chitosan-TGA-MNA tablets was significantly increased due 
to introduction of 6-MNA ligand and the presence of disulfide bonds within the polymeric 
network. Chitosan tablets swelled quickly and reached maximum within 2 h. However, 
chitosan-TGA tablets swelled slowly and continuously with greater extent than the 
unmodified chitosan. The presence of disulfide bonds might explain the enhanced water 
absorbing capacity of chitosan-TGA. On the other hand, chitosan-TGA-MNA tablets 
swelled to a lesser extent (1.5-fold) than chitosan-TGA tablets, which could be due to the 
presence of hydrophobic 6-MNA ligand. Additionally, chitosan-TGA-MNA resulted in a 
constant sustained release of antide and after 8 h, only 65% released. However, the % of 
antide released from chitosan-TGA and unmodified chitosan were 77 and 100%, 
respectively. The in vivo study in male Sprague Dawley rats, however, indicated only a 
slightly higher plasma concentration of antide, but not statistically significant (p > 0.05) 
using chitosan-TGA-MNA compared to chitosan-TGA. The authors claimed that this 
compromise in the oral bioavailability of antide could be due to the enhanced cohesiveness 
and controlled release of chitosan-TGA-MNA tablets. These two properties are essentially 
important in the design of mucoadhesive formulations as if the polymer is not cohesive 
enough it might collapse and therefore the peptide might not be protected and rapidly 
released into the lumen of the gastrointestinal tract and degraded and no longer contributes 
to the concentration gradient (Dünnhaupt et al., 2012a). 
1.4.3.9 Other thiolated chitosans 
Thiolated methylated dimethylaminobenzyl chitosan has been synthesized by Hakimi et al. 
(2017). Although the authors claimed that the modified chitosan had better water-solubility 
profile and potential for drug delivery, in their work, apart from cytotoxicity, they did not 
perform any studies related to the application of this type of thiolated chitosan as a 
mucoadhesive polymer. Clearly, this chitosan derivative will be of interest for evaluation of 
its mucoadhesive properties.  
1.4.4 Acrylated chitosan 
The use of acrylate groups in the development of mucoadhesive materials was pioneered by 
Davidovich-Pinhas and Bianco-Peled (2010). The mechanism of mucoadhesion is believed 
to be due to Michael-type addition reaction between the acrylate vinyl groups of the 





was proved by 1H-NMR study, where the intensity of the peaks related to the vinyl groups 
of polyethylene glycol diacrylate hydrogels was decreased after their reactions with mucin 
dispersion (Davidovich-Pinhas & Bianco-Peled, 2010). Thus, the presence of covalent 
interactions with mucus is a common feature of acrylated and thiolated mucoadhesive 
materials (Bernkop-Schnürch et al., 2003; Davidovich-Pinhas & Bianco-Peled, 2010, 2011; 
Irmukhametova et al., 2011; Štorha et al., 2013; Bonengel & Bernkop-Schnürch, 2014; 
Eshel-Green & Bianco-Peled, 2016; Mun et al., 2016). The idea of acrylated chitosan 
synthesis was developed by Ma et al. (2009). However, they did not demonstrate any 
application in the mucosal drug delivery. This chitosan derivative is water-soluble, can be 
cross-linked under ultraviolet light using photoinitiator 2959 and has less antimicrobial 
activity compared to parent chitosan (Ma et al., 2009). 
Shitrit and Bianco-Peled (2017) synthesized acrylated chitosan by reacting chitosan solution 
(1% w/v in 2% v/v acetic acid, molecular weight 207 kDa, degree of deacetylation 77.6%) 
with poly(ethylene glycol) diacrylate (PEGDA) via Michael-type reaction (Figure 1.11). 
Two different molecular weight PEGDA (0.7 and 10 kDa) were used. The acrylated chitosan 
was characterized using 1H-NMR spectroscopy and ninhydrin test. It was found that using 
smaller molecular weight (0.7 kDa PEGDA) at chitosan/PEGDA ratio of 1:4 resulted in 
more acrylation (98%) than using higher molecular weight PEGDA (10 kDa, 30%). The 
authors believed that this could be due the presence of greater molar amount of acrylate 
groups leading to a more efficient reaction. However, using chitosan/PEGDA 1:2 molar ratio 






Figure 1.11 Synthetic pathway to acrylated chitosan (Shitrit & Bianco-Peled, 2017). 
 
The mucoadhesion was evaluated using tensile strength and rotating cylinder method using 
tablets of chitosan, thiolated and acrylated chitosan on porcine intestinal mucosa. The order 
of detachment force was the following: chitosan-PEGAc (10 kDa) ˃ thiolated chitosan ˃ 
chitosan = chitosan-PEGAc (0.7 kDa). Unexpectedly, the maximum detachment force of 
chitosan-PEGAc (0.7 kDa) was not significantly different from chitosan tablets. Both 
chitosan-PEGAc (10 kDa) and thiolated chitosan remained attached to the intestinal mucosa 
for more than 6 h, whereas chitosan-PEGAc (0.7 kDa) detached after 1 min. Chitosan tablets 
detached after 1.1 ± 0.2 h. The authors claimed that chitosan-PEGAc (0.7 kDa) has greater 
degree of acrylation than chitosan-PEGAc (10 kDa) and this means higher grafting density 
of PEG, which could result in the steric hindrance and preventing the covalent bonding with 
the cysteine-rich domain of mucus (Shitrit & Bianco-Peled, 2017). Similar trend with 
polyacrylic acid was observed; 450 kDa showed a stronger interaction with porcine gastric 
mucin whereas 2 kDa did not exert any effect (Albarkah et al., 2015). Additionally, shorter 
PEG (smaller molecular weight) cannot deeply penetrate the mucosal tissues and results in 
a lower mucoadhesive strength, since mucoadhesive properties of polymers are proportional 
to the molecular weight (Shitrit & Bianco-Peled, 2017). Other studies reported that an 
optimum molecular weight of polymers is required to achieve maximal mucoadhesion. 
Small molecular weight polymers form weak gels and easily dissolve whereas high 





available to interact with the mucus components. Therefore, in both cases, weak 
mucoadhesion can be observed (Smart, 2005). 
1.4.5 Half-acetylated chitosan 
Half-acetylated chitosan is another type of chitosan derivatives, which can be prepared by 
reacting chitosan with acetic anhydride. Several studies explored the solubility of half-
acetylated chitosan and its subsequent effect on the antimicrobial and mucoadhesive 
properties of chitosan (Qin et al., 2006; Sogias et al., 2008; Sogias et al., 2010; Sogias et al., 
2012). Qin et al. (2006) found that half-acetylated chitosan had no antimicrobial activity 
against Staphylococcus aureus, Escherichia coli and Candida albicans. However, 
unmodified chitosan had antimicrobial effects against these microorganisms. They claimed 
that chitosan can interact with the components of the microorganism surfaces and thus be 
absorbed on their surfaces. Since the pH of bacterial and fungal cells is around 7, unmodified 
chitosan precipitates and forms an impermeable layer around the cells. This layer blocks the 
channels, which are essential for the cells survival. However, half-acetylated chitosan fully 
dissolved at neutral pH, thus did not form an impermeable layer, and led to a better survival 
of cells compared to unmodified chitosan. 
Sogias et al. (2010) demonstrated that half-acetylated chitosan (the degree of acetylation = 
52 ± 4 mol%) was soluble over a broad pH range and did not precipitate below pH 7.4. This 
improved solubility profile of half-acetylated chitosan over unmodified chitosan was related 
to the reduced crystallinity (caused by disruption of inter- and intra-molecular hydrogen 
bonds) upon N-acetylation (Sogias et al., 2008; Sogias et al., 2010). In another study, Sogias 
et al. (2008) found that, at pH 2, half-acetylated chitosan interacted with porcine gastric 
mucin particles at a higher polymer/mucin ratio than unmodified chitosan, which was due to 
the decrease in the number of free amino groups in half-acetylated chitosan. At this pH, the 
amino groups undergone protonation and were responsible for the electrostatic interaction 
between chitosan macromolecules and mucin. They also revealed that at pH 7, where 
unmodified chitosan precipitates, half-acetylated chitosan was still able to interact with 
mucin particles. To explore the mechanisms of mucoadhesion, the polymer-mucin 
interaction was studied in the presence of sodium chloride (0.2 M), urea (8 M) and ethanol 
(10% v/v). These agents are known to disrupt the electrostatic interaction, hydrogen bonding 
and hydrophobic effects, respectively. The results indicated that all these forces were 
involved in the mucoadhesion of chitosan and half-acetylated chitosan. In case of half-





the mucoadhesive interactions. This may be due to the higher negative charge density of 
mucin particles at pH 7 compared to pH 2 (Sogias et al., 2008). However, the mucoadhesive 
properties of unmodified chitosan at pH 7 were not evaluated, which could be due to its 
insolubility at this pH. 
Sogias et al. (2012) prepared microparticles containing ibuprofen and either chitosan or half-
acetylated chitosan by two different techniques; spray-drying and co-grinding. 65 mg tablets 
were prepared from spray-dried chitosan and half-acetylated chitosan, spray-dried mixtures 
of chitosan or half-acetylated chitosan with ibuprofen and co-ground mixtures of the 
polymers and the drug. It was found that tablets of half-acetylated chitosan significantly 
enhanced ibuprofen release at pH 7. The force of detachment between unmodified chitosan 
tablets and porcine gastric mucosa was decreased when measured at very acidic (pH 1) and 
neutral (pH 7) media (Figure 1.12). However, the mucoadhesion of half-acetylated chitosan 
tablets was only decreased at low pH and increased linearly up to pH 7. Half-acetylated 
chitosan tablets were generally less mucoadhesive than chitosan tablets. This could be due 
to the reduction of cationic charge density upon acetylation, which diminished the 
electrostatic interaction with mucin (Sogias et al., 2012). Incorporation of ibuprofen in 









Figure 1.12 (1) Detachment force (a) and work of adhesion (b) for chitosan (  ) and half-
acetylated chitosan (HACHI) (  ) tablets as a function of pH on porcine gastric 
mucosal tissues at 37 ± 0.1 °C. Mean ± SD, n = 3. (2) Work of adhesion of tablets 
on porcine gastric mucosa at pH 7.0 and 37 ± 0.1 °C. Chit.: chitosan, Ibu.: 
ibuprofen, SD: spray-dried, CG: co-ground. Mean ± SD, n = 3. Reprinted from 
(Sogias et al., 2012) with permission of Elsevier. 
 
1.4.6 Glycol chitosan 
Glycol chitosan is a hydrophilic chitosan derivative, which can be prepared by adding 
ethylene glycol groups to chitosan backbone. It is soluble in water at any pHs (Trapani et 
al., 2009; Palazzo et al., 2017). It is commercially available from Sigma-Aldrich. 
Glycol chitosan has been used in the design of nanoparticles for the delivery of poorly water- 
soluble drugs. Trapani et al. (2009) prepared 6-coumarin-loaded glycol chitosan-TPP 
nanoparticles using ionic gelation method. Different cyclodextrins were used to form an 
inclusion complex with this dye. It was found that nanoparticles containing (2,6-di-O-
methyl)-ß-cyclodextrin could be internalized by Caco2 cells, which could be due to the 
mucoadhesive nature of chitosan.  
Glycol chitosan has been modified to prepare amphiphilic chitosan derivatives. Below, we 
will discuss two examples of these amphiphilic glycol chitosan derivatives. 
1.4.6.1 Palmitoyl glycol chitosan 
Palmitoyl glycol chitosan is a hydrophobically-modified glycol chitosan. Its use in drug 





imparts it an amphiphilic character (Uchegbu et al., 1998; Uchegbu et al., 2014). It has ability 
to self-assemble into vesicles suitable for delivery of water-soluble drugs such as bleomycin 
(Uchegbu et al., 1998). Its quaternized form (quaternary ammonium palmitoyl glycol 
chitosan) can self-assemble into micelles with a high drug loading capacity. It also facilitated 
transport of hydrophobic drugs including griseofulvin and propofol and hydrophilic drugs 
(but to a lower degree) including ranitidine through biological barriers such as intestinal and 
blood brain barriers, respectively, led to enhanced bioavailability (Qu et al., 2006; Siew et 
al., 2012). It is conceivable that, the hydrophilic groups (–OH and –NH2) of glycol chitosan 
located in the external shell of the micelles and the hydrophobic groups in the cores. Thus, 
the mucoadhesive property of glycol chitosan should be well maintained upon self-assembly 
as these groups are mainly responsible for the mucoadhesive nature of chitosan and its 
derivatives (Sogias et al., 2008; Bonferoni et al., 2010). 
The hydrophobicity is one of the important factors affecting the mucoadhesive character of 
materials. Martin et al. (2002) investigated this by synthesizing palmitoyl glycol chitosan 
with various degrees of palmitoylation (a hydrophobic group). First, glycol chitosan was 
dissolved in water before sodium bicarbonate and absolute ethanol were added. To this, 
ethanolic solution of palmitoyl-N-hydroxysuccinimide was added and then the mixture was 
stirred for 72 h in the dark (Figure 1.13). This was followed by dialysis and recovery of the 
product. The physically crosslinked gels were prepared by freeze drying the products and 
evaluated for their bioadhesive strength by measuring the force necessary to detach the gels 
from porcine buccal mucosa. It was found that by increasing the hydrophobicity (represented 
by the degree of palmitoylation), the hydration and erosion of the gels decreased. On the 
other hand, bioadhesion could be enhanced by increasing the hydrophobicity. Although no 
comparison with chitosan has been shown, palmitoyl glycol chitosans were found to be less 
bioadhesive than hydroxypropylmethyl cellulose/carbopol control. The most hydrophobic 
palmitoyl glycol chitosan gel (20.31 ± 2.22 mol% palmitoylation) resulted in the slowest 






Figure 1.13 Synthetic pathway to palmitoyl glycol chitosan (Martin et al., 2002). 
 
Siew et al. (2012) developed nanoparticles based on quaternary ammonium palmitoyl glycol 
chitosan, which enhanced the oral absorption of both hydrophilic (ranitidine) and lipophilic 
drugs (griseofulvin and cyclosporine A). The bioavailability enhancement was believed to 
be due to a combination of increased drug dissolution rate (as a result of a great surface area 
of drug-loaded nanoparticles) and the mucoadhesive nature of chitosan, which increased the 
intestinal residence time of the nanoparticles, bringing them in close contact with the 
absorptive epithelial cells and thereby reducing the absorption barrier of the mucosal 
membrane (Siew et al., 2012). This is because the established adhesion of the nanoparticles 
to the mucus layer provides some degree of penetration into the mucosal membranes 
(Khutoryanskiy, 2011). 
1.4.6.2 Hexanoyl glycol chitosan 
Cho et al. (2016b) synthesized hexanoyl glycol chitosan by N-acylation of glycol chitosan 
(Figure 1.14). To do that, glycol chitosan was dissolved in water and then diluted with 
methanol. Then, various amounts of hexanoic anhydride were added and the reaction 
mixture was continuously stirred for 24 h. The hexanoyl-glycol chitosan was precipitated by 






Figure 1.14 Synthetic pathway to hexanoyl glycol chitosan (Cho et al., 2016b). 
 
Interestingly, hexanoyl glycol chitosan with 39.5 ± 0.4% degree of hexanoylation had a 
thermosensitive gelling property as it underwent gelation at 37 °C. The in vitro release study 
showed no significant difference between brimonidine-loaded hexanoyl glycol chitosan-
based formulation and the marketed eye drops (Alphagan P). However, the in vivo pre-ocular 
(inferior fornix of the eyes) retention study in rabbits revealed that hexanoyl glycol chitosan 
enhanced the retention of rhodamine in the pre-ocular tissues (Figure 1.15). The fluorescence 
signal from rhodamine was still strong after 60 min post administration, and became weak 
after 90 min. On the other hand, weak fluorescence signal was observed after only 10 min 
(and become weaker after 60 min) when both PBS (negative control) and unmodified glycol 
chitosan were used indicating their poor retention in pre-ocular tissues (Figure 1.15). 
Additionally, the intra-ocular pressure was significantly dropped and the therapeutic action 
was prolonged compared to unmodified glycol chitosan as well as conventional eye drops 






Figure 1.15 (a) Photograph of rabbit eyes showing the eyeball and the inferior fornix. (b) 
The fluorescence images of rabbit eyes at different time intervals after ocular 
administration of rhodamine-loaded PBS (RD-PBS), glycol chitosan (RD-GC) and 
hexanoyl glycol chitosan with 39.5 ± 0.4% degree of hexanoylation (RD-HGC 3). 
The eyeball and the inferior fornix (into which the formulations were administered) 
were shown by the black and white arrows, respectively. Scale bars are 5 mm. 
Reprinted from (Cho et al., 2016b) with permission of Elsevier. 
 
Subsequently, Cho et al. (2016a) have further modified hexanoyl glycol chitosan by reacting 
it with glycidyl methacrylate (Figure 1.16) to form methacrylated hexanoyl glycol chitosan, 
which demonstrated a thermo-reversible sol–gel transition behaviour in aqueous solutions. 
Moreover, the thermally-induced hydrogels could be chemically crosslinked by photo-
crosslinking under UV-radiation. Although no studies, to our knowledge, reported the 
mucoadhesive potential of methacrylated hexanoyl glycol chitosan, the presence of a 
methacrylated part within this polymer can potentially lead to a strong interaction with the 
mucin because of the covalent bonding between methacrylate part of methacrylated 
hexanoyl glycol chitosan and the thiol groups of the mucin components. 
 





1.4.7 Chitosan conjugates 
1.4.7.1 Chitosan-enzyme inhibitors 
These systems have been developed to protect orally administered peptide-based drugs from 
enzymatic degradation in the gastrointestinal lumen. Some mucoadhesive polymers 
including carbomer could also act as weak enzyme inhibitors (Akiyama et al., 1996), 
however, chitosan lacks this property. Examples of enzyme inhibitors include antipain, 
chymostatin, elastatinal and Bowman–Birk inhibitor (Bernkop-Schnürch  & Kast, 2001). It 
has been shown that enzyme inhibitors are toxic to certain types of cells. They also could 
induce pancreatic secretion of secretin and cholecystokinin in rats (Watanabe et al., 1992). 
These characters could limit the application of free enzyme inhibitors in the formulation of 
peptide-based drugs. However, covalent attachment of enzyme inhibitors to mucoadhesive 
polymers such as chitosan could reduce the unwanted effects as their absorption can be 
reduced. Bernkop-Schnürch et al. (1997) synthesized chitosan-antipain conjugate. The 
synthetic approach based on the formation of amide bond between carboxylic acid groups 
of enzyme inhibitors and the primary amino groups of chitosan which was mediated with 
EDAC and sulfo-N-hydroxysuccinimide. Chitosan-antipain conjugate not only showed 
mucoadhesive properties similar to unmodified chitosan, it also inhibited the action of 
trypsin. Tablets containing 5% chitosan-antipain conjugate protected insulin from trypsin 
inactivating effect. A sustained insulin release for 6 h was also achieved. 
1.4.7.2 Chitosan-complexing agent 
Ethylenediaminetetraacetic acid (EDTA) is a potent chelating agent and has US FDA 
approval for the treatment of heavy metal poisoning since 1950s (Song et al., 2014). 
Removal of ions has been shown to enhance the permeation of antiviral drugs such as 
dolutegravir across Caco2 cells monolayer and rat intestinal mucosa ex vivo (Grießinger et 
al., 2016). EDTA is also able to decrease pre-systemic metabolism of peptide-based drugs 
by inhibiting brush border membrane bound enzymes by their deprivation of ions such as 
Zn2+ in the mucous membrane (Bernkop-Schnürch  & Kast, 2001; Netsomboon et al., 2017). 
However, the rapid biodistribution of EDTA limits this application. Thus, chitosan-based 
EDTA system has been developed which has mucoadhesive properties on one side and metal 
chelating ability on the other side (Bernkop-Schnürch & Scerbe-Saiko, 1998 ; Netsomboon 





Compared to unmodified chitosan, chitosan-EDTA tablets showed better retention on 
porcine intestinal mucosa. The mucoadhesive strength decreased with the reduction of the 
% of EDTA attached to chitosan. It also inhibited Zn- and Co-dependent proteases including 
carboxypeptidase A and aminopeptidase N. This is because chitosan-EDTA conjugate 
strongly bound to Zn and Co. (Bernkop-Schnürch & Krajicek, 1998). 
S-protected thiolated chitosan-EDTA has also been synthesized to combine the advantages 
of EDTA, thiolation and pre-activation or protection of thiol groups. The synthetic pathway 
is shown in Figure 1.17 (Netsomboon et al., 2017). The multifunctional thiolated chitosan 
exhibited 5.6- and 3.6-fold longer residence time on porcine intestinal mucosa compared to 
chitosan-EDTA and chitosan-EDTA-cysteine, respectively (Figure 1.18). 
 
Figure 1.17 Synthetic pathway to chitosan-EDTA-cysteine-2-mercaptonicotinamide 






Figure 1.18 Mucoadhesion time of mini-tablets containing 30 mg of Ch-EDTA, Ch-EDTA-
cys or Ch-EDTA-cys-2MNA studied by rotating cylinder method using porcine 
intestinal mucosa. Ch: chitosan, cys: cysteine, 2MNA: 2-mercaptonicotinamide. 
(Mean ± SD, n = 5, * denotes statistical significant difference at p < 0.05). Reprinted 
from (Netsomboon et al., 2017) with permission of Elsevier. 
 
1.4.7.3 Chitosan-EDTA-enzyme inhibitors 
By combining enzyme inhibitors and complexing agents coupled with chitosan, the 
degradation of peptide-based drugs by the gut luminal enzymes could be significantly 
minimized (Bernkop-Schnürch & Scerbe-Saiko, 1998 ). Additionally, as EDTA could bind 
to ions such as Zn2+ and Ca2+, the concentration of free forms of these ions can be reduced. 
This decreases the formation of non-absorbable complexes between some drugs and these 
ions leading to enhanced drug permeation (Song et al., 2014; Grießinger et al., 2016). Thus, 
chitosan-EDTA-serine protease inhibitors were synthesized using a two-step approach. First, 
to form chitosan-serine protease inhibitors, covalent attachment of antipain, chymostatin and 
elastatinal to chitosan was performed. Second, chitosan-enzyme inhibitors were bound to 
EDTA. Tensile study using porcine intestinal mucosa demonstrated that the mucoadhesive 
strength of the chitosan-EDTA-serine inhibitor was lower than both chitosan-EDTA and 
chitosan. The reduction of the mucoadhesion of chitosan-EDTA-serine protease inhibitors 
could be due to the substitution of the free amino groups of chitosan or chitosan-EDTA upon 






1.4.8 Chitosan-catechol (Chi-C) 
Catechol is a naturally occurring compound. It is an essential component of L-3,4-
dihydroxyphenylalanine (L-DOPA), which is an amino acid secreted by certain marine 
mussels (e.g., Mytilus edulis), which have ability to adhere to various substrates under wet 
conditions (Kim et al., 2015). This adhesive property is mainly linked to the ability of 
catechol to form covalent and non-covalent bonds to different organic, inorganic, and 
metallic surfaces (Ryu et al., 2011; Kim et al., 2013). Generally, chitosan-catechol can be 
synthesized by chemical, electrochemical and enzymatic methods. The chemical method 
includes three main approaches: amide bond formation using carbodiimide chemistry 
(Figure 1.19), reductive amination using aldehyde-terminated catechol and reducing agents 
such as NaCNBH3 or NaBH4, and formation of catechol-amine adducts using oxidizing 
agents such as NaIO4 (Kim et al., 2015; Ryu et al., 2015). 
Inspired by mussel adhesion to surfaces, Kim et al. (2015) synthesized chitosan-catechol 
conjugate by reacting chitosan with 3,4-dihydroxy hydrocinnamic acid mediated with 
EDAC (Figure 1.19). Mucoadhesion was evaluated in vitro using mucin-particle interaction, 
turbidimetry, surface plasmon resonance (SPR) spectroscopy and rheological 
characterization as well as in vivo fluorescence imaging technique and fluorescence 
measurement in various organs of mice. Chitosan-catechol conjugate showed superior 
mucoadhesion than both unmodified chitosan and polyacrylic acid. The in vivo study 
explored the difference in the retention of different polymers in different body sites. No 
fluorescence was detected in organs lacking mucosal tissues including liver, spleen, and 
kidney (Figure 1.20). However, at 3 h post-oral administration, strong fluorescence signal 
from chitosan-catechol conjugate in intestinal tissues was observed (Figure 1.20). This could 
be due to the formation of strong covalent bonds via Michael-type addition reaction upon 
the reaction of oxidized form of catechol (quinone) and amine or thiol functionalities of 
mucins or Schiff base formation reaction (Kim et al., 2015). The electrostatic attractive 
interaction between the positively charged groups of chitosan and negatively charged 
carboxyl and sulfate groups of mucin could lead to an initial contact stage and the adsorption 
of chitosan-catechol macromolecules on the mucosal surfaces. This was then followed by an 
established consolidation stage via the covalent interaction (Smart, 2005; Kim et al., 2015). 
Unmodified chitosan and polyacrylic acid showed poor fluorescence signal. The retention 
of chitosan-catechol conjugate decreased significantly in both stomach and esophagus. The 





pH of mucin solution was 7 compared to pH 2 (Kim et al., 2015). This might explain better 
retention in small intestine, where pH is near neutral compared to poor retention in stomach 
(highly acidic) and esophagus (slightly acidic, pH 4–6) (Kim et al., 2015). The oxidation of 
catechol to quinone in alkaline environment is more likely than in acidic environment, which 
could provide additional adhesive interactions (Lee et al., 2006; Ryu et al., 2011; Kim et al., 
2015). On the other hand, polyacrylic acid showed slightly greater mucoadhesion to 
esophagus than stomach and intestine (Figure 1.20-C). The difference in the pH of these 
organs might explain this observation as it may affect the structures of both polyacrylic acid 
and the mucus layer resulting in a different nature and extent of mucoadhesive interactions 
at different pHs (Patel et al., 2003). Some studies reported that the mucoadhesive nature of 
polyacrylic acid may be due to its ability to form hydrogen bonds with the mucus 
components (Riley et al., 2001; Patel et al., 2003; Albarkah et al., 2015; Kim et al., 2015), 
which is strongest at slightly acidic pHs, depending on the type of the polymer (Mortazavi 
et al., 1993; Riley et al., 2001). However, Kim et al. (2015) suggested further studies to 
investigate the organ-specific mucoadhesive properties of chitosan, chitosan-catechol and 
polyacrylic acid. Chitosan-catechol conjugate also enhanced the oral bioavailability of 
insulin and Cmax reached after 2 h compared to unmodified chitosan which was 30 min 
(Figure 1.20-D). 
 







Figure 1.20 Chitosan-fluorescein isothiocyanate (Chi-FITC), polyacrylic acid-fluorescein-
5-thiosemicarbazide (PAA-FTSC) and chitosan-catechol-fluorescein 
isothiocyanate (Chi-C-FITC) were orally administered to BALB/c mice and the 
animals were euthanized after 3 or 10 h. (A) The extracted organs were imaged 
using in vivo imaging system. (B) The relative fluorescence intensity of Chi-FITC, 
PAA-FTSC and Chi-C-FITC in the gastrointestinal tract (esophagus, stomach and 
intestine) at 10 h after administration. (C) The fluorescence in the liver, spleen, 
kidneys, esophagus, stomach, and small/large intestine at 10 h after administration 
are shown (mean ± SD, n = 3 mice/time point). (* denotes statistical significant 
difference at p < 0.05, ** indicates p < 0.005). (D) The human-insulin (closed 
triangle), h-insulin/chitosan (closed circle) and h-insulin/chitosan-catechol (open 
circle) were orally administered to Wistar rats and blood insulin concentration was 
measured using enzyme-linked immunosorbent assay (ELISA) (n = 4 rats/time 
point). Reprinted from (Kim et al., 2015) with permission of Elsevier. 
 
1.4.9 Methyl Pyrrolidinone Chitosan 
Methyl pyrrolidinone chitosan can be synthesized by reacting chitosan with levulinic acid 
(Figure 1.21) (Muzzarelli, 1992; Muzzarelli et al., 1993). Specific experimental conditions 
including pH of the reaction mixture, type and the rate of addition of reducing agents 
(NaCNBH3 or NaBH4), molar ratio of levulinic acid/chitosan/reducing agents are required 





(Rinaudo et al., 2001; Kurita & Isogai, 2010). Sandri et al. (2004) studied the mucoadhesive 
and penetration enhancing properties of various chitosans including 5-methyl pyrrolidinone 
chitosan, low molecular weight chitosan, a partially re-acetylated chitosan and chitosan HCl 
using buccal or submaxillary bovine mucin dispersion, vaginal mucosa or porcine gastric 
mucin dispersion. It was found that different chitosans behaved differently in different 
substrates. In submaxillary mucin dispersion, chitosan HCl was the most mucoadhesive. 
However, 5-methyl pyrrolidinone chitosan showed the greatest mucoadhesion among other 
polymers in all other studied substrates and provided the greatest permeation of acyclovir 
through porcine cheek mucosa and deepest penetration into the vaginal mucosa. This could 
be due to the penetration enhancing effect of 5-methyl pyrrolidinone, which has been 
demonstrated in other studies (Sasaki et al., 1991; Kim et al., 1993). 
 
Figure 1.21 Synthetic pathway to 5-methyl pyrrolidinone chitosan. 
 
1.4.10 Cyclodextrin-chitosan 
Cyclodextrins can enhance solubility and dissolution of poorly water-soluble drugs by 
forming inclusion complexes. In 2001, the idea of grafting cyclodextrin to chitosan was 
adopted by Auzély-Velty and Rinaudo (2001), who used a reductive amination approach, 
where a solution of chitosan in acetic acid/methanol was reacted with aldehyde-containing 
cyclodextrin derivative in the presence of sodium cyanoborohydride (NaCNBH3). The 
reaction was mediated with EDAC. The inclusion ability of the grafted-cyclodextrin was 
studied using NMR spectroscopy and found that it could form inclusion complexes with two 
model compounds tert-butylbenzoic acid and (+)-catechin. 
In 2006, Venter et al. (2006) studied the mucoadhesion of this cyclodextrin-chitosan 
derivative by tensile separation test (microbalance method) using partially purified porcine 
gastric mucin type III (Sigma, UK) as a substrate. Figure 1.22 shows the experimental set-
up for the mucoadhesion study. Briefly, the aluminum plates of the apparatus were coated 





solution (30% w/v) was prepared and placed in a water bath (25 °C). The polymer-coated 
plate was lowered to contact with the mucin solution for 2 min. Then, the maximum 
detachment force to separate the polymeric films from the mucin solution was measured 
using a computerized system. It was found that upon derivatization, chitosan lost its 
mucoadhesive properties by 13.5%, but, it was 12% stronger than pectin. 
In another study, Chaleawlert-umpon et al. (2011) synthesized citrated cyclodextrin-g-
chitosan. In this study, citric acid was used to facilitate cyclodextrin mobility. Glycidyl 
trimethylammonium chloride was also used to quaternize chitosan. The mucoadhesion study 
using mucin-particle interaction method and SPR revealed that combination of 
quaternization and citrate modification led to a significant enhancement in the mucoadhesive 
interactions. This could be due to an increase in the cationic charge of chitosan as well as 
hydrogen bonding between carboxyl and hydroxyl groups of the spacer and the mucus 
components. 
 
Figure 1.22 Experimental set-up for evaluation of mucoadhesion using microbalance method 
according to Venter et al. (2006) with some modifications. 
 
1.4.11 Oleoyl-quaternised chitosan 
Yostawonkul et al. (2017) developed a nanostructure lipid carrier for the delivery of 
lipophilic drug molecules using high-pressure homogenization technique. They found 
coating of these carriers with oleoyl-quaternised chitosan enhanced carcinoma Caco-2 
cellular uptake of the model drug (alpha-mangostin). This enhancement could be due to the 
mucoadhesive properties of oleoyl-quaternised chitosan, which was evaluated by mucin-
particle interaction method. However, cytotoxicity of the carriers was also increased and 






1.5 Comparison of different chitosan derivatives 
Table 1 illustrates the advantages and disadvantages of different chitosan-based systems 
reported in the literature together with the drug model, administration routes and mucus 
substrates types that were used to evaluate them. 
Table 1.1 A summary of chitosan derivatives properties with examples of drug candidates 
used in the mucoadhesive drug delivery evaluation. 
Chitosan 
Derivatives 






Soluble at broad range of pHs (2-12), 
strong mucoadhesion; decreased 
TEER; increased paracellular 












nasal mucosa  
(Sieval et al., 
1998; Thanou 







Decreased TEER; increased 
paracellular permeability of anionic 
macromolecules 
Insoluble at pH 3-
7 (depending on 










Oral, rat small 
intestine; 
Ocular, rabbit 
eyes, in vivo 
(Chen & Park, 
2003; Di Colo 
et al., 2004; 




Same mucoadhesion as unmodified 
chitosan, improved cohesion 
compared to unmodified chitosan, 





reactions led to 


















50-fold longer retention time than 
unmodified chitosan, biodegradability 
as indicated by the reduction of its 
solution viscosity after addition of 












Controlled drug release, longer 
disintegration time (up to 100-fold) 
and 26-fold longer mucoadhesion 
time against unmodified chitosan 
Need of mediator 














Strong mucoadhesion, permeation 
enhancing effect, controlled release, 





















Much quicker synthetic reaction rate 
than chitosan-TBA (1.5 h vs 24 h), 
8.9-fold longer mucosal detachment 
time than unmodified chitosan, 
controlled release, no cyclisation side 











Improved stability compared to 
unmodified chitosan, enhanced 
mucoadhesion (9.9-fold increased 
adhesion force and 55-fold longer 
adhesion time), 4.9-fold higher 
permeation-enhancing effect against 
unmodified chitosan, used as 
oxidative stress suppressant 
Stability issues Thymopen
tin 
Oral, tablets, in 








al., 2005a; Jin 
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Improved stability and mucoadhesion 
compared to unmodified chitosan and 



















Strong mucoadhesion, water-soluble Use of low 
molecular weight 
PEGDA results in 
a weaker 
mucoadhesion  









Better solubility at higher pH (up to 
7.4) compared to unmodified 
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1.6 Conclusions 
In this review, general methods of synthesis of potential mucoadhesive chitosan derivatives 
have been highlighted. Some properties of chitosan and chitosan derivatives have been 
discussed. These include solubility profile, stability, mucoadhesive and permeation 
enhancing effects. The mucoadhesive properties of the derivatives have been particularly 
considered. It was shown that the mucoadhesive properties of some derivatives have been 
significantly increased compared to unmodified chitosan. In the majority of cases, this 
resulted in an enhancement in the bioavailability and a significant improvement of the 
therapeutic efficacy of several candidate drugs compared to unmodified chitosan. In some 
others, the mucoadhesive character either did not change or slightly decreased. This 
however, was compensated with an improvement of other important chitosan properties 
including solubility in physiological pH and cohesiveness, which are crucial parameters in 
mucoadhesion. Therefore, improvement in the properties of chitosan derivatives discussed 
in this review clearly demonstrate that its chemical modification could potentially lead to 
further advances in transmucosal drug delivery. However, chemical modification of chitosan 
has limitations. These include low reproducibility, especially with hydrophobically-
modified chitosans, poor solubility of chitosan in organic solvents used for the synthesis and 
changes with the degree of acetylation during chemical modification. 
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This chapter outlines the aims and the objectives of this thesis. Then, it provides an 
introduction to the silica nanoparticles, a brief explanation of the common methods of 
preparation of silica nanoparticles and highlights their potential in mucosal drug delivery. 





















2.1 Aims and objectives of this thesis 
The aim of this thesis was to develop mucoadhesive and mucus-penetrating nanoparticles 
for oral and nasal mucosal drug delivery. The objectives were as follows: 
1. To test the hypothesis that thiolated silica nanoparticles are mucoadhesive in the rat 
intestinal mucosal model and functionalisation of these nanoparticles with 
hydrophilic polymers reduces their mucoadhesiveness. Therefore, three types of 
silica nanoparticles with different surface functionalities (thiolated, PEGylated and 
POZylated) were synthesised. The mucoadhesive properties of these nanoparticles 
were evaluated using rat intestinal mucosa in vitro.  
2. To test the hypothesis that nanoparticles prepared from a more hydrophilic chitosan 
(modified chitosan) diffuse faster in bovine submaxillary mucin (BSM) solution and 
penetrate deeper into nasal mucosa compared to the nanoparticles prepared from 
unmodified chitosan. To this end, different chitosan nanoparticles were prepared 
using ionic gelation between unmodified or four different modified chitosan 
(polyethylene glycol (PEG)-, polyhydroxyethyl acrylate (PHEA)-, poly-2-ethyl-2-
oxazoline (POZ)- and polyvinyl pyrrolidone (PVP)-chitosan) and TPP. The diffusion 
of chitosan nanoparticles in BSM solution was evaluated using nanoparticle tracking 
analysis. Their ability to penetrate into sheep nasal mucosa was evaluated using 
fluorescence microscopy.  
3. To explore the possibilities of loading centrally acting drugs (haloperidol and 













2.2 Introduction  
Among inorganic nanomaterials, silica nanoparticles have attracted a particular attention in 
nanomedicine. Basically, silica nanoparticles can be classified into nonporous (solid) and 
mesoporous (with 2-50 nm pore size) both with amorphous silica structure (Tang & Cheng, 
2013). Mobil Crystalline Materials-41 (MCM-41) is a type of mesoporous silica 
nanoparticles which has been extensively used in drug delivery (Slowing et al., 2008; Tang 
et al., 2012; Manzano & Vallet-Regí, 2018; Narayan et al., 2018). Figure 2.1 shows the 




Figure 2.1 Transmission electron microscopy image of (A) nonporous and (B) mesoporous 
(MCM-41) silica nanoparticles. Reprinted from (Liu et al., 2015) and (Manzano & 
Vallet-Regí, 2018) with permission of Dove Medical Press and Springer US, 
respectively. 
 
Generally, both types of silica nanoparticles have similar composition, however, 
mesoporous silica nanoparticles have a porous structure, lower density and a larger effective 
surface area compared to the nonporous counterpart (Tang et al., 2012). Due to these unique 
features, silica nanoparticles provide high loading efficiency and are considered as 
promising nanocarriers for various agents including, small molecules, macromolecules and 
vaccines (Wang et al., 2012). Depending on the silica source, silica nanoparticles can also 
be categorised into inorganic (prepared from pure alkoxysilanes typically 
tetraethylorthosilicate (TEOS)) and organosilica (from substituted alkoxysilanes, R-
Si(OR′)3) nanoparticles (Du et al., 2009). Silica exists in nature abundantly and is generally 





et al., 2012). Additionally, silica nanoparticles are biocompatible, can be prepared by 
relatively simple methods using basic laboratory equipment, and can be functionalised using 
varieties of polymers and fluorescent dyes. 
Due to the insolubility of silica and its stability in the harsh gastrointestinal environment 
(gastric acid and proteases), silica nanoparticles can potentially be used to protect molecules 
such as enzymes, DNAs and RNAs that are liable to degrade in such environment, and can 
potentially control their release (Slowing et al., 2008; Wang et al., 2012). This can be an 
advantage over the biodegradable nanocarriers including polymeric nanoparticles and 
liposomes, due to their “soft” unstable structure, the drugs would leak out of the carriers 
once they become in contact with the physiological environment resulting in a premature 
drug release. This, in most cases, will lead to ineffective therapeutic outcomes and the failure 
of the site-specific delivery of the drugs (Slowing et al., 2008).  
2.3 Common methods of preparation of silica nanoparticles  
Traditionally, silica nanoparticles are prepared using the Stöber method (Stöber et al., 1968) 
in which TEOS is used as a silica source, water and ethanol as solvent and ammonia as a 
catalyst (Figure 2.2). 
 
 
Figure 2.2 A reaction scheme showing the synthesis of silica nanoparticles from TEOS. 
 
Other silica source such as tetramethoxysilane (TMOS), tetrakis-2-
hydroxyethylorthosilicate and trimethoxyvinylsilane have been used in the synthesis of silica 
nanoparticles (Narayan et al., 2018). Several modifications of the Stöber method have been 
made in order to obtain particles with specific physicochemical properties for example size, 
polydispersity index, shape and surface functionalities (Rao et al., 2005; Guo et al., 2018). 





concentration of the precursor, the type of the solvent and the catalyst and the reaction 
temperature (Rao et al., 2005; Tang et al., 2012; Gao et al., 2016; Guo et al., 2018). To 
prepare mesoporous silica nanoparticles surfactants as structure directing agents including 
cetyltrimethylammonium bromide (CTAB) and cetyltrimethylammonium chloride (CTAC) 
are added to the reaction mixture allowing the condensation of the silica precursors in these 
templates. At the final step, the surfactants will be removed leaving a porous silica 
nanostructure (Qiao et al., 2009; Lin & Haynes, 2010). Also, pore-expanding agents 
including alkanes are used to increase the size of the pore as a method to enhance the loading 
efficiency of the particles (Kao & Mou, 2013). The morphology of the mesoporous silica 
nanoparticles can be tailored by changing the ratio of the reactants, for instance, doubling 
the concentration of TEOS, CTAB and NaOH, kept the pore structure and pore size while 
resulted in the formation of tubes instead of regular sphere silica nanoparticles (Huh et al., 
2003). 
Nakamura and Ishimura (2007) synthesised thiolated organosilica nanoparticles from 
organosilicate (3-mercaptopropyltrimethoxysilane, MPTS) using the Stöber method. Later, 
they reported the possibilities of formation of silica nanoparticles using other organosilicates 
(3-mercaptopropyltriethoxysilane and 3-mercaptopropylmethyldimethoxysilane) using the 
Stöber method (with ethanol) and a complete aqueous synthetic technique (without ethanol) 
(Nakamura & Ishimura, 2008a). These types of the nanoparticles have abundant internal and 
surface thiol groups enabling their modification with fluorescent dyes and various 
biomolecules via thiol-maleimide chemistry (Nakamura & Ishimura, 2008b). However, they 
observed that all these types of organosilica nanoparticles had a wide size distribution 
(Nakamura & Ishimura, 2007, 2008a). In 2010, they found that performing the synthetic 
reaction at high temperature (100 °C) instead of room temperature could narrow the size 
distribution of the MPTS silica nanoparticles  (Nakamura et al., 2010). 
Silica nanoparticles can also be synthesised using reverse microemulsion method where the 
silica source (TEOS or TMOS) is added to a preformed water-in-oil emulsion  (Osseo-Asare 
& Arriagada, 1990). Again here, the size of the nanoparticles can be tuned by the 
composition and the pH of the aqueous phase, changing the type of emulsifier, water to 
emulsifier ratio, amount of TEOS and the type of organic solvent comprising the organic 





2.4 Applications of silica nanoparticles in mucosal drug delivery  
Silica nanoparticles have a range of potential applications including drug delivery (mucosal 
and controlled delivery) (Wani et al., 2012; Florek et al., 2017; Maleki et al., 2017; 
Watermann & Brieger, 2017; M. Ways et al., 2018), diagnostics (Cha & Kim, 2019) and 
tissue engineering (mainly for bone) (Rosenholm et al., 2016; Yang et al., 2018). This section 
highlights some of the studies involving silica nanoparticles for mucosal drug delivery. 
There are several obstacles in mucosal drug delivery, which include luminal (pH and 
enzymes), mucus and epithelial barriers. The use of nanoparticles have been studied as an 
approach to overcome these barriers (Laffleur & Bernkop-Schnürch, 2013; Florek et al., 
2017). Among these, silica nanoparticles have been studied as a potential nanocarrier for 
mucosal drug delivery.  
Thiolated silica nanoparticles with the size of ~ 50 nm were synthesised by our group using 
MPTS as a silica source, NaOH as a basic catalyst and DMSO as a solvent (Irmukhametova 
et al., 2011). The size of these nanoparticles can be tuned by changing the synthetic 
conditions (Al Mahrooqi et al., 2018). The particles can be functionalised with polyethylene 
glycol (PEG) (Irmukhametova et al., 2011), poly-2-ethyl-2-oxazoline (POZ) (Mansfield et 
al., 2015) and hydroxyethylcellulose (Mansfield et al., 2018). These nanoparticles exhibited 
mucoadhesive properties in vitro on bovine cornea (Irmukhametova et al., 2011), porcine 
bladder mucosa (Mun et al., 2016) and rat intestinal mucosa model (M. Ways et al., 2018). 
Their mucoadhesiveness was decreased upon their PEGylation (Irmukhametova et al., 2011; 
Mun et al., 2016) and POZylation (M. Ways et al., 2018), however, these resulted in an 
enhancement of their diffusion in porcine gastric mucin dispersion and penetration into 
porcine gastric mucosa (Mansfield et al., 2015). Mun et al. (2014) showed that neither 
thiolated nor PEGylated (with 750 and 5000 Da PEG) silica nanoparticles penetrated the 
intact bovine cornea. They also revealed that thiolated silica nanoparticles did not penetrate 
the de-epithelialised cornea which could be due to the interactions of their thiol groups with 
the cysteine domains of the corneal stroma. Also, PEGylated (with 750 Da PEG) silica 
nanoparticles did not penetrate the de-epithelialised cornea as they contained some 
remaining thiol groups available for binding with the cysteine domains of the stroma. 
However, PEGylated (with 5000 Da PEG) silica nanoparticles penetrated the de-
epithelialised cornea, which could be due to the substitution of a larger number of thiol 
groups with PEG (compared to PEGylated nanoparticles with 750 Da PEG), decreasing the 





Zhang et al. (2014) synthesised β-cyclodextrin modified mesoporous silica nanoparticles 
with three different surface functionalities namely hydroxyl, amino and thiol groups. They 
investigated the mucoadhesive properties of these nanoparticles using particle-mucin 
interaction (the size of the mixture of mucin suspension and the nanoparticles suspension 
measured by dynamic light scattering). This was also supported by confocal microscopic 
study of porcine bladder mucosa exposed to the fluorescein isothiocyanate-labelled 
nanoparticles followed by washing with artificial urine. They found that the thiol-
functionalised silica nanoparticles had a superior mucoadhesiveness compared to both 
amine- and hydroxyl-functionalised counterparts. This was evident from a higher change in 
the size of the thiol-functionalised silica nanoparticles compared to amine- and hydroxyl-
functionalised nanoparticles upon mixing with mucin suspension. Also, the mucoadhesion 
study showed a stronger fluorescence signal (only images without quantitative analysis are 
provided in their paper) from thiol-functionalised silica nanoparticles compared to amine- 
and hydroxyl-functionalised counterparts. Additionally, the thiol-functionalised silica 
nanoparticles provided a sustained doxorubicin release, and shown to be slower at the pH of 
artificial urine (6.1) compared to the pH of phosphate buffer solution (7.4) (~ 13% and 63% 
cumulative release after 48 hours, respectively) (Zhang et al., 2014).   
Several studies demonstrated that uncoated undecylenic acid  modified  thermally  
hydrocarbonized  porous  silica (UPS) nanoparticles interact weakly  with Caco-2/HT29-
MTX (mono- and co-culture) cells, possibly due to the negatively charged surfaces of the 
nanoparticles. However, this interaction was enhanced when UPS nanopartilces were coated 
with chitosan either with physical adsorption or chemical conjugation, which they related to 
the fact that chitosan can adhere to the mucus secreted by HT29-MTX cells (Araújo et al., 
2014; Shrestha et al., 2015).  Shrestha et al. (2016) modified UPS nanoparticles with chitosan 
and then these were further modified with either cysteine or cell penetrating peptide (CPP) 
to generate cysteine-functionalised (cysteine-UPS) or CPP-functionalised (CPP-UPS) 
nanoparticles, respectively. They showed  that both types of cysteine-UPS and CPP-UPS 
nanoparticles enhanced the intestinal permeation of insulin through triple coculture of Caco-
2, HT29-MTX and Raji B cells monolayers. In case of cysteine-UPS nanoparticles, this was 
due to the presence of thiol groups in the structure of the nanoparticles, which form disulfide 
bonds with cysteine rich domain of the mucus glycoproteins. However, in case of CPP-UPS 
nanoparticles, the cell penetrating ability of CPP was the major reason for the enhanced 





enhanced the insulin oral bioavailability in a type 1 diabetic rat model, which they related to 
the possible degradation of the peptide layer of CPP-UPS nanoparticles by the rats 
gastrointestinal tract (GIT) luminal enzymes or the different nature of the mucus barrier of 
the in vivo model compared to the in vitro cells model (Shrestha et al., 2016). 
Sarparanta et al. (2012) showed the strong mucoadhesion of hydrophobin-functionalised 
porous silica nanoparticles in an in vitro model of human adenocarcinoma cells, possibly 
due to the electrostatic and hydrophobic interactions between specific amino acid residues 
of hydrophobin and the mucus components of the cells. Additionally, the authors suggest 
the formation of disulfide bonds between the cysteine residue of hydrophobin and the thiol 
groups of mucus glycoprotein. The in vivo study in rats showed that these nanoparticles 
could actually retain in the glandular part of the stomach for up to 3 hours, due to their 
adhesion to the loosely bound mucus layer, followed by their transit into the small intestine. 
The organ-specific affinity of functionalised silica nanoparticles was also shown by other 
researchers.  For example, in an in vivo study in mice, Desai et al. (2016) showed that 
polyethylene imine (PEI)-functionalised silica nanoparticles had a greater affinity to the 
small intestine whereas combined PEG-PEI-functionalised silica nanoparticles to the colon. 
Such types of nanoparticles have the potential applications in the design of targeted drug 
delivery systems for drugs like antibiotics and anticancer used for the treatment of various 
GIT diseases including infections and cancers. 
The effect of hydrophilic polymers on the interaction of silica nanoparticles with mucin was 
also investigated by other researchers. Andreani et al. (2015) revealed that both alginate and 
chitosan coated silica nanoparticles interact strongly with mucin particles (evident by the 
reduction of the zeta potential of the nanoparticles after dispersing them in mucin solution), 
whereas both non-coated and PEG coated nanoparticles showed a weak interaction. This 
may indicate the ability of non-coated and PEG coated silica nanoparticles to diffuse into 
the mucus network.  
Liu et al. (2013) studied mesoporous silica nanoparticles as a dual-drug loaded carrier for a 
hydrophobic (indomethacin) and a hydrophilic (human peptide, PYY3-36) compound. They 
found that the presence of PYY3-36 in the indomethacin /PYY3-36 loaded silica 
nanoparticles increased the permeation of both indomethacin and PYY3-36 through co-





by HT29 cells, leading to the cell-silica nanoparticles interactions resulting in a high local 
drug concentration close to the cells monolayers. 
Several other studies demonstrated the potential of silica nanoparticles in mucosal drug 
delivery. Few examples are illustrated in Table 2.1. 
Table 2.1 Some examples of mucosal drug delivery using silica nanoparticles in the 
literature. 
Drugs Potential treatments Routes of 
administration 
Models Advantages References 
5-amino 
salicylic acid  
Inflammatory 
bowel disease 
Oral In vivo 
mice 
Delayed  drug release and targeted 
delivery to the  inflamed tissues 




Type 2 diabetes 
mellitus 
Oral  In vitro 
intestinal 
cells 
Chitosan coated silica 
nanoparticles provided high drug 
loading capacity, sustained drug 
release and enhanced drug 
permeation 
(Araújo et al., 
2014) 
Curcumin  Neurodegenerative 
diseases 




Bypassing blood brain barrier, 






2.5 Safety concerns and biodistribution of silica nanoparticles 
The safety and biodistribution of silica nanoparticles are controversial and found to be highly 
dependent on the size, shape, surface properties, the types of cells or animals, the dose and 
the methods of administration. Using the everted gut sac method, Yoshida et al. (2014) 
demonstrated that silica nanoparticles with various sizes (70, 300 and 1000 nm)  and surface 
functionalities (carboxyl or amine groups) were absorbed by the rat small intestine. 
However, they observed no abnormalities in mice after 28-days oral exposure to these 
nanoparticles indicated by blood biomarkers, histopathology examination of the liver, 
kidney, brain, lung, spleen, heart, stomach and intestine and hematological analysis. Using 
transmission electron microscopy, Yoshida et al. (2013) found that following nasal 
administration of  silica nanoparticles in mice (20 μL, at a concentration of 500 μg/mouse 
daily for 7 days), the particles with a size of 30, 70 and 100 nm were absorbed by the nasal 





detected in the nasal cavity and lung, however, 300 nm particles were only detected in the 
lung. Both 300 and 1000 nm particles were not detected the liver. Yoshida et al. (2013) did 
not provide any explanation on the difference observed with the biodistribution of these 
nanoparticles, but suggested that the transmission electron microscopy is only a qualitative 
method and thus no quantitative data can be obtained. They also hypothesised the 
possibilities of degradation of the larger nanoparticles (300 nm and 1000 nm) in the 
biological environment, leading to a smaller size nanoparticles compared to the size of the 
administered nanoparticles (Yoshida et al., 2013), which could be a reason for the inability 
to detect these nanoparticles in the liver.  Only 30 and 70 nm nanoparticles prolonged the 
bleeding time of mice compared to the control, whereas no adverse biological effects was 
observed with the other nanoparticles (Yoshida et al., 2013).  
In rats, subcutaneous injection of mesoporous silica particles (150-4000 nm) had no toxicity, 
however, intravenous and intraperitoneal injections in mice led to the death of the animals 
possibly due to pulmonary thrombosis (Hudson et al., 2008).  The oral and ocular 
administration of nonporous silica nanoparticles to rats for 12 weeks was found to be safe 
(Kim et al., 2017).  
Li et al. (2015) observed possible renal impairment with sphere-like mesoporous silica 
nanoparticles but not with rod-like mesoporous silica nanoparticles when orally 
administered to mice. They also reported that the silica nanorods were mainly accumulated 
in the liver and spleen of the mice, whereas the silica nanospheres were mainly found in the 
spleen. Some other investigators revealed the impact of silica nanoparticles shape on their 
toxicity, biodistribution and biocompatibility (Huang et al., 2011; Yu et al., 2011; Zhao et 
al., 2017) 
2.6 Conclusion 
Silica nanoparticles are promising drug nanocarriers for mucosal drug delivery. They have 
several advantages including their relatively simple methods of preparation, surface 
functionalisation, controlling the size and shape, high drug loading and controlled drug 
delivery. Silica nanoparticles were generally found to be relatively safe, however, some 
studies have pointed out some safety concerns, suggesting further investigation is needed 
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In this study, we synthesised thiolated silica nanoparticles using 3-
mercaptopropyltrimethoxysilane and functionalised them with either 5 kDa methoxy 
polyethylene glycol maleimide (PEG) or 5 kDa alkyne-terminated poly(2-ethyl-2-oxazoline) 
(POZ). The main objectives of this study are to investigate the effects of pH on the size and 
ξ-potential of these nanoparticles and evaluate their mucoadhesive properties ex vivo using 
rat intestinal mucosa. The sizes of thiolated, PEGylated and POZylated silica nanoparticles 
were 53 ± 1, 68 ± 1 and 59 ± 1 nm, respectively. The size of both thiolated and POZylated 
nanoparticles significantly increased at pH ≤ 2, whereas no size change was observed at 
pH 2.5–9 for both these two types of nanoparticles. On the other hand, the size of PEGylated 
nanoparticles did not change over the studied pH range (1.5–9). Moreover, thiolated 
nanoparticles were more mucoadhesive in the rat small intestine than both PEGylated and 
POZylated nanoparticles. After 12 cycles of washing (with a total of 20 mL of phosphate 
buffer solution pH 6.8), a significantly greater amount of thiolated nanoparticles remained 
on the intestinal mucosa than FITC-dextran (non-mucoadhesive polymer, p < 0.005) and 
both PEGylated and POZylated nanoparticles (p < 0.05 both). However, both PEGylated and 
POZylated nanoparticles showed similar retention to FITC-dextran (p > 0.1 for both). Thus, 
this study indicates that thiolated nanoparticles are mucoadhesive, whereas PEGylated and 
POZylated nanoparticles are non-mucoadhesive in the ex vivo rat intestinal mucosa model. 







3.1  Introduction 
Oral drug delivery is the preferred administration route for most drugs, as it has several 
advantages over other routes, including better patient adherence (especially for chronic 
diseases) and possibilities for flexible dosing (Date et al., 2016). In addition, oral dosage 
forms generally cost less to manufacture than other formulations (e.g. injectable, eye drops 
and inhalators) as they do not require sterilisation (Yun et al., 2013; Date et al., 2016) or use 
of complex delivery device. However, about 70% of new drugs do not reach pre-clinical 
development due to low bioavailability resulting from poor oral absorption (Gao et al., 
2013). Drug absorption in the gastrointestinal tract (GIT) is hampered by a number of 
physiological barriers, including the mucus, the harsh pH and digestive environment of the 
GIT, tight junctions, epithelial cells and sub-epithelial tissues (Lundquist & Artursson, 
2016).  
Mucus is a viscous gel secreted by goblet cells, which are found in various organs, including 
the eye (Kessler & Dartt, 1994), the GIT (Deplancke & Gaskins, 2001)  and the respiratory 
tract (Spicer et al., 1983). It consists mainly of water (~ 95%), alongside cross-linked and 
entangled mucin fibres, lipids,  proteins, salts, cellular debris and bacteria (Moghissi et al., 
1960; Bansil & Turner, 2006; Johansson et al., 2011; Leal et al., 2017)).  Mucus can be 
targeted using mucoadhesive drug delivery systems that adhere to this layer to prolong the 
residence time of the dosage forms, leading to sustained release of the loaded drugs and 
enhanced bioavailability compared to conventional non-mucoadhesive formulations 
(Bernkop-Schnürch, 2005; Khutoryanskiy, 2011).  
Several types of nanoparticles have been shown to have the potential as drug delivery 
systems (Nguyen et al., 2016; Hu et al., 2017; Davoudi et al., 2018). Siew et al. (2012) 
developed nanoparticles based on mucoadhesive quaternary ammonium palmitoyl glycol 
chitosan. These nanoparticles enhanced the oral absorption of both hydrophilic (ranitidine) 
and hydrophobic drugs (griseofulvin and cyclosporine A). In separate studies, Bernkop-
Schnürch and co-workers have developed thiolated polymers and shown their potential in 
the design of mucoadhesive nanoparticulate drug delivery systems (Dünnhaupt et al., 2011; 
Bonengel & Bernkop-Schnürch, 2014). Prego et al. (2006) designed chitosan nanocapsules 







result of their mucoadhesive properties and strong interaction with the intestinal mucous 
membranes. 
Previously, Khutoryanskiy et al. have developed thiolated silica nanoparticles and 
demonstrated their mucoadhesive properties on ocular (Irmukhametova et al., 2011) and 
urinary bladder mucosa (Mun et al., 2016). They also demonstrated that these nanoparticles 
could be easily functionalised via fluorescent labelling, PEGylation and POZylation 
(introduction of polyethylene glycols and polyoxazolines, respectively) (Irmukhametova et 
al., 2011; Irmukhametova et al., 2012; Mun et al., 2014a; Mansfield et al., 2015; Mansfield 
et al., 2016). PEGylation of thiolated silica nanoparticles was found to reduce the retention 
of thiolated silica nanoparticles on the ocular (Irmukhametova et al., 2011) and urinary 
bladder mucosal surfaces (Mun et al., 2016). More recently, Mansfield et al. (2015; 2016) 
demonstrated that POZylation of these nanoparticles could enhance their penetration into 
porcine gastric mucosa.  
Clearly, the nature of the adhesion between two surfaces (here, the nanoparticles and the 
mucous membrane) is highly dependent on the properties of both (Smart, 2005; Varum et 
al., 2010; Khutoryanskiy, 2011). For example, we previously showed that thiolated and 
PEGylated silica nanoparticles were less retentive on the ocular surface compared to the 
urinary bladder mucosal surface (Irmukhametova et al., 2011; Mun et al., 2016). This 
difference in retention might be due to the rougher structure of the latter resulting in an 
increased contact area (Irmukhametova et al., 2011; Khutoryanskiy, 2011; Mun et al., 2016). 
The mucoadhesion of our POZylated silica nanoparticles has never been studied previously. 
Therefore, in the present work, we sought to investigate the retentive properties of these 
silica nanoparticles in the rat intestinal mucosa. We further analysed the physicochemical 
properties of these nanoparticles, particularly their pH-stability profiles. 
3.2 Material and methods 
3.2.1 Materials 
3-mercaptopropyltrimethoxysilane (MPTS), maleimide terminated methoxy poly(ethylene 
glycol) (PEG) 5 kDa, alkyne terminated poly(2-ethyl-2-oxazoline) (POZ) 5 kDa 
(polydispersity index, PDI ≤ 1.2), 5,5ʹ-dithiobis (2-nitrobenzoic acid) (DTNB), fluorescein 







124 kDa), FITC-dextran (3.5-5 kDa) and triethyl amine (TEA) were purchased from Sigma-
Aldrich (Gillingham, UK). FITC-chitosan was made in house (Symonds et al., 2016a). 
Fluorescein-O-methacrylate (FMA), dimethyl sulfoxide (DMSO) and NaOH were 
purchased from Fisher Scientific (UK). Dialysis membrane with molecular cut-off 12-14 
kDa was purchased from Medicell International Ltd., UK.  
3.2.2 Synthesis of thiolated silica nanoparticles 
Thiolated silica nanoparticles were synthesised according to a published method 
(Irmukhametova et al., 2011). In brief, 20 mL DMSO and 0.5 mL of 0.5 M NaOH solution 
were added to 0.75 mL MPTS. The mixture was continuously stirred and aerated for 24 
hours at room temperature. Next, the nanoparticle suspensions were dialysed against 
deionised water (4 L, 8 changes of water over 2 days) using the dialysis membrane. The 
purified nanoparticle suspensions were refrigerated at 4 °C until use. 
3.2.3 Synthesis of PEGylated and POZylated silica nanoparticles 
Thiolated silica nanoparticles were functionalised using two different polymers; PEG and 
POZ. To synthesise PEGylated nanoparticles, 100 mg PEG was added to 10 mL thiolated 
nanoparticle suspension and the mixture was stirred for 24 hours at room temperature. To 
synthesise POZylated particles, 5 mL of thiolated nanoparticle suspension was diluted with 
5 mL DMSO and then 100 mg POZ was added to the diluted thiolated nanoparticles. To this 
mixture, 200 µL TEA was added to enhance the thiol-yne click reaction (Mansfield et al., 
2015). The reaction mixture was left for 24 hours with continuous stirring. The nanoparticles 
were purified by dialysis as described in section 3.2.2 and refrigerated at 4 °C until use.   
3.2.4 Fluorescent labelling of nanoparticles 
Each of the thiolated, PEGylated and POZylated silica nanoparticle suspensions (5 mL) were 
diluted with DMSO (5 mL). To this, 2 mL (3.59 µmol) of 1.8 mM fluorescein-O-
methacrylate solution (in 1:1 deionised water: ethanol) and 200 µL TEA was added. The 
reaction mixture was stirred in the dark for 24 hours. Subsequently, the fluorescently labelled 







3.2.5 Characterisation of nanoparticles 
The size and ξ-potential of the nanoparticles were measured using Zetasizer Nano-ZS 
(Malvern, UK). For the size measurements, the samples were diluted 1:100 with ultrapure 
water before analysis. A refractive index of 1.475 and an absorbance of 0.1 were used for all 
measurements. Measurements were conducted in triplicate for 10 seconds per run, with 12 
runs per reading at 25 °C. ξ-potential values were measured using DTS-1070 folded capillary 
tube cuvettes (Malvern, UK). Samples were measured using 3 repeats of 20 sub-runs per 
reading. At least 3 samples were measured and processed using the Smoluchowski model 
(Fκa = 1.50).  
Transmission electron microscopy (TEM) was conducted using a JEM-2100 PLUS Electron 
Microscope (JEOL, USA) at an accelerating voltage of 200 kV. Three drops of nanoparticle 
suspensions were placed on a carbon-coated copper grid and left for 1 minute before being 
loaded into the instrument. The morphology of the nanoparticles was investigated without 
any staining.  
3.2.6 Determination of thiol content 
Ellman’s assay was used to quantify the free thiol groups available on the surface of the 
nanoparticles. Initially, the nanoparticles were lyophilised using the Heto Power Dry LL 
3000 freeze-drier (Thermo Electron Corporation). The nanoparticles (3 mg) were suspended 
in 10 mL phosphate buffer solution (0.5 M, pH 8). Then, 0.5 mL aliquots of nanoparticle 
suspension was reacted with 0.5 mL DTNB (0.3 mg/mL) in the dark for 2 hours. Next, the 
product was centrifuged for 10 minutes at 13000 rpm (Sanyo, Micro Centaur, UK) and 200 
µL aliquots of supernatant was loaded into a 96 well-plate. The light absorbance was 
measured at 420 nm using an Epoch microplate reader (BioTek Instruments, Inc.). In order 
to obtain a calibration curve, serial solutions of L-cysteine HCl over the concentration range 
of 0.634 to 0.004 µmol/mL were prepared and reacted with DTNB under the same conditions 
as the nanoparticles. Phosphate buffer solution (pH 8) was used as the blank control. Finally, 







3.2.7 FTIR spectroscopy 
FTIR spectra of the freeze-dried nanoparticles were recorded using a Spectrum 100 FTIR 
spectrophotometer (Perkin-Elmer, UK). The spectra were collected from an average of 4 
scans, with a resolution of 4 cm-1 over the range of 4000-650 cm-1. 
3.2.8 Thermogravimetric analysis  
Freeze-dried samples were analysed for all three types of silica nanoparticles using the 
Q50 thermogravimetric analyser (TA Instruments, UK) equipped with nitrogen to provide 
an inert environment. The instrument was zeroed against an empty differential scanning 
calorimetry aluminium pan. The samples were placed in an aluminium pan and then in a 
platinum thermogravimetric analysis pan and loaded into the instrument. The initial 
temperature was set at 35 °C and the thermal decomposition of the samples was studied 
between 35 and 500 °C, at 5 °C /minute heating rate. 
3.2.9 Fluorescence spectroscopy 
Fluorescently labelled nanoparticle suspensions were diluted (1:400-1:12,800) with PBS 
(pH 7.4). The fluorescence emission spectra were measured between 500 -700 nm (emission 
wavelength) using a fluorescence spectrometer (Cary Eclipse, Varian Inc., US) at 490 nm 
excitation wavelength. 
3.2.10 pH-stability study 
Unlabelled nanoparticle suspensions were diluted with ultrapure water (1:100, 60 mL and 
40 mL of the diluted nanoparticle suspensions were prepared for experiments of decreasing 
and increasing pH, respectively). The pH was adjusted using 1 M HCl or 1 M NaOH 
solutions. Then at each pH point, the size and ξ-potential of the nanoparticles were measured 
as described in section 3.2.5. 
3.2.11 Determination of minimum detection limit of nanoparticles by fluorescence 
microscopy 
The minimum detection limit of the nanoparticles was determined by first measuring the 
concentration of fluorescently labelled thiolated nanoparticles by gravimetry (1.15 ± 0.20 
mg/mL; n = 3). This was performed by placing 1 mL of thiolated nanoparticles in a glass 







sample was weighed periodically and re-heated until a constant weight was obtained, 
indicating complete drying of the nanoparticles. Then, serial suspensions of fluorescently 
labelled thiolated nanoparticles were prepared in deionised water over the concentration 
range of 0.004–0.533 mg/mL. Diluted thiolated nanoparticle suspensions (20 µL) were 
applied on 0.8 × 1.2 cm2 rat intestinal mucosa (tissues sample was used within 10 minutes 
of thawing). Fluorescent images were recorded using a fluorescence microscope (Leica 
Microsystems, UK) at 160 ms exposure time. The images were then analysed by ImageJ 
(National Institutes of Health, USA) and the coefficient of determination (R2) was 
calculated. 
3.2.12 Mucoadhesion study 
Fluorescence microscopy was used to investigate the mucoadhesion of the synthesised 
nanoparticles. A Leica MZ10F fluorescence microscope (Leica Microsystems, UK) with 
ET-GFP filter, maximum excitation light intensity and 160 ms exposure time was used (in 
case of FITC-chitosan, however, 211 ms exposure time was used to compensate its poor 
fluorescence emission). In this study, freshly isolated small intestinal tissue from healthy 3 
to 4 month-old Sprague Dawley female rats was used. The intestines were cut open to 
approximately 0.8 × 1.2 cm2 and placed on a microscope slide. Fluorescence micrographs 
of the mucosal surface were taken as background fluorescence intensity. Thereafter, a 20 µL 
suspension of fluorescently labelled nanoparticles was placed on the intestinal mucosal 
surface and incubated for 5 minutes, before fluorescence micrographs were again recorded. 
The tissues were transferred to a sloped channel and washed with 1 mL or 5 mL of phosphate 
buffer solution (100 mM, pH 6.8, 37 ± 1 °C) for the total of 13 cycles. Fluorescence 
micrographs were recorded sequentially after each wash cycle. The images were analysed 




 × 100                                     Equation 3.1 
  
where, I is the fluorescence intensity of a given tissue sample nanoparticles after each wash 
cycle, Ib is the background fluorescence intensity of that tissue sample, and Io is the initial 
fluorescence intensity of that sample (i.e. following nanoparticles incubation but preceding 







intensity. The experiments were performed in triplicate using tissues obtained from 4 rats, 
and the order in which each nanoparticle type was studied in any individual experiment was 
randomised. FITC-chitosan (1 mg/mL in 0.1 M acetic acid) and FITC-dextran (1 mg/mL in 
deionised water) were used as positive and negative controls, respectively. 
In addition, WO50 (Mun et al., 2016) and WO70 values were quantified. These values 
represent the amount of phosphate buffer solution necessary to attenuate the fluorescence 
intensity on the mucosal surface by 50% and 70%, respectively. The values were calculated 
by extrapolation of the average wash-off data using 6th order polynomial fitting and 
Wolfram Alpha (a computational knowledge engine). 
3.2.13 Statistical analysis 
Unless otherwise stated, all measurements were collected in triplicate and the data are 
expressed as mean ± standard deviation (SD). The data were analysed using the SPSS 
Statistics 21 program (IBM, US). The statistical significance of any difference between 
groups was determined using one-way analysis of variance (ANOVA) with the least 
significant difference (LSD) post-hoc test. Differences were considered statistically 
significant at p ˂ 0.05.  
3.3 Results and discussion 
3.3.1 Nanoparticles synthesis and characterisation 
Thiolated nanoparticles were synthesised via hydrolysis and subsequent condensation of the 
methoxysilane groups of MPTS, forming a cross-linked nanoparticle structure through Si-
O-Si and disulfide bonds. All nanoparticle samples exhibited acceptable PDI (PDI ˂ 0.2, as 
determined by DLS), with a single peak around the z-average of the particles (Figure 3.1 and 
Table 3.1). Particles with PDI < 0.05 are highly monodisperse but rarely seen unless with 
standard nanoparticles. Nanoparticles with PDI ˃ 0.7 have generally very broad size 
distribution and not recommended to be sized using DLS technique. Thus, lower PDI 
indicates higher homogeneity of the nanoparticles and vice versa  (Malvern Instruments Ltd., 
2011). The particle size increased in the order of thiolated < POZylated < PEGylated 















Figure 3.1 Exemplar dynamic light scattering size distribution of thiolated, PEGylated 
and POZylated silica nanoparticles.  
 
 
Table 3.1 Characteristics of unlabelled thiolated, PEGylated and POZylated silica 
nanoparticles (mean ± SD, n = 3); for size and ξ-potential measurement, the 
nanoparticles suspensions were diluted with ultrapure water (1:100). 
Types of 
particles 







Thiolated 53 ± 1 0.118 ± 0.012 
 
-42 ± 2 
  
  6 ± 2 368 ± 11 
 PEGylated 68 ± 1 
 
0.128 ± 0.002 
 
-22 ± 3 
 
  
 13 ± 1 175 ± 2 
 
 
POZylated 59 ± 1 0.134 ± 0.014 
 
  -31 ± 4   5 ± 1 53 ± 18 
a measured by freeze drying 
The difference in particle size between each pair of nanoparticle type was statistically 
significant (p ˂ 0.05). The larger PEGylated and POZylated nanoparticles indicate 
successful grafting of the polymers onto the thiolated nanoparticles core. PEG 5 kDa 
contains 113 repeating units of ethylene glycol (Mr= 44), whereas POZ 5 kDa consists of 50 
repeating units of 2-ethyl-2-oxazoline (Mr=99). This means that the PEG chains were longer 






























Another possible reason for the size discrepancy between PEG and POZ nanoparticles is 
related to the different spatial arrangement of PEG and POZ around the core nanoparticles. 
Typically, PEG molecules form long-brush or mushroom configurations. The former 
happens when the density of PEG on the surface of nanoparticles is high, while the latter 
occurs in cases of low surface coverage (Owens & Peppas, 2006). In contrast, POZ forms 
star-shaped structures (Rossegger et al., 2013). Also, it can be hypothesised that different 
polymer chain folding and relaxation behaviour in water may also contribute to the 
difference in the size of the corresponding nanoparticles. 
The concentration of the nanoparticles was estimated using freeze drying by determining the 
dry weight of the nanoparticles in 1 mL of suspensions. The results showed that PEGylated 
nanoparticles were more concentrated than both thiolated and POZylated nanoparticles 
(Table 3.1). These concentration estimates were used to quantify the free thiol contents of 
the nanoparticles.  
In this study, all three types of silica nanoparticles (thiolated, PEGylated and POZylated) 
were labelled with a fluorescent marker, by reacting them with FMA (Figure 3.2 and Figure 
3.3). The fluorescent molecules were covalently bound to the nanoparticles via thiol-ene 
click reaction between the thiol groups of the nanoparticles and the vinyl groups of FMA. 
Fluorescent labelling enabled facile quantification of the nanoparticles on the surface of rat 
intestinal mucosa, with virtually no change in the particle size (see Table 3.1 and Table 3.2). 
In addition, no signs of aggregation or flocculation was observed for both fluorescently 
labelled and unlabelled particles during the study (ca. 6 months). This indicates that FMA 
imparted a characteristic fluorescent signal to the particles without impairing the colloidal 






















Figure 3.2 Fluorescence spectra of different types of silica nanoparticles diluted with 

















Figure 3.3 Calibration curves showing the linear relationships between fluorescence 
intensity and the concentration of FMA-labelled silica nanoparticles (mean ± SD, n 


































Ellman’s assay showed a statistically significant difference in free thiol content among all 
three types of nanoparticles (p ˂ 0.05). Free thiol content decreased in the order of thiolated 
> PEGylated > POZylated nanoparticles (Table 3.1). This result indicates successful 
functionalisation of both PEGylated and POZylated nanoparticles, since PEGylation and 
POZylation were expected to replace free thiol groups with the corresponding polymers. The 











Figure 3.4 A calibration curve used to determine free thiol content of the silica 































Table 3.2 Properties of fluorescently labelled thiolated, PEGylated and POZylated silica 
nanoparticles (for fluorescence measurement, nanoparticles were diluted with PBS pH 7.4, 
1:1,600), mean ± SD, n = 3. 
Types of 
particles 
Size (d-nm) PDI Max. emission 
(nm) 
Max. intensity          
(a.u.) 






0.200 ± 0.018 512 411 ± 36 
PEGylated 71 ± 2 
 
 
0.106 ± 0.020 
 
 
512 233 ± 14 
POZylated 61 ± 3 0.117 ± 0.027 512 405 ± 38 
 
In agreement with our previous study (Irmukhametova et al., 2011), TEM results show that 
thiolated nanoparticles aggregated and formed ‘necklaces’(Figure 3.5). A possible reason 
for the aggregation is disulfide bond formation between the nanoparticles, facilitated by 
drying during TEM sample preparation. In contrast, TEM images of PEGylated and 
POZylated nanoparticles did not show any sign of aggregation. This observation, together 
with DLS data, confirm the presence of primarily non-aggregated PEGylated and POZylated 
particles in the samples. Thus, although the ξ-potential of both PEGylated and POZylated 
nanoparticles had significantly decreased compared to the parent thiolated nanoparticles 
(Table 3.1), their colloidal stability seemed to have dramatically improved. In addition to 
the overall reduction in reactive thiol groups in PEGylated and POZylated nanoparticles, 
steric hindrance (i.e. shielding of remaining thiol groups by the hydrophilic polymeric shells 
on the particle surface) is believed to be a major contributing factor to the improvement of 
























Figure 3.5 TEM images of unlabelled thiolated (A), PEGylated (B) and POZylated (C) 
silica nanoparticles. Thiolated nanoparticles formed necklace-like structure 
whereas both PEGylated and POZylated nanoparticles were mainly 
individually distributed.   
 
The FTIR spectra of the silica nanoparticles are shown in Figure 3.6. Thiolated nanoparticles 
showed characteristic peaks of asymmetric CH2 stretching, Si-O-Si asymmetric stretching 
and Si-O-Si bending vibration at 2933, 1103 and 1024 cm-1, respectively. PEGylated 
nanoparticles showed a very specific peak at 1710 cm-1, related to C=O of the maleimide 
part of PEG. POZylated nanoparticles demonstrated a peak at 1635 cm-1, which is attributed 
to C=O stretching of POZ. In addition, asymmetric vibration of the CH3 group in POZ 



























Figure 3.6 FTIR spectra of thiolated, PEGylated and POZylated silica nanoparticles.  
 
 
Thermogravimetric analysis (Figure 3.7) indicate the successful grafting of both PEG and 
POZ to thiolated silica nanoparticles. A higher weight proportion of residues (62%) 
remained in thiolated nanoparticles compared to PEGylated and POZylated nanoparticles 
(44 and 36%, respectively). In other words, thiolated nanoparticles had lost just 38% of 
weight while PEGylated and POZylated nanoparticles had lost 56 and 64%, respectively. 
The greater percentage weight loss (% wloss) in the PEGylated and POZylated nanoparticles 
was assumed to be due to thermal decomposition of PEG and POZ moieties, which were 
absent from the thiolated nanoparticles. The nanoparticles core, synthesised from MPTS, 
was composed of inorganic SiO2 which would have been resistant to thermal decomposition 
within the temperature range used in the thermogravimetric analysis study (35 to 500 °C) 
(Mun, 2014). By subtracting the % wloss of thiolated nanoparticles from that of PEGylated 
and POZylated nanoparticles, the amount of each polymer in the functionalised 
nanoparticles was calculated. It was found that PEGylated nanoparticles had 18% w/w bound 












































Figure 3.7 Thermogravimetric analysis of thiolated, PEGylated and POZylated silica 
nanoparticles. 
 
As shown in Figure 3.2, Figure 3.3 and Table 3.2, PEGylated nanoparticles fluoresced less 
intensely (p ˂ 0.05) than thiolated particles. This is most likely due to the screening effect 
of non-fluorescent PEG on the surface of these PEGylated nanoparticles. However, 
POZylated nanoparticles showed similar fluorescence intensity compared to thiolated 
nanoparticles (p > 0.05), which was significantly higher (p ˂ 0.05) than that of PEGylated 
nanoparticles. The shorter POZ chain length (50 repeating units) compared to PEG (113 
repeating units) (Mansfield et al., 2015) potentially led to less fluorescence screening 






























3.3.2 pH-stability study 
The dosage form administered orally is expected to pass through regions of GIT with 
different pH values. The pH along the GIT ranges from around 2 in the stomach, to 6-7 in 
the small intestine and about 8 in the colon. We therefore evaluated the stability of thiolated, 
PEGylated and POZylated silica nanoparticles over the pH range of 1.5–9, in terms of 
particle size, PDI and ξ-potential. The initial pH of the diluted thiolated, PEGylated and 
POZylated silica nanoparticle suspensions were 5.93, 5.67 and 6.08, respectively. Thiolated 
and POZylated nanoparticles were stable over the pH range of 2.5-9 as no change in their z-
average size was observed. However, they aggregated at pH ≤ 2, resulting in a significant 
increase in particle size (z-average: 4.29 ± 0.78 µm for thiolated and 6.84 ± 0.52 µm for 
POZylated nanoparticles) and a polydisperse system (Figure 3.8-A, B and C). This 
aggregation was irreversible as particle size was not reduced when higher pH was restored. 
The aggregation of the particles at pH < 2 could be a result of Si-O-Si covalent bond 
formation between the nanoparticles, owing to the availability of SiOH groups on the 
surface of the particles (Irmukhametova et al., 2012). The instability of thiolated and 
POZylated nanoparticles at pH ≤ 2 may potentially limit their application for oral drug 
delivery; however, this limitation could potentially be overcome by encapsulating these 
particles into a vehicle protected with pH-sensitive enteric coating such as Eudragits or their 
complexes with other polymers (Moustafine et al., 2011; Mustafin, 2011). In contrast, 
PEGylated nanoparticles were stable over the entire pH range investigated (1.5-9), as they 






























Figure 3.8 (A) DLS average size, (B) PDI  at different pH environments, (C) particle size 
distribution at pH 1.5 and (D) ξ-potential of thiolated, PEGylated and POZylated 
silica nanoparticles in different pH environments, mean ± SD, n = 3. No error bars 
shown in (C). 
 
The ξ-potential of the nanoparticles was lower at low pH than at high pH (Figure 3.8-D). 
Thiolated nanoparticles, however, had a more positive value (20 ± 1 mV) compared to 
PEGylated and POZylated nanoparticles (-0.17 ± 5 mV and 2 ± 1 mV, respectively). The 
reduction in the ξ-potential could be due to the association of the negatively charged SiO-  
and S- ions with positively charged H+ ions, resulting in neutral SiOH or SH (Dyab, 2012). 
Interestingly, at low pH (~1.5) both PEGylated and POZylated nanoparticles showed a lower 
ξ-potential than thiolated nanoparticles. This could be explained by the fact that a significant 







3.3.3 Ex vivo mucoadhesion study 
In order to conduct the evaluation of mucoadhesive properties of the nanoparticles, the 
minimal detectable concentration of fluorescently labelled particles on the surface of rat 
intestinal mucosa was determined. The fluorescence of labelled particles was detectable 
even upon dilution by nearly 60-fold (Figure 3.9). This result is also important for future 
studies involving the monitoring of these fluorescent nanoparticles in the GIT following oral 
administration, as the particles are likely to be diluted by GI fluids. As shown in Figure 3.9, 
there is a linear relationship (R2 = 0.9968) between the concentration of thiolated 




Figure 3.9 Fluorescence level of serial suspensions of thiolated silica nanoparticles applied 
on the rat intestinal mucosa. Inset: fluorescence micrographs showing 0.533 (A) 
and 0.066 (B) mg/mL thiolated nanoparticles on the rat intestinal mucosa, scale bar 











Using a wash-off technique (Ranga Rao & Buri, 1989; Nielsen et al., 1998)  in combination 
with fluorescence microscopy, the retention of fluorescently labelled nanoparticles on the 
surface of rat intestinal mucosa was studied.  This technique has been previously used to 
study the retention of various materials on different surfaces including animal tissues and 
plant leaves (Irmukhametova et al., 2011; Štorha et al., 2013; Cook et al., 2015; Mun et al., 
2016; Symonds et al., 2016b; Tonglairoum et al., 2016).  
Samples were applied on the surface of rat intestinal mucosa and then washed with 
phosphate buffer pH 6.8 over several cycles. The fluorescence intensity on the mucosa was 
monitored following each wash cycle (Figure 3.10). Based on the linear relationship 
established between nanoparticles concentration and fluorescence intensity (Figure 3.9), the 
amount of fluorescent nanoparticles remaining on the tissue was estimated. As both 
fluorophores (FMA and FITC) were covalently bound to the materials used in this study 
(nanoparticles, chitosan and dextran), it can be assumed that the fluorescence intensity was 
directly proportional to the percentage of the materials retained on the mucosal surface. 
However, this method is likely to underestimate the amount of labelled 
nanoparticles/macromolecules as they are diluted by phosphate buffer solution during the 
wash cycles. In addition, a portion of the nanoparticles/macromolecules may diffuse into the 
mucus layer, resulting in attenuation or even obliteration of the fluorescent signal. However, 
both these factors were excluded in this particular study and the % remaining of all 
nanoparticles, FITC-chitosan and FITC-dextran (positive and negative controls) were 
































Figure 3.10 Exemplar fluorescence microphotographs showing retention of FITC-chitosan 
(postive control used as a mucoadhesive material), thiolated, PEGylated and 
POZylated silica nanoparticles and FITC-dextran (negative control used as a non-
mucoadhesive material) on rat intestinal mucosa following wash-out with 
phosphate buffer solution at pH 6.8. The values of the normalised fluorescence 
intensity were inserted into the top right corners of the representative images (a.u.). 
After washing the fluorescent nanoparticles by certain amounts of phosphate buffer 
solution, the fluorescence intensity from thiolated nanoparticles were greater than 
both PEGylated and POZylated nanoparticles. The scale bar is 5 mm. 
























At the end of each wash cycle, the % of thiolated nanoparticles remaining was significantly 
greater (p ˂ 0.05) than FITC-dextran, which was used as a non-mucoadhesive material 
(negative control) (Figure 3.11). Several studies have reported the non-mucoadhesive nature 
of dextran, which is likely due to its non-ionic character leading to muco-inertness instead 
of mucoadhesion (Khutoryanskiy, 2011; Withers et al., 2013; Mun et al., 2016). Thiolated 
nanoparticles also showed better retention than both PEGylated and POZylated 

















Figure 3.11 Fluorescence level of rat intestinal mucosa exposed to FITC-chitosan , 
thiolated, PEGylated and POZylated silica nanoparticles and FITC-dextran 
washed by phosphate buffer solution (100 mM, pH 6.8) (n = 3 using 4 rats, 









FITC-chitosan (positive control) showed remarkably higher retention than FITC-dextran 
(Figure 3.11). Many studies have confirmed the adhesion of chitosan to the mucus layers of 
various surfaces, including the eye, stomach and urinary bladder, owing to its cationic nature 
and ability to form electrostatic and hydrogen bonds with mucus components (Sogias et al., 
2008; Mun et al., 2016; Tonglairoum et al., 2016). Over the first 3 wash cycles, thiolated 
nanoparticles showed a similar retention profile to FITC-chitosan (p ˃ 0.05). However, at 
the end of each wash cycle, neither PEGylated nor POZylated nanoparticles showed any 
statistically significant difference compared to FITC-dextran (p ˃ 0.05). This similarity of 
PEGylated and POZylated nanoparticles with FITC-dextran was persistent until the end of 
all wash cycles. In contrast, POZylated and PEGylated nanoparticles showed significantly 
less mucoadhesion than FITC-chitosan starting from the first and second wash cycle, 
respectively (p < 0.05 for both POZylated and PEGylated nanoparticles) (Figure 3.11).  
Mun et al. (2016) showed that about 80% of thiolated silica nanoparticles, and only about 
40% of PEGylated nanoparticles, remained on the surface of bladder mucosal tissues after 
washing with 10 mL artificial urine. In comparison, we found less retention for all three 
types of nanoparticles (thiolated: 21%, PEGylated: 11%, POZylated: 10%) after washing 
with the same volume of the bio-relevant fluid (Figure 3.11). The reason for this difference 
is not clear yet, but it could be related to the differences in the structure, chemical 
compositions, concentration and types of mucin on the mucosal surfaces. 
In addition to the method developed by Mun et al. (2016) to determine WO50, we propose to 
calculate WO70 of the formulations. WO50 and WO70 represent the volume of phosphate 
buffer solution required to wash out 50% and 70%, respectively, of the formulations from 
the rat intestinal mucosa. Calculation of WO70  is important as generally a greater amount of 
both thiolated and PEGylated nanoparticles were washed off from rat intestinal mucosa 
compared to urinary bladder mucosa (Mun et al., 2016). Similar differences in mucosal 
retention have also been reported by Irmukhametova et al. (2011), Mun et al. (2016) and 
Štorha et al. (2013) on bovine corneal and porcine urinary bladder tissues. A few studies 
reported the similarity of the thickness and the structure of the mucus of human GIT to that 
of porcine and showed some resemblance of the two (Varum et al., 2010, 2012). However, 
rat intestinal mucosa is an ex vivo model widely used to measure the oral absorption of drugs 







including nanoparticles (Lehr et al., 1992; Keely et al., 2005; Dünnhaupt et al., 2011; 
Merchant et al., 2014; Maisel et al., 2015; Oltra-Noguera et al., 2015; Lozoya-Agullo et al., 
2016). 
Therefore, using WO70   allows the comparison of different nanoparticles in terms of their 
wash-off profiles. Table 3.3 shows that WO50 values for FITC-chitosan (1.9 mL) and 
thiolated nanoparticles (1.58 mL) are nearly double to those for PEGylated (0.95 mL) and 
POZylated nanoparticles (0.88 mL). The WO70 for FITC-chitosan could not be determined 
since a sizeable proportion (> 40%) of the formulation remained tenaciously on the intestinal 
mucosa withstanding the multiple washing cycles (Figure 3.10 and Figure 3.11). On the 
other hand, the WO70 for thiolated nanoparticles was approximately 3-fold higher than 
PEGylated and POZylated nanoparticles. This indicates that thiolated nanoparticles resisted 
a greater amount of wash buffer than both PEGylated and POZylated nanoparticles. WO50 
and WO70 of both PEGylated and POZylated nanoparticles were close to that of FITC-
dextran denoting the non-mucoadhesive nature of these two types of nanoparticles (Table 
3.3). 
 
Table 3.3 Values of WO50 and WO70 for FITC-chitosan, thiolated, PEGylated and POZylated 
silica nanoparticles, as well as FITC-dextran in rat intestinal mucosa.  
Types of materials WO50 (mL) WO70 (mL) 
FITC-chitosan 1.90 NA 
Thiolated silica nanoparticles 1.58 5.26 
PEGylated silica nanoparticles 0.95 1.73 
POZylated silica nanoparticles 0.88 1.58 
FITC-dextran 0.76 1.32 
Polynomial fitting (6th order) was used to calculate WO50 and WO70, the values of R
2 were 
between 0.94-0.98, WO50 and WO70: volume of phosphate buffer solution required to wash 









The reason for the better retention of thiolated nanoparticles compared to PEGylated and 
POZylated nanoparticles was most likely the formation of disulfide bridges between the 
thiolated nanoparticles and cysteine-rich domains of mucosal layers, since these 
nanoparticles had a greater free thiol content than PEGylated and POZylated nanoparticles. 
Conversely, PEGylated and POZylated nanoparticles were effectively removed after a few 
wash cycles probably due to less disulfide bridge formation by virtue of their lower thiol 
contents. 
As all 3 types of the nanoparticles used in this study were negatively charged, the 
discrepancy in their mucoadhesive properties is unlikely to be related to the difference in 
charge. According to the electronic theory of mucoadhesion, anionic particles do not show 
any signs of adhesion to mucosal surfaces, which are also negatively charged, as like charges 
repel each other. However, mucoadhesion can be the result of one or more mechanisms, 
including ionic interaction, covalent bonding, hydrogen bonding, hydrophobic interaction, 
wetting, adsorption, diffusion and entanglement (Smart, 2005). Additionally, as the particles 
are dispersed in water, the effect of dispersion media on the mucoadhesive properties of the 
particles was excluded. Finally, the mucoadhesion was studied at pH 6.8, which was close 
to the pH of the ultrapure water used to dilute the nanoparticles for DLS size measurement. 
From the DLS data (Table 3.1 and Table 3.2 and Figure 3.1 and Figure 3.8), it is clearly 
seen that the nanoparticles were stable at neutral pH and did not show any sign of 
aggregation. Therefore, their retention would not be due to their deposition on the mucosal 
surfaces and rather was due to their ability to form disulfide bonds with cysteine residues in 
mucus.  
Several studies have shown that decorating nanoparticles with PEG facilitates their diffusion 
or penetration through mucus barriers (Lai et al., 2007; Mun et al., 2014b; Maisel et al., 
2015). Lai et al. (2007) reported that PEGylation of conventional large polystyrene 
nanoparticles (200 and 500 nm) led to their rapid transport through fresh human 
cervicovaginal mucus (CVM) and their diffusion coefficient (Dc) in mucus was just 4 to 6-
fold smaller than in water. In contrast, the Dc of uncoated polystyrene nanoparticles in CVM 
was 2400 to 40000-fold lower than in water. POZ has been studied as an alternative to PEG 
for the development of mucus-penetrating nanomaterials (Khutoryanskiy, 2018). For 







through porcine gastric mucosa. Similarly, in this study, the PEGylated and POZylated 
nanoparticles showed less mucoadhesion than thiolated nanoparticles. Based on these and 
our previous findings, we postulate that the PEGylated and POZylated nanoparticles may 
diffuse through rat intestinal mucus and thus be mucus-penetrating, which is a desirable 
property in some drug delivery applications. In other words, the fact that the PEGylated and 
POZylated nanoparticles exhibited less mucosal retention may not diminish their importance 
as a drug delivery system relative to the more mucoadhesive thiolated nanoparticles. The 
selection of either mucoadhesive or mucus-penetrating carriers depends on the drug being 
delivered, the mucosal surface being targeted, the mucus turnover rate, the presence of water, 
the disease state and the intended release profile. Generally, mucoadhesive nanoparticles are 
advantageous for ocular and intravesical drug delivery where lacrimation in the eye and urine 
voiding from bladder remove a substantial amount of the drug at the site of 
application/absorption. Mucus-penetrating carriers, on the other hand, are desirable in the 
design of oral drug delivery where deeper mucus gel penetration and a broader particle 
distribution through the absorptive epithelia are required (Mun et al., 2014b; Maisel et al., 
2015; Mun et al., 2016; Netsomboon & Bernkop-Schnürch, 2016).  
3.4 Conclusions 
In this study, we have investigated the pH-stability profiles of thiolated, PEGylated and 
POZylated silica nanoparticles and evaluated their mucoadhesive properties in rat intestinal 
mucosa. PEGylated nanoparticles showed similar size over a broad pH range (1.5-9). Also, 
in case of thiolated and POZylated nanoparticles, no change in size was observed at pH 2.5-
9. Thiolated nanoparticles were mucoadhesive in rat intestinal mucosa ex vivo but to a lesser 
extent than to urinary bladder mucosa as reported in our previous study. These mucoadhesive 
nanoparticles can potentially be used to prolong drug release. PEGylated and POZylated 
nanoparticles showed less mucoadhesion which suggests better permeability through the 
mucus layer compared to thiolated nanoparticles. This property may allow the particles to 
diffuse more easily through the mucus barrier to the deeper absorptive epithelia, leading to 
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Chapter 4: Synthesis of POZylated and PEGylated chitosan 




























In this chapter, we contrast and compare various approaches for the synthesis of POZylated 
and PEGylated chitosan. The final aim of this study was to prepare nanoparticles using the 
unmodified and modified chitosan for mucosal drug delivery. Using turbidimetry, it was 
found that the dispersion of PEGylated chitosan in 1% v/v acetic acid showed less turbidity 
than the POZylated, thiolated and the unmodified chitosan counterparts at neutral and basic 
pH. However, none of these modified chitosan were fully soluble at any pH. It is believed 
that oxidation of thiol groups of thiolated, POZylated and PEGylated chitosan and the 
subsequent formation of disulfide bonds were responsible for their incomplete solubilisation 























Chitosan is a natural cationic polysaccharide which has been widely used in the design of 
mucosal drug delivery systems (MDDS) including nanoparticles (Illum et al., 1994; Illum et 
al., 2001; Issa et al., 2005). However, poor aqueous solubility of chitosan at pH > 6 limits 
its applications. Additionally, the mucoadhesive strength of chitosan is limited only to a 
certain degree which is often not satisfactory and justifies investigating approaches to 
enhance chitosan mucoadhesive properties. One such approach is the chemical modifications 
of chitosan. For example, thiolated chitosan was first investigated by Bernkop-Schnürch and 
co-workers (2003) and showed better mucoadhesive properties than the unmodified chitosan 
in vitro and in vivo rat models for oral (Dünnhaupt et al., 2011; Dünnhaupt et al., 2012) and 
nasal (Krauland et al., 2006) route of administration. Whereas, our group demonstrated that 
methacrylated chitosan showed an enhanced mucoadhesive properties compared to 
unmodified chitosan using excised porcine bladder mucosa (Kolawole et al., 2018).  
For certain applications, for example when a deeper mucus-penetration is required as in the 
case of oral and respiratory drug delivery, mucus-penetrating nanoparticles are more useful 
compared to mucoadhesive nanoparticles. Mucus-penetrating nanoparticles can be prepared 
via surface modification of nanoparticles using certain hydrophilic polymers including 
polyethylene glycol (PEG) and poly-2-ethyl-2-oxazoline (POZ). For example, Lai et al. 
(2007) showed that coating polystyrene nanoparticles with dense PEG (2 kDa) resulted in a 
rapid transport of the nanoparticles through human cervicovaginal mucus. Maisel et al. 
(2015) showed that, when carboxylate-modified polystyrene nanoparticles were orally 
administered to mice, they aggregated in the mucus layer of mice intestinal lumen and could 
not reach the highly folded absorptive surfaces of villi. In contrast, PEG-coated carboxylate-
modified polystyrene nanoparticles diffused freely in the intestinal mucus gel and distributed 
evenly throughout the intestinal epithelial tissues. Mansfield et al. (2015) demonstrated that 
the coating of thiolated silica nanoparticles with either PEG or POZ led to an increase in 
their diffusivity in mucin dispersion and enhanced penetration into the freshly excised 
porcine gastric mucosa.  
In this study an attempt has been made to synthesise thiolated chitosan by reacting chitosan 
with 2-iminothiolane HCl which was then further modified by reacting it with POZ or PEG 







respectively. The main aim of this study was to prepare nanoparticles using unmodified and 
each of thiolated, POZylated and PEGylated chitosan and evaluate their mucus-penetrating 
properties. It has been hypothesised that both unmodified and thiolated chitosan 
nanoparticles would potentially be mucoadhesive (thiolated chitosan > unmodified chitosan) 
whereas both POZylated and PEGylated counterparts mucus-penetrating.  
4.2 Materials and methods 
4.2.1 Materials 
Medium molecular weight chitosan (190-310 kDa based on viscosity, 75-85% degree of 
deacetylation), 2-iminothiolane hydrochloride, 5,5ʹ-dithiobis-2-nitrobenzoic acid (DTNB, 
Ellman’s reagent), anhydrous L-cysteine hydrochloride, maleimide-terminated methoxy 
polyethylene glycol (PEG) 5 kDa, alkyne-terminated-poly-2-ethyl-2-oxazoline (POZ) 5 kDa 
(PDI ≤ 1.2) and triethyl amine (TEA) were purchased from Sigma-Aldrich (Gillingham, 
UK). Dialysis tubing with molecular weight cut off 12-14 kDa was purchased from Medicell 
International Ltd., UK. All other reagents were of analytical grade. 
4.2.2 Synthesis of thiolated chitosan 
The original chitosan was modified according to the method described by Bernkop-Schnürch 
et al. (2003) with minor modification. Briefly, 500 mg chitosan (1% w/v) was dissolved in 
50 mL of 1% v/v acetic acid. Then, the pH was increased to 5 using 5 M NaOH. After that, 
200 mg 2-iminothiolane HCl (0.4% w/v) was added and stirred for 24 hours at room 
temperature. Then, the reaction mixture was dialysed using 5 mM HCl (once), then 5 mM 
HCl containing 1% w/v NaCl (twice), followed by 5 mM HCl and finally 0.4 mM HCl (once) 
(each with 4 L over 72 hours). Finally the product was lyophilised and stored at 4 °C until 
further use.  
4.2.3 Determination of thiol content 
Ellman’s assay was used to quantify the immobilised thiol groups on the modified polymers. 
The polymers were hydrated in ultrapure water (at 1 or 2 mg/mL) for 1 hour. Then, 0.25 mL 
of the polymer solution was mixed with 0.25 mL phosphate buffer solution (0.5 M, pH 8) 
and this was reacted with 0.5 mL Ellman’s reagent (0.3 mg/mL) in the dark for 2 hours, then 







of the supernatant were loaded into a 96 well plate. The absorbance was measured at 420 nm 
using a BioTek Epoch plate reader. Serial standard solutions of L-cysteine HCl over the 
concentration range of 0.004 to 0.634 µmol/mL were prepared and reacted under the same 
condition of the modified chitosan. Finally, the amount of free thiols per one gram of the 
polymer was calculated.  
4.2.4 Synthesis of POZylated chitosan 
Thiolated chitosan (100 mg) was dispersed in 50 mL deionized water. Then, 200 µL of TEA 
and 100 mg POZ were added and stirred for 18 hours. Thereafter, the pH was lowered to 5 
using 1% v/v acetic acid and the reaction mixture was stirred for 5 hours. The product was 
dialysed against deionised water (4 L, 5 times, over 24 hours) using 12-14 kDa dialysis 
membrane (Medicell International Ltd., UK,). The product was freeze dried and stored at 4 
°C until further studies.  
4.2.5 NMR spectroscopy 
1H NMR spectra were recorded using a Bruker Nanobay 400 MHz NMR spectrometer.  
Unmodified chitosan (5 mg) was dissolved in D2O (1 mL) with 10 µL of trifluoroacetic acid 
(TFA). D2O was used as a solvent for thiolated and POZylated chitosan (2.5 mg/mL) and 
PEGylated chitosan (10 mg/mL). The degree of acetylation (DA) of the unmodified chitosan 
was calculated according to Equation 4.1 (Sogias et al., 2008): 
 
 
Where I CH3  is the intergral intesity of N-acetylated proton and I H2 − H6 is the summation 
of the integral intesity of proton number 2, 3, 4, 5 and 6. 
4.2.6 FTIR spectroscopy 
The FTIR spectra of unmodified chitosan and freeze dried modified chitosan were recorded 
using a spectrum 100 FTIR spectrophotometer (Perkin-Elmer, UK). The spectra were 
collected from an average of 4 scans, with a resolution of 4 cm-1 over the range of 4000-650 
cm-1. 
     𝐷𝐴 =  
I CH3/3    
I H2− H6/6







4.2.7 Synthesis of PEGylated and POZylated chitosan; Optimisation study 
Since poor water solubility of the resultant POZylated chitosan was observed, another 
approach was used to synthesise POZylated chitosan. Here, thiolated chitosan was used 
before freeze drying (i.e. just after the dialysis) as it was expected that the insolubility of the 
POZylated chitosan was originated from the cross-linking of the precursor thiolated chitosan 
which could have happened during the freeze drying process of the thiolated chitosan 
aqueous solution. This approach was also used to synthesise PEGylated chitosan. It should 
be noted that for this purpose, similar method (section 4.2.2) was used to synthesise thiolated 
chitosan except the concentration of chitosan and 2-iminothiolane HCl was reduced to 0.5% 
w/v and 0.2% w/v, respectively.  
Table 4.1 shows the composition of the reaction mixtures of PEGylated and POZylated 
chitosan. Thiolated chitosan was diluted with deionised water before PEG or POZ was added 
with or without TEA. Then, the reaction mixtures were left at room temperature for 24 hours 
under continuous stirring. Following this, the resulting products were dialysed against 
deionised water (4 L, 8 times, over 4 days) using 12-14 kDa dialysis membrane. The products 
were characterised in terms of particle size by dynamic light scattering (DLS), ξ-potential 
using Zetasizer Nano-ZS (Malvern, UK) and concentration by freeze drying. The freeze-
dried products were used for Ellman’s assay and NMR spectroscopy. Thiolated chitosan 
reacted under the same condition of PEGylated and POZylated chitosan but without PEG or 














Table 4.1 Composition of reaction mixtures of PEGylated and POZylated chitosan 
 






PEG (mg) POZ (mg) TEA 
(µL) 
Control  5 20 - - - 
PEG-chitosan 1 5 20 50 - - 
PEG-chitosan 2 5 20 100 - - 
PEG-chitosan 3 5 20 50  10 (pH 6) 
POZ-chitosan 1 5 20 - 50 - 
POZ-chitosan 2 5 20 - 100 - 
POZ-chitosan 3 5 20 - 50 5 (pH 5) 
 
4.2.8 pH-solubility profile 
Solubility of the unmodified and modified chitosan was measured at different pH at room 
temperature using turbidimetric technique. The polymers were dissolved/dispersed (0.5 
mg/mL) in 1% v/v acetic acid and left stirring for 24 hours. The turbidity (absorbance) of 
the systems was measured with a Jenway 7315 UV-visible spectrophotometer at 400 nm 
using 1% v/v acetic acid as a blank. The pH was adjusted using 1 M NaOH solution. 
4.3 Results and discussion 
Thiolated chitosan was synthesised according to the method described by Bernkop-Schnürch 
et al. (2003) (Figure 4.1). The method involves the covalent attachment of 2-iminothiolane 
HCl to chitosan leading to the immobilisation of thiol groups (-SH) on chitosan as a result 
of amidine bond formation. In this method, reaction mediators including 1-ethyl-3-(3-







are not required. In contrast, the methods based on amide bond formation require these 




























The thiolated chitosan synthesised in this study had a white-faint yellow colour with a 
fibrous structure. Using Ellman’s assay, it was found that the thiolated chitosan had 432 ± 
28 µmol/g free thiol groups. Also, the reaction showed a high yield (69.8%). These results 
were in agreement with the results reported by Bernkop-Schnürch et al. (2003). For instance, 
their thiolated chitosan had a free thiol groups of 408.9 ± 49.8 µmol/g and had a white 
appearance with a fibrous structure. However, compared to thiolated chitosan synthesised 
by Roldo et al. (2004) (263.8 ± 47.4 µmol/g), thiolated chitosan synthesised in the current 
study (432 ± 28 µmol/g) showed a higher amount of free thiol groups. Nevertheless, the 
weight ratio of chitosan/2-iminothiolane HCl, the pH of the reaction mixture and the 
molecular weight of the chitosan seem to influence the thiol content of the resultant thiolated 
chitosan (Bernkop-Schnürch et al., 2003; Roldo et al., 2004). A higher free thiol content 
would potentially lead to better mucoadhesive properties. Also, these free thiol groups can 
potentially react with alkyne and alkene groups via thiol-yne and thiol-ene click reactions. 
Therefore, POZylated chitosan was synthesised by reacting thiolated chitosan with alkyne 
terminated POZ (Figure 4.1). The product yield was 78% and it had a white colour with a 
soft structure. 
As shown in Figure 4.2, the 1H NMR assignments of unmodified chitosan were as follows; 
chemical shift (δ) = 3.06 ppm (H2), δ = 3.57-3.80 ppm (H3-H6) and δ = 1.97 ppm 
(NHCOCH3). The peak of H1 was not observed. The degree of acetylation was 25%. No 
difference between the 1H NMR spectrum of unmodified and thiolated chitosan was 
observed (Figure 4.2). We believe that the peaks of H7, H8 and H9 were overlapped in δ 
=3.61-3.80 ppm (H3-H8) and δ = 3.07 ppm (H2 and H9). The POZylated chitosan, however, 
showed very characteristic peaks at δ = 1 ppm (H12) and δ = 2.29 ppm (H11), in addition to 
the peaks of thiolated chitosan (Figure 4.2). From the NMR spectra of pure POZ (Figure 












Figure 4.2 1H NMR spectra of unmodified, thiolated and POZylated chitosan, HAc = 
acetylated hydrogen. The proposed molecular structure of POZylated chitosan is 
shown. The red arrow indicates the possible bond formed leading to thiolated 
chitosan, whereas the purple arrow shows the possible bond formed leading to 
POZylated chitosan.  
 
The FTIR spectra of unmodified, thiolated and POZylated chitosan are shown in Figure 4.3. 
As noted, a characteristic broad peak appeared at 3362 cm-1 related to the stretching vibration 
of both –OH and NH2 groups of the unmodified chitosan. In case of thiolated chitosan, these 
peaks were also observed, but with a slight change in their intensities which is believed to 
be due to the reduction in the number of –NH2 group upon thiolation. Amide bond peaks 
were observed at 1650 and 1630 cm-1 for unmodified and thiolated chitosan, respectively. 
Additionally, in the spectrum of thiolated chitosan, a new peak was observed at 1523 cm-1 
which can be associated with the stretching vibration of C=N of amidine groups. These 
results are in agreement with the study of Sakloetsakun et al. (2010). POZylated chitosan 
showed a sharp strong peak at 1631 cm-1 due to the stretching vibration of C=O of POZ. In 
addition, a medium peak at 1470 cm-1 appeared which belongs to the bending vibration of 










Figure 4.3 FTIR spectra of unmodified, thiolated and POZylated chitosan 
 
4.3.1 Optimisation study 
The DLS study revealed the presence of some large particles (few µm, Table 4.2) in the 
aqueous dispersions of all types of the modified chitosan. This means the systems were not 
molecularly dispersed in water and rather aggregates of some macromolecules were formed. 
Their polydispersity index (PDI) was high, which indicated high polydispersity of the 
products. Both PEGylated and POZylated chitosan had lower ξ-potential than thiolated 
chitosan which could be due to the grafting of PEG or POZ to thiolated chitosan. Moreover, 
the concentration of both PEGylated and POZylated chitosan dispersions were higher than 
the control due to the incorporation of PEG or POZ. This was further increased with 
increasing the amount of PEG or POZ in the reaction mixture but did not significantly change 































Table 4.2 Characteristics of PEGylated and POZylated chitosan dispersions just after the 
dialysis; samples were diluted with ultrapure water (1:100) before the measurement (mean 
± SD, n = 3). PEG-chitosan 1, 2, 3 and POZ-chitosan 1, 2, 3 refer to the products synthesised 
according to conditions described in Table 4.1.  
Types of polymers Z-average 
(nm, DLS) 
PDI ξ-potential (mV) Conc. (mg/mL) 
Thiolated chitosan 3319 ± 170 0.384 ± 0.227 50.85 ± 8.29 11.51 ± 2.82 
Control thiolated chitosan 6748 ± 6063 0.759 ± 0.182 36.17 ± 1.50 1.23 ± 0.01 
PEG-chitosan 1 2329 ± 220 0.703 ± 0.102 20.77 ± 4.15 2.79 ± 0.01 
PEG-chitosan 2 2105 ± 842 0.790 ± 0.127 27.68 ± 3.01 4.32 ± 0.01 
PEG-chitosan 3 2888 ± 432 0.685 ± 0.075 23.22 ± 5.38 3.01 ± 0.01 
POZ-chitosan 1 2611 ± 665 0.540 ± 0.167 30.10 ± 7.10 2.45 ± 0.03 
POZ-chitosan 2 3272 ± 643 0.757 ± 0.174 34.14 ± 2.42 3.44 ± 0.05 
POZ-chitosan 3 2988 ± 969 0.906 ± 0.125 29.30 ± 2.06 2.46 ± 0.04 
 
Ellman’s assay showed that all three PEG-chitosan conjugates did not contain any free thiol 
groups. This suggested that all free thiol groups of thiolated chitosan were reacted with 
maleimide double bonds of PEG. However, in case of POZ-chitosan conjugates, only POZ-
chitosan 2 exhibited complete consumption of all free thiol groups, whereas both POZ-
chitosan 1 and POZ-chitosan 3 showed 43.2 ± 5.5 and 47.0 ± 14.1 µmol/g of free thiol 
groups, respectively (Figure 4.4). This indicated that an increase in the concentration of POZ 
resulted in a higher degree of substitution (DS). On the other hand, the addition of TEA to 
the reaction mixture did not increase the DS of POZylated chitosan. Although some studies 
showed that TEA could facilitate thiol-yne click reaction (Ganivada et al., 2015; Mansfield 
et al., 2015), no improvement in the DS was achieved upon addition of TEA. This could be 
attributed to the small amount of TEA (5 µL) which was less than the amount used by 







leads to the precipitation of thiolated chitosan and formation of disulfide bonds which leads 
to the reduction of free thiol groups. Thus, in our study, minimum amount of TEA was used. 
Based on these results, PEG-chitosan 2 and POZ-chitosan 2 were selected for 1H NMR 
spectroscopy and pH-solubility studies which will be discussed further. 
 
Figure 4.4 Thiol content of thiolated and POZylated chitosan; *** denotes p < 0.001; no 
significant difference between thiolated chitosan and control thiolated chitosan (p 
= 0.689) and also between POZ-chitosan 1 and POZ-chitosan 3 (p = 0.507) was 
observed (one way ANOVA). 
 
The 1H NMR spectrum of pure PEG showed peaks at 3.34, 3.47-3.84 and 6.84 ppm related 
to protons a, b, c, d and e, respectively which are highlighted in Figure 4.5 (Luo et al., 2016; 
Ananda K.  et al., 2008). The 1H NMR spectrum of PEG-chitosan 2 (Figure 4.5) also showed 
all these peaks except the maleimide-related peak at 6.84 ppm which confirmed the 
disappearance of the double bond of maleimide and subsequent formation of C-S single 
bond. Chitosan-related peaks were also observed. The 1H NMR spectrum of POZ-chitosan 
2 showed peaks related to POZ, however, peaks related to chitosan were not clearly visible 










Figure 4.5 1H NMR spectra of PEG and PEG-chitosan 2 in D2O (10 mg/mL), HAc = 
acetylated hydrogen. 
 
Since the main challenge with chitosan is its poor aqueous solubility (especially when pH is 
higher than its pKa (pH 5.5–6.5)) (Casettari et al., 2012), the turbidimetric technique was 
used to determine the pH-solubility profiles of unmodified and modified chitosan (Figure 
4.6). It was found that the unmodified chitosan was soluble at acidic pH ranges. However, it 
underwent rapid precipitation at pH higher than 7.3. Thiolated and POZylated chitosan 
dispersions, however, showed more turbidity than unmodified chitosan at acidic pH, whereas 







chitosan showed better dispersibility (illustrated by its low turbidity, about 0.04 a.u.) at 
acidic pH than both thiolated and POZylated chitosan. Interestingly, its turbidity did not 
change after the pH was increased to 11 but it still was not completely soluble. This result 
could be due to the grafting of PEG on chitosan macromolecules which could reduce the 
crystallinity of chitosan by reducing intra and inter-molecular hydrogen bonding, leading to 
enhanced solubility (Sogias et al., 2010). Nevertheless, the incomplete solubilisation of 
thiolated, POZylated and PEGylated chitosan could be due to the formation of disulfide 
bonds upon oxidation of thiol groups which eventually leads to the formation of insoluble 
crosslinked structure (Bernkop-Schnürch et al., 2003). Decreasing the number of free amino 
groups due to their substitution with 2-iminothiolane HCl can also be another possible reason 
for the poor solubility of thiolated, POZylated and PEGylated chitosan. The amino groups 
are essential for complete dissolution of chitosan as they undergo protonation and enhance 
the solubility of chitosan (Saito et al., 1997; Mao et al., 2005; Casettari et al., 2012). 
Some other studies also reported the incomplete solubilisation of thiolated chitosan 
synthesised from chitosan with the molecular weights of 50, 100 and 400 kDa in 0.2 M nitric 
acid even at pH 1 (Bravo-Osuna et al., 2006; Bravo-Osuna et al., 2007a; Bravo-Osuna et al., 
2007b).  Also it has been observed that aqueous solution of thiolated chitosan with thiol 
content of 46.59 ± 15.04 µmol/g was slightly viscous, however a higher thiol content made 
the polymer insoluble in the aqueous media (Maculotti et al., 2005). Conversely, Masuko et 
al. (2005) suggested that even the solution of thiolated chitosan with 913 µmol/g in 1% v/v 
acetic acid was completely soluble over the pH range of 7-10 indicated by a very low 
absorbance at 650 nm. Masuko et al. (2005) performed the thiolation reaction at a higher 
temperature (55 °C), for a short time (4-10 hours) and using a high molar ratio of 2-








Figure 4.6 pH-solubility profiles of unmodified, thiolated, PEGylated and POZylated 
chitosan using turbidimetry.  
 
Several studies have reported the effect of PEGylation on water solubility of chitosan and 
suggested that the solubility of the PEGylated chitosan is largely dependent on the molecular 
weight and the type of the parent chitosan and the DS of the PEGylated chitosan.  Casettari 
et al. (2010) demonstrated that PEGylated chitosan was fully soluble in aqueous buffer at 
pH 2 to 9.6. Jeong et al. (2008) conjugated PEG to low molecular weight chitosan (10 kDa) 
and found that the PEGylated chitosan did not only show good transparency (higher than 
90%) in aqueous buffers but was also soluble in common organic solvents including DMSO 
and DMF. Chitosan used in our study was larger than the chitosan used by Jeong et al. (2008) 
(medium molecular weight versus 10 kDa). On the other hand, Mao et al. (2005) synthesised 
PEGylated trimethyl chitosan (PEG-TMC) where TMC with 40% degree of quaternisation 
was prepared, then native chitosan and TMC was PEGylated. The results showed that 
solutions of PEG-native chitosan, even with high DS, were not clear at pH 7. However, 
solutions of PEG-TMC were clear over the entire pH ranges regardless of PEG molecular 
weight and DS. The authors believed that the lower water solubility of PEG-native chitosan 







which was also confirmed by the decrease in melting temperature (Tm). In addition, Saito et 
al. (1997) found that PEGylated chitosan with DS of 78.5 and 92.7 %w/w were soluble up 
to pH 6.5. However, when the pH was increased to 6.8, PEGylated chitosan with DS of 
78.5% w/w showed a cloudy solution while PEGylated chitosan with DS of 92.7% w/w 
remained clear.  
In the current study, Ellman’s data indirectly showed that PEGylated and POZylated 
chitosan had similar DS (as in both cases no free thiol content was detected). However, 
PEGylated chitosan dispersion was less turbid compared to POZylated chitosan counterpart.  
4.4 Conclusion  
In the present study, thiolated chitosan was synthesised by reacting unmodified chitosan with 
2-iminothiolane HCl. Then, the thiolated chitosan has been reacted with alkyne-terminated 
POZ and maleimide-terminated PEG to synthesise POZylated and PEGylated chitosan, 
respectively. Generally, all the modified chitosans showed incomplete solubilisation in water 
discouraging the subsequent formation of the nanoparticles using these modified chitosan. 
Studies towards improving the solubility of thiolated chitosan could potentially result in 
better solubility of both POZylated and PEGylated chitosan which could lead to some 
interesting materials for mucosal drug delivery. It seems the main cause of insolubility of 
thiolated chitosan is the oxidation of its free thiol groups (-SH) and formation of disulfide 
bonds (S-S) leading to a crosslinked structure. Although this seems to be an unavoidable 
issue, performing the thiolation reaction under inert condition (e.g. nitrogen) and dark could 
potentially improve the solubility of thiolated chitosan. If any thiol groups of thiolated 
chitosan oxidised to form disulfide bonds, these bonds would possibly remain in the 
POZylated and PEGylated chitosan and would potentially make these two products only 
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The administration of drugs via the nasal route offers the benefits of avoiding pre-systemic 
metabolism, rapid absorption, the possibility of accessing the brain and a better patient 
compliance. However, the nasal route also includes the presence of a highly viscous mucus 
and mucociliary clearance mechanism, which normally protect the human body by 
preventing the entrance of harmful chemicals and microorganisms, but often generate 
obstacles in the absorption of drugs and nanoformulations leading to poor efficacy. The 
design of mucus-penetrating nanoparticles can overcome the barrier function of mucus and 
mucociliary clearance which may lead to better therapeutic outcomes. Thus, in this study, 
unmodified and modified chitosan (grafted with 5 kDa polyethylene glycol (PEG)-, 
polyhydroxyethyl acrylate (PHEA)-, poly-2-ethyl-2-oxazoline (POZ)- and polyvinyl 
pyrrolidone (PVP)-CO-NH-chitosan) nanoparticles were prepared by an ionic gelation 
method using sodium tripolyphosphate. The nanoparticles were characterised using DLS, 
TEM and NTA. A method to evaluate the diffusion of chitosan nanoparticles in bovine 
submaxillary mucin (BSM) solution using NTA has been developed. It was found that 
modified chitosan nanoparticles diffuse faster in BSM solution than unmodified chitosan 
nanoparticles. The penetration into the sheep nasal mucosa study corroborated the diffusion 
data. Our findings in this study, encourage researchers to use these mucus-penetrating 


















Nasal route of drug administration is advantageous as it avoids first pass metabolism, 
provides rapid onset of action and is non-invasive (Ugwoke et al., 2005). It is also considered 
as a potential direct transport route of drugs from the nasal cavity to the brain useful for the 
treatment of various central nervous system diseases including epilepsy, schizophrenia, 
migraine, Alzheimer's and meningitis which require the delivery of the drugs to the brain 
(Mistry et al., 2009; Kozlovskaya et al., 2014).  The nasal mucosa is covered by a viscoelastic 
mucus gel layer similar to other mucosal surfaces, e.g. the gastrointestinal tract, eyes and 
respiratory system. The mucus layer acts as a protective barrier preventing the entrance of 
harmful substances into the human tissues. However, the protective function of mucus also 
inhibits the diffusion of lipophilic drugs and nanoformulations and can result in a significant 
reduction of their efficacy (Lai et al., 2009; Sigurdsson et al., 2013). 
Human nasal cavity and upper airways produce about 1.5-2 L of nasal mucus daily which 
forms a 5 µm thick mucus bilayer (lower sol and upper gel layer) (Ugwoke et al., 2005). 
However, in the case of respiratory diseases including chronic rhinitis, asthma and chronic 
obstructive pulmonary disease, excessive mucus production and mucosal hyper-
responsiveness lead to the formation of thick and tenacious mucus layer (Baraniuk, 1997; 
Rogers & Barnes, 2006; Sin & Togias, 2011; Ramos et al., 2014). It is known that the mucus 
layer is continuously renewed during mucus turnover within various times depending on the 
type of mucosal surfaces. The rapid movement of cilia propels the nasal respiratory mucus 
(known as mucociliary clearance) from the interior toward the posterior part of the nasal 
cavity resulting in a short mucus turnover time (15-20 minutes, in human) (Illum, 2003). In 
rats, the mucus turnover time of nasal respiratory mucosa is about 10 minutes (Harkema et 
al., 2006). The mucociliary clearance and the mucus turnover significantly decrease the 
residence time of both conventional (e.g. simple solution) and mucoadhesive drug delivery 
systems at the nasal mucosa (Lai et al., 2009). Due to the protective mechanism of the mucus 
barrier, alternative drug delivery systems that allow rapid penetration through the mucus 
layer and overcome the mucociliary clearance must be sought. 
It has been shown that mucoadhesive chitosan-based nanoemulsion could improve the nose 
to brain transport of small molecular weight drugs including risperidone in rats compared to 
the uncoated nanoemulsion and the simple resperidone solution (Kumar et al., 2008). 





excised porcine respiratory mucosa compared to unmodified chitosan nanoparticles and 
leuprolide solution (Shahnaz et al., 2012). Also, thiolated chitosan nanoparticles improved 
the bioavailability of leuprolide after nasal administration to Sprague–Dawley rats compared 
to the unmodified chitosan nanoparticles and leuprolide solution. These effects could be due 
to the mucoadhesive properties of thiolated chitosan, the ability of thiolated chitosan to open 
the tight junctions (the hydrophilic channels between the epithelial cells) and protect 
leuprolide against enzymatic degradation (Shahnaz et al., 2012).  
Surface modification has been shown to enhance the penetration of nanoparticles into the 
nasal mucosa (Sonvico et al., 2018). For example, Vila et al. (2004) demonstrated an 
enhanced nasal mucosal penetration of high density polyethylene glycol coated polylactic 
acid (PEG-coated PLA) nanoparticles compared to low density PEG-coated and non-coated 
PLA nanoparticles in rat. Lai et al. (2011) showed that 200 nm PEG-coated polystyrene 
nanoparticles diffused significantly faster than 200 nm uncoated polystyrene nanoparticles 
in human chronic rhinosinusitis mucus which was collected from maxillary sinus cavities. 
In the same study, they also showed the enhanced diffusivity of 188 nm Pluronic-F127-
coated polylactide-co-glycolide (PLGA) nanoparticles compared to 129 nm uncoated PLGA 
nanoparticles. In an ex vivo porcine model, Mistry et al. (2015) found that chitosan-coated 
polystyrene nanoparticles entrapped in the mucus layer and could not reach the epithelial 
layer of olfactory mucosa. However, the polysorbate-80-coated polystyrene nanoparticles 
showed some degree of penetration into the epithelial cells. Nevertheless none of these two 
types of nanoparticles were able to cross the excised porcine olfactory mucosa in significant 
quantity.  
PEG has been used as a gold standard polymer with stealth properties, however, its efficiency 
as a coating material in the mucus penetrating nanoparticles is controversial. For example, 
using atomic force microscopy, Kirch et al. (2012) showed that PEG-coated dextran-iron 
oxide magnetic composite nanoparticles (500 nm) are less mucoadhesive than their chitosan-
coated counterpart when 1% w/v mucin solution was used as a substrate. However, upon 
conducting capillary penetration experiment using mucus from the distal part of horse 
bronchia, no difference in the mucus penetration ability between the two types of 
nanoparticles was observed. On the other hand, Schneider et al. (2017) demonstrated that 
PEG coating significantly improved the mobility of both polystyrene and PLGA 





PLGA nanoparticles. In a mouse model of acute lung inflammation, they also showed that 
inhalation of dexamethasone sodium phosphate loaded PEG-coated PLGA nanoparticles 
enhanced the anti-inflammatory effect compared to free dexamethasone sodium phosphate 
and dexamethasone sodium phosphate loaded non-coated PLGA nanoparticles (Schneider et 
al., 2017). 
Previously, we showed that PEGylated and poly-2-ethyl-2-oxazoline (POZ)ylated silica 
nanoparticles had a greater diffusivity in porcine gastric mucin (PGM) dispersion and 
porcine gastric mucosa compared to their thiolated counterpart (Mansfield et al., 2015). 
Later, we demonstrated that nanoparticles coated with a more hydrophilic polyoxazoline 
derivative (poly-2-methyl-2-oxazoline)  penetrated deeper into the porcine gastric mucosa 
compared to the nanoparticles coated with a less hydrophilic polyoxazoline derivatives (POZ 
and poly-2-n-propyl-2-oxazoline) (Mansfield et al., 2016). Considering the above aspects, 
in this study, we sought to determine the potential of some hydrophilic polymers in the 
design of mucus-penetrating chitosan nanoparticles for nasal drug delivery. Thus, we 
prepared 4 types of nanoparticles (PEG-, polyhydroxyethyl acrylate(PHEA)-, POZ- and 
polyvinyl pyrrolidone(PVP)-CO-NH-chitosan-TPP) (hereinafter refer to PEG-, PHEA-, 
POZ- and PVP-chitosan nanoparticles) and compared their diffusivity in mucin solution and 
sheep nasal mucosa against unmodified chitosan nanoparticles.  
5.2 Materials and methods 
5.2.1 Materials 
Medium molecular weight chitosan (degree of deacetylation 75-85%), trifluoroacetic acid 
(TFA), D2O, methoxy-PEG-COOH (5 kDa), 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide hydrochloride (EDAC), N-hydroxysuccinimide (NHS), mucin from bovine 
submaxillary glands Type I-S (BSM), sodium tripolyphosphate (TPP), 4′,6-diamidino-2-
phenylindole dihydrochloride  (DAPI), ninhydrin and D-(+) glucosamine hydrochloride 
were purchased from Sigma-Aldrich (Gillingham, UK). Uranyl acetate dihydrate was 
purchased from Agar Scientific (UK). Sodium acetate trihydrate, Molecular Probes™ Alexa 
Fluor™ 546  NHS ester (Alexa Fluor™ 546), glacial acetic acid, dimethyl 
sulfoxide (DMSO), sodium hydroxide (NaOH) and Cellpath™ OCT embedding matrix 
(OCT) were purchased from Fisher Scientific (UK). Dialysis membrane with molecular cut-
off 12–14 kDa was purchased from Medicell International Ltd., UK. Phosphotungstic acid 





destabilized by passing the monomer through a basic aluminum oxide column prior to 
polymerization. N-Vinylpyrrolidone (NVP, 99%, Acros) was purified by vacuum 
distillation. 2,2’-Azobis(isobutyronitrile) (AIBN), potassium ethyl xanthogenate and 2-
bromopropionic acid 99% were obtained from Sigma-Aldrich. AIBN was purified by 
recrystallization twice in methanol before use. HPLC grade solvents N,N-dimethylacetamide 
(DMA), diethyl ether and dichloromethane were obtained from Sigma Aldrich, N,N-
dimethylformamide (DMF) from Biosolve and n-hexane from Fischer Scientific. 2-
(butylthiocarbonothioylthio)propanoic acid (BTTCP) was synthesized as described by 
Ferguson et al. (2005). Xanthate CTA (2-((ethoxycarbonothioyl)thio)propanoic acid) 
(ECTTPA) was synthesized by a general procedure described previously by Pound et al. 
(2008). Acetonitrile (Aldrich) was dried in a solvent purification system (J. C. Meyer). 2-
Ethyl-2-oxazoline (EtOx; Aldrich), methyl 2-bromoacetate and piperidine were distilled 
over barium oxide and stored under argon. All other chemicals were purchased from Sigma-
Aldrich or Acros Organics and used as received. 
 
The synthetic method presented in sections 5.2.2, 5.2.3, 5.2.4 and 5.2.5 were carried out 
in Prof Richard Hoogenboom research group at University of Ghent, Belgium.  
5.2.2 Synthesis of PHEA-COOH  
The RAFT polymerization of HEA was performed in a 25 mL Schlenk tube under an argon 
atmosphere. An example of RAFT polymerization with BTTCP was as follows. HEA (4.0 
g, 34.4 mmol), 2-(butylthiocarbonothioylthio)propanoic acid (BTTCP) (82.0 mg, 0.35 
mmol) and AIBN (5.7 mg, 0.035 mmol) were dissolved in 9.6 mL DMF in a 25 ml Schlenk 
vial. The solution was then degassed by bubbling with argon over 50 min, immersing in ice 
bath, after which the Schlenk vial was filled with argon and immersed in an oil bath 
preheated at 70 oC while stirring. The polymerization was performed for 20 min and stopped 
by immersing the Schlenk vial into a dry ice/isopropanol bath. Polymeric product was then 
isolated by manual precipitation in a cold 50/50 mixture of diethyl ether and hexane and 
dried under vacuum to yield PHEA-COOH. By determining the monomer conversion via 
gas chromatography, a theoretical molecular weight, Mn,th, of 4.3 kDa was measured. Size 
exclusion chromatography (SEC) in dimethylacetamide (DMA) showed Mn,SEC = 10.1 kDa 





5.2.3 Synthesis of POZ-COOH 
A solution of EtOx (4.7582 g, 48.00 mmol), methyl 2-bromoacetate (90.9 μL, 0.96 mmol) 
and potassium iodide (0.1753 g, 1.06 mmol) in acetonitrile with an initial monomer 
concentration of 4 M was prepared in a microwave vial and closed with a crimp cap under 
argon. The polymerization mixture was heated to 140 °C for 7 min 45 sec under microwave 
irradiation and subsequently cooled to ambient temperature. To the polymer solution 
piperidine (378.6 µL, 3.83 mmol) was added and the obtained mixture was stirred overnight. 
The solution was concentrated under reduced pressure, and the residue was dissolved in 
water. Lithium hydroxide (230 mg, 9.6 mmol) was added to the solution and the mixture 
was stirred overnight. The solution was acidified using hydrochloric acid (10%) until pH 2 
was obtained. The solution was dialyzed (Spectra/Por CE membrane, MWCO 500 – 1000 
D) against water until neutral pH was obtained. POZ-COOH was obtained after freeze-
drying. DMA-SEC: Mn = 6.8 kDa, Đ = 1.06. 
5.2.4 Synthesis of PVP-COOH 
The MADIX/RAFT polymerization of NVP was performed in a 25 mL Schlenk tube under 
argon atmosphere. NVP (4 g, 36.0 mmol), ECTTPA (46.6 mg, 0.24 mmol), AIBN (3.94 mg, 
2.4 x 10-2 mmol) and 7.8 mL anisole were added to the Schlenk flask at a molar ratio of 
monomer/CTA/AIBN of 150/1/0.1. After degassing by 3 freeze-pump thaw cycles the 
Schenk flask was placed in an oil bath set at 60 °C for 12 h. The polymer was isolated by 
precipitation in hexane. Further, the polymer was dissolved in dichloromethane (DCM) and 
re-precipitated in hexane three times and were recovered as a white powder. By determining 
the monomer conversion via gas chromatography a theoretical molecular weight, Mn,th, of 
6.7 kDa was measured. SEC in DMA showed Mn,SEC = 4.9 kDa against PMMA standards 
and a dispersity (Đ) of 1.21. 
5.2.5 Characterization of PHEA-, POZ- and PVP-COOH 
A Bruker Avance 300 MHz Ultrashield was used to measure the 1H-nuclear magnetic 
resonance (1H NMR) spectra at room temperature, the chemical shifts are given in parts per 
million (δ) relative to tetramethylsilane (TMS).  
Size-exclusion chromatography (SEC) was performed on an Agilent 1260-series HPLC 
system equipped with a 1260 online degasser, a 1260 ISO-pump, a 1260 automatic liquid 





PLgel 5 µm mixed-D columns and a guard column in series, a 1260 diode array detector 
(DAD) and a 1260 refractive index detector (RID). The used eluent was N,N-
dimethylacetamide DMA containing 50 mM of LiCl at a flow rate of 0.593 mL/min. The 
spectra were analyzed using the Agilent Chemstation software with the GPC add-on. Molar 
mass and Đ values were calculated against POZ (for POZ-COOH) and PMMA (for PHEA- 
and PVP-COOH) standards. 
5.2.6 Synthesis of PEG-, PHEA-, POZ- and PVP-CO-NH-chitosan 
Four modified chitosan (PEG-, PHEA-, POZ- and PVP-CO-NH-chitosan, hereinafter refer 
to PEG-, PHEA-, POZ- and PVP-chitosan) were synthesised as follows.  To 80 mg medium 
molecular weight chitosan, 11.5 mL acetic acid (1% v/v) was added. The mixture was 
continuously stirred for 20 hours at room temperature. The pH of chitosan solutions was 
increased to 6 using 5 M NaOH solution. PEG-COOH (117 mg), PHEA-COOH (117 mg 
dissolved in 5 mL deionised water) and POZ-COOH (117 mg) and PVP-COOH (100 mg) 
was added to the chitosan solutions. Then after 5 minutes stirring, NHS (13.5 mg) was added 
to each and stirred for 30 minutes. EDAC (22.4 mg) was then added and stirred for 24 hours. 
The products were dialysed against deionised water (4 L, 8 total changes, 12-14 kDa) at 
room temperature for at least 3 days. The products were recovered by lyophilisation using 
Heto Power Dry LL 3000 freeze-drier (Thermo Electron Corporation). The % of yield was 
calculated according to Equation 5.1. 
 
                                                                                    Equation 5.1 
 
W1 is the weight of the freeze dried modified chitosan. 
 W2 and W3 are the weight of unmodified chitosan and modifying polymers (PEG-, PHEA-, 













The percentage of grafting in weight (GW %) was calculated according to the method 
reported by Bhattarai et al. (2005) (Equation 5.2). 
                                                                                    
                                                                          Equation 5.2 
 
 
Where Wg is the weight of the freeze dried grafted polymer and Wn is the weight of native 
chitosan in the reaction mixture. 
5.2.7 NMR spectroscopy 
1H NMR spectra were recorded using a Bruker Nanobay 400 MHz NMR spectrometer. The 
polymers were added to acidified D2O (made from 1 mL D2O with 10 µL of TFA) and stirred 
for 16 hours at room temperature. The degree of acetylation (DA) of the unmodified chitosan 
was calculated using Equation 5.3 (Sogias et al., 2008): 
 
                                                                              Equation 5.3 
 
Where ICH3 is the integral intensity of N-acetylated proton and IH2-H6 is the sum of the integral 
intensity of proton number 2, 3, 4, 5 and 6. 
The degree of substitution (DS) of the modified chitosan was calculated using 1H NMR 
spectroscopy by integrating related peaks of the grafted polymers against specific chitosan 
peak in the modified chitosan. The related peaks were marked in Figure 5.1, Figure 5.2, 
Figure 5.4 and Figure 5.6. 
5.2.8 FTIR spectroscopy 
FTIR spectra of the polymers were recorded using a NICOLET iS5 FTIR spectrophotometer 
(ThermoScientific, UK). The spectra were collected from an average of 16 scans, with a 
resolution of 4 cm-1 over the range of 4000-400 cm-1. 
 
GW % = 
Wg - Wn 
Wg











5.2.9 pH-solubility profile  
Solubility of the modified and unmodified chitosan was measured at different pHs at room 
temperature using turbidimetric technique. The polymers were dissolved (0.5 mg/mL, 20 
mL) in 1% v/v acetic acid and left stirring for 24 hours. The turbidity (absorbance) of the 
systems was measured at room temperature using a BioTek Epoch plate reader at 400 nm 
using 1% v/v acetic acid as a blank.  200 µL aliquots were used. The pH was adjusted by the 
addition of either 1 M NaOH solution or 1% v/v acetic acid. The results are reported as the 
average of the turbidity of 3 samples at each pH point ± standard deviation.  
5.2.10 Ninhydrin assay 
Ninhydrin assay was performed to determine free amino groups to find out the DA of 
unmodified chitosan and the DS of modified chitosan. Ninhydrin reagent was prepared by 
dissolving ninhydrin powder in DMSO (2% w/v, stirred for 1 hour) at room temperature in 
the dark. Solutions of glucosamine (standard) and the polymers were prepared by dissolving 
the calculated amounts of the materials in 1% v/v acetic acid (glucosamine 0.3 to 0.125% 
w/v, unmodified chitosan 0.5 to 0.15% w/v and modified chitosan 0.6 to 0.25% w/v). 100 
µL of each solution was mixed with 250 µL of 0.5 M sodium acetate buffer solution (pH 
5.4) and 1 mL of ninhydrin reagent. The final mixtures were incubated in a 95 °C water bath 
for 40 minutes. The mixtures were then allowed to cool down for 15 minutes. Then, 200 µL 
aliquots from each mixture were analysed using a BioTek Epoch plate reader at a wavelength 
of 570 nm. The curve of concentration versus absorbance was plotted. Then the DA of 
unmodified chitosan and the DS of modified chitosan were calculated according the 
published method (Shitrit & Bianco-Peled, 2017) with some modifications using   Equation 
5.4 and Equation 5.5, respectively.       
                                                                                        Equation 5.4 
         
 
 





Where m is the gradient of the trendlines (Figure 5.8). 
 
DA = [1- (
munmodified chitosan
mglucosamine 
)]×100                     
DS = [1- (
mmodified chitosan
munmodified chitosan 






5.2.11 Unmodified and modified chitosan Alexa Fluor™ 546 labelling 
Chitosan was dissolved in acetic acid (1% v/v, 5 mg/mL, 9.66 mL). The pH was increased 
to 6 using 5 M NaOH solution. Alexa Fluor™ 546  was dissolved in DMSO (5 mg/mL), 
vortexed for 2 minutes then 138 µL  Alexa Fluor™ 546  solution (equivalent to 0.69 mg 
Alexa Fluor™ 546) was added to chitosan solution and the reaction mixture was stirred for 
4 hours at room temperature in the dark. Then the product was dialysed against deionised 
water in the dark using 12-14 kDa MWCO dialysis membrane (for 96 hours, 1 L for 5 
changes). To determine Alexa Fluor™ 546 content, chitosan solutions (0.2 mg/mL in 1% 
v/v acetic acid) were prepared by stirring overnight in the dark. Then the solutions were 
diluted according to the calibration curve with ultrapure water in the dark. The pH was 
adjusted to 6 using 0.5 M NaOH solution. The fluorescence intensity of three separate 
samples was measured using a fluorescence spectrometer (Cary Eclipse, Varian Inc., US). 
In order to establish a calibration curve, serial dilutions of Alexa Fluor™ 546 in ultrapure 
water (50, 25, 12.5, 6.25 and 3.125 ng/mL) were prepared by diluting Alexa Fluor™ 546 
stock solution (5 mg/mL in DMSO). Finally, Alexa Fluor™ 546 content was calculated with 
reference to the calibration curve. 
5.2.12 Preparation of chitosan nanoparticles 
Unmodified chitosan and modified chitosan nanoparticles were prepared using an ionic 
gelation method according to Calvo et al. (1997) but with some modifications. After, 
optimisation steps, where various factors including the concentration of chitosan solution, 
chitosan/TPP weight ratio, the pH of chitosan and TPP solutions, the concentration of acetic 
acid and the temperature of crosslinking, a protocol was selected. Briefly, to prepare 
unlabelled chitosan nanoparticles, chitosan solutions (1 mg/mL in 1% v/v acetic acid) were 
prepared and the pH was increased to 5.5 using 5 M NaOH solution. 1 mg/mL TPP solution 
was prepared by dissolving calculated amount of TPP in deionised water. Before mixing, 
both TPP and chitosan solutions (pH 5.5) were filtered through 0.2 µm syringe filter. Then, 
4 mL TPP solution was added dropwise to the chitosan solutions (8 mL) over the period of 
5 minutes. The suspensions were stirred for another 30 minutes at room temperature. Alexa 
Fluor™ 546-labelled unmodified chitosan and PEG-chitosan nanoparticles were also 
prepared as mentioned for unlabelled chitosan nanoparticles.  However, for Alexa Fluor™ 
546-labelled PHEA-, POZ- and PVP-chitosan nanoparticles, 2 mL TPP solution was added 





described for the unlabelled chitosan nanoparticles. In case of Alexa Fluor™ 546-labelled 
nanoparticles, the experiments were conducted in the dark. 
5.2.13 Characterisation of the nanoparticles 
5.2.13.1 Dynamic light scattering (DLS) 
The size and ξ-potential of the nanoparticles were measured using a Zetasizer Nano-ZS 
(Model: ZEN3600, Malvern, UK). For the size measurements, the samples were diluted 
(1:100 for unlabelled nanoparticles and 1:20 for Alexa Fluor™ 546-labelled nanoparticles) 
with ultrapure water before analysis. A refractive index of 1.59 and an absorbance of 0.01 
were used for all measurements. Viscosity (0.8872 cP) and refractive index (1.33) of water 
were used as dispersant parameters. The samples were incubated for 60 seconds and the 
measurements were conducted in triplicate for 10 seconds per run, with 12 runs per reading 
at 25 °C. The measurement angle was set to 173° backscatter. For the data processing, the 
normal resolution analysis model was selected. ξ-potential values were measured using 
DTS-1070 folded capillary tube cuvettes (Malvern, UK). Samples were diluted with 
ultrapure water (1:10) before analysis. Samples were measured using 3 repeats of 20 sub-
runs per reading. For ξ-potential, data was processed using auto mode analysis model. At 
least 3 samples were measured and processed using the Smoluchowski model (Fκa = 1.50).  
5.2.13.2 Nanoparticle tracking analysis (NTA) 
The nanoparticles were also characterised by NTA using NanoSight instrument (LM10 
system, LM14 laser module, top plate and green 532 nm laser, Malvern, UK). For the NTA 
measurements, Alexa Fluor™ 546-labelled nanoparticles suspensions were diluted 
(1:10,000) with ultrapure water (pH 5.5, acidified with 1% v/v acetic acid). Fluorescence 
mode was used for the NTA measurement of the nanoparticles. 1 mL diluted sample was 
taken using a 1 mL syringe and the syringe was loaded onto an NTA syringe pump. A 
sCMOS camera and an NTA 3.2 software were used to capture and process the motion of 
the nanoparticles. The camera level was set to 16 and the detection thresholds were 5. The 
syringe pump speed of 50 AU was selected to minimise the settlement and the subsequent 
adhesion of the nanoparticles to the surface of the instrument chamber. The viscosity of 
water was used as the diluent viscosity. Automatic maximum jump mode, blur and minimum 
track length were used for all NTA measurements. The temperature was fixed at 25 °C. For 





separate samples were analysed. Finally, the mean and the mode of size and the mean 
diffusion coefficient were reported. 100 nm nonfluorescent polystyrene latex (diluted 
1:150,000 with ultrapure water) was used as a standard, however, the scatter mode was used 
to measure the size of this standard nanoparticles. 
5.2.13.3 Transmission electron microscopy (TEM) 
TEM was conducted using a JEM-2100 PLUS Electron Microscope (JEOL, USA) at an 
accelerating voltage of 200 kV. One drop of nanoparticles suspensions were placed on a 
piece of parafilm. A carbon-coated copper grid was dipped into the nanoparticles 
suspensions and left for 1 minute. The excess nanoparticles suspensions were then removed 
by a filter paper. Then a drop of 2% w/v phosphotungstic acid solution was placed on the 
parafilm. The grid was then immersed in the stain solution for 30 seconds and any excess 
stain was removed using a filter paper.  The samples were then air dried and analysed. At 
least 3 images were taken and the size of the nanoparticles were measured using ImageJ 
software (Version 1.50b, National Institutes of Health, USA).  
5.2.13.4 Fluorescence spectroscopy 
Fluorescence emission spectra of Alexa Fluor™ 546-labelled chitosan nanoparticles and 
0.5% w/v BSM solution were obtained between 560-750 nm at excitation wavelength of 554 
nm using a fluorescence spectrometer (Cary Eclipse, Varian Inc., US). For the measurement, 
the nanoparticles were diluted (1:50) with ultrapure water, whereas the mucin solution was 
measured without dilution. The experiments were conducted in triplicate. 
5.2.14 Viscosity measurement of BSM solution 
0.5% w/v BSM solutions (3 × 25 mL) were prepared by dissolving the required amount of 
BSM in ultrapure water. The samples were stirred overnight at room temperature. After 
complete hydration, the pH of the solutions was decreased to 5.5 using 1% v/v acetic acid. 
Rheological analysis was performed using an AR 2000ex rheometer (TA Instruments, UK) 
with a 40 mm parallel plate. First, 0.5 mL sample was measured to find the linear visco-
elastic region of BSM. This measurement was conducted at 25 °C and the solvent trap was 
placed. Thus, at a constant frequency of 1 Hz, strain sweep was performed between 0.01-
10%. Then, at a constant strain of 4% a frequency sweep between 0.01-10 Hz was performed. 
Then, it was found that frequency of 1 Hz and strain of 4% is optimum as it provided a linear 





to 40 °C) were performed at frequency of 1 Hz and strain of 4%. Then values of viscosity 
was plotted as a function of temperature. Finally, viscosity of the mucin solution at 25 °C 
was calculated using the trendline equation which was later used in the NTA diffusion study 
of the nanoparticles in BSM solution. 
5.2.15 Evaluation of diffusion of chitosan nanoparticles in BSM solution 
NTA was used to evaluate the diffusion of chitosan nanoparticles in BSM solution. Initially, 
four different concentrations of BSM solution (0.1, 0.25, 0.5 and 1% w/v) were evaluated 
for their background fluorescence noise and their consistency. Alexa Fluor™ 546-labelled 
chitosan nanoparticles were first diluted in ultrapure water (pH 5.5, 1:100) and then mixed 
with 0.5% w/v BSM solution (pH 5.5, 1:100). 1 mL of the mixture was injected into the 
NTA system with flow rate set at 50 AU. The diffusion of the nanoparticles in mucin solution 
was visualised at 25 °C. The videos were recorded through a 565 nm cut-on filter. Each 
individual mucin solution (0.5% w/v, 3 separate samples) was mixed 3 times with each of 
the nanoparticles type and thus generated 9 × 6 × 60 second videos (n = 9). The measured 
viscosity of 0.5% w/v BSM solution (3.05 cP, which was found from the rheological 
analysis) was used for processing the diffusion data. The other parameters were set as 
described for size measurement of the nanoparticles using NTA in section 5.2.13.2. 
5.2.16 Penetration of chitosan nanoparticles into sheep nasal mucosa 
The penetration of chitosan nanoparticles was studied using whole thickness sheep nasal 
septum mucosa. The tissues were used immediately after obtained from a local abattoir (P.C. 
Turner Abattoirs, Farnborough, UK). The nasal septum mucosa was segmented into 1 × 1.5 
cm2 and placed in a plastic Petri dish and transferred to a temperature controlled incubator 
(32 °C). 20 µL Alexa Fluor™ 546-labelled chitosan nanoparticles were added onto the nasal 
mucosal tissues and incubated at 32 °C for 5, 15 and 30 minutes. After each time point, 
tissues were transferred and covered with OCT and placed on dry ice for overnight storage. 
The rectangular frozen tissue blocks were then stored in sealed bags at -80 °C freezer until 
processing.  
To prepare tissue slices, the tissues were cross-sectioned using a Bright 5040 cryostat  
(Bright Instrument Co. Ltd., UK) which was loaded with an MB35 Premier Disposable 
Microtome blade (34° cutting angle, length × width × thickness:  80 × 8 × 0.25 mm, Thermo 





specimen and chamber temperature was -20 and -25 °C, respectively.  The slices were cut 
upward through the mucosal layer and transferred to SuperFrost Plus™ Adhesion slides 
(Thermo Scientific, UK) and air dried for 30 minutes before storage. At least 10 slices were 
prepared for each time point. Sheep nasal mucosa without any exposed nanoparticles was 
used as a background control. 
The fluorescence microscopy was performed using a Leica MZ10F fluorescence 
stereomicroscope (Leica Microsystems, UK). The images were taken  at exposure time 344 
ms, gain 3X, gamma 1, pseudocolour 565 nm, maximum intensity, magnification of 3.2 and 
ET CY3 filter. At least 10 images were recorded for each time point.  
The images were analysed using ImageJ software (National Institutes of Health, USA) and 
the depth of penetration was measured according to Mansfield et al. (2015) with some 
modifications. The images were opened using the software and the scale was set. A line was 
drawn along the mucosal layer and the fluorescence intensity profile of the line was plotted. 
The plot showed the fluorescence peak width which indicates the depth of penetration of the 
nanoparticles into the nasal mucosa. The graphical profile was converted into numbers using 
list option. The depth of penetration was calculated by subtracting the value of the start point 
from the value of the end point of the peak. For each image, this procedure was repeated 5 
times at random regions of mucosal barrier and thus for each sample at each time point, 50 
profiles were generated.  
Additionally, to investigate how far the nanoparticles penetrated into the nasal mucosa, 75 
µL DAPI solution (1.5 µg/mL in deionised water) was added to stain the cross sections and 
incubated overnight in the dark at room temperature. At least 6 slices were stained.  DAPI 
solution was kept at 4 °C in the fridge and used within 1 week of preparation. Fluorescence 
microscopy was performed in the following day in the dark using Zeiss Axio Imager.A1 
upright epifluorescent microscope with AxioVision Rel. 4.8 software. At least 3 images for 
each time point were taken. Each image was taken first with Alexa 546 (yellow) and then 
with DAPI (blue) filters. The images were then merged and exported as composite images 
using AxioVision Rel. 4.8 software. 
5.2.17 Statistical analysis 
Unless otherwise stated, all measurements were collected in triplicate and the data are 





Statistics 21 program (IBM, US). The statistical significance of any difference between 
groups was determined using one-way analysis of variance (ANOVA) with the least 
significant difference (LSD) post-hoc test. Independent sample t-test was performed to 
compare each pair of data sets. Differences were considered statistically significant at 
p < 0.05. 
5.3 Results and discussion 
5.3.1 Characterisation of unmodified and modified chitosan 
Chitosan is a cationic mucoadhesive polysaccharide having free amino and hyroxyl groups. 
The presence of these groups in chitosan allows possible chemical modifications (M. Ways 
et al., 2018a). We hypothesised that modification of chitosan into a more hydrophilic 
derivative can impart stealth properties to the modified chitosan which can be used in 
formulating mucus penetrating nanoparticles. In this study, four chitosan derivatives have 
been synthesised by reacting chitosan with water soluble polymers (carboxyl terminated-
PEG, PHEA, POZ and PVP) using EDAC/NHS chemistry. The DA of unmodified chitosan 
was determined using 1H NMR (Figure 5.1) and ninhydrin assay and was found to be 25.03% 
and 71.73 ± 1.60%, respectively. The synthetic procedure provided high yield (Table 5.1). 


















Figure 5.1 1H NMR spectrum of (A) unmodified chitosan in acidified D2O, (B) PEG-COOH 












Table 5.1 Characterisation of the synthesised modified chitosan. 
Types of materials Yield (%) GW (%) DSa (%, 
NMR) 
 DS (%, 
ninhydrin) 
PEG-chitosan 77.15 47.36 16.33 50.05 ± 2.22 
PHEA-chitosan 63.05 36.36 6.39 64.70 ±  1.64 
POZ-chitosan 65.48 37.98 15.97 34.58 ± 1.86 
PVP-chitosan 80.00 44.44 NA 38.99 ± 2.57 
a Degree of substitution (DS) was calculated using 1H NMR spectroscopy by integrating 
related peaks of the grafted polymers against specific chitosan peak in the modified chitosan 
as marked in Figure 5.1, Figure 5.2, Figure 5.4 and Figure 5.6.  
 
As shown in Figure 5.1, the 1H NMR spectrum of unmodified chitosan contains peaks at 
3.06, 3.57-3.80 and 1.97 ppm corresponding to H2, H3-6 and NHCOCH3, respectively. H1 
was not observed and this is consistent with the literature claiming that H1 can only be 
determined at a temperature higher than 25 °C (Wu et al., 2007). 
The NMR spectrum of PEG-chitosan showed a peak at 3.33 ppm due to the OCH3 group of 
PEG-COOH and the peaks related to H3, H4, H5 and H6 were overlapped with the peaks of 
the OCH2CH2 and OCH2 groups (b, c and d) (3.35-3.89 ppm) (Figure 5.1). The appearance 
of the peaks of PEG-COOH and PEG-chitosan were identified and compared as highlighted 
in the literature (Luo et al., 2016). The DS (DPEG %) was calculated according to Equation 
5.6. 
 






DPEG % = 
I (OCH3)/3 
I (H2)








The NMR spectrum of PHEA-chitosan showed additional peaks related to PHEA (most 
notably the peak at 4.10 ppm (b), Figure 5.2). The NMR spectrum of PHEA-COOH is also 
shown in Figure 5.3. The DS (DPHEA %) was calculated using our proposed method 
according to Equation 5.7.  
                                           


















Figure 5.3 1H NMR spectrum of PHEA-COOH measured in D2O (this data was recorded, 
















The NMR spectrum of POZ-chitosan showed 2 new characteristic peaks related to POZ 
appeared at 0.96 ppm (CH3 of side chain i.e. 3 H) and 2.27 ppm (CH2 of side chain i.e. 2 H 
and N-CH2 of the end group). 4 H of CH2 of main chain were overlapped with H2-H6 peaks 
of chitosan (Figure 5.4). The NMR spectrum of POZ-COOH is also shown in Figure 5.5. 
The DS (DPOZ %) was calculated according to Equation 5.8 .  
 
                                                                                                        



















Figure 5.5 1H NMR spectrum of POZ-COOH measured in CDCl3 (this data was recorded, 
















The NMR spectrum of PVP-chitosan also showed peaks related to PVP, however, the DS of 
PVP-chitosan could not be determined by NMR as the peaks of PVP and chitosan were 
overlapped (Figure 5.6). The NMR spectrum of PVP-COOH is also shown in Figure 5.7.  
Instead, ninhydrin assay was used to determine the DS of PVP-chitosan, which will be 




















Figure 5.7 1H NMR spectrum of PVP-COOH measured in DMSO-d6 (this data was 




Ninhydrin assay showed  a higher DS than NMR data (Table 5.1), which is in agreement 
with literature (Kolawole et al., 2018). This could be due to the fact that different solvent 
environment (most notably pH, ionic strength and polarity) has been used in the two 
methods. This in turn could lead to different conformations of the polymers and the 
availability of free amino groups to react with the ninhydrin reagent (Kolawole et al., 2018). 
Additionally, it can be argued that ninhydrin assay is less precise than the NMR technique 
as the intensity of the colour of the blue product is not exactly linearly dependent on the 
concentration of the amino groups in the analyte. This was indicated by a relatively low R2 
value (Figure 5.8). This could be due to the non-stoichiometric nature of the ninhydrin 








Figure 5.8 Calibration curves used for the ninhydrin assay of glucosamine (y = 8.5211x - 
0.8384, R² = 0.973), unmodified chitosan (y = 2.4063x - 0.3331, R² = 0.8094), PEG-
chitosan (y = 1.2002x - 0.525, R² = 0.9328), PHEA-chitosan (y = 0.8479x - 0.5089, 
R² = 0.8547), POZ-chitosan (y = 1.5731x - 0.7691, R² = 0.955) and PVP-chitosan 
(y = 1.4659x - 0.7322, R² = 0.963). Data represent mean ± SD, n = 3. 
 
The FTIR spectra of the unmodified and modified chitosan are shown in Figure 5.9. The 
FTIR spectrum of unmodified chitosan showed peaks at 3000-3600 cm-1 due to stretching 
vibration of O-H and N-H bonds and 1649 cm-1 due to amide group (N-C=O) stretching. For 
PEG-chitosan, characteristic peaks due to PEG backbone at 842, 961 and 2882 cm-1 were 
observed. The peak at 1654 cm-1 was believed to be due to amide groups in the linker 
between PEG and chitosan. A very weak ester peak at 1746 cm-1 was also observed (Casettari 
et al., 2010). The FTIR spectrum of PHEA-chitosan showed a characteristic carbonyl peak 
(C=O stretching) at 1724 cm-1, the aliphatic C-H stretching peak at 2929 cm-1, CH2 stretching 
at 1447 cm-1 and O-H stretching at 3357 cm-1. POZ-chitosan showed peaks related to POZ 
at 1633 cm-1 (C=O stretching), 1471 cm-1 (C-H deformation), 1423 cm-1 (CH3 symmetrical 
deformation/CH2 bending) and 1239 cm
-1 (C-N stretch). The FTIR spectrum of PVP-
chitosan showed peaks at 3370 cm-1  (O-H stretching), 2921 cm-1  (symmetric stretching CH2 
ring), 1654 cm-1  (C O stretching), 1288 cm-1  (CH2 wag), 1152 cm
-1  (C-N stretch), 845 











































Figure 5.9 FTIR of unmodified chitosan, PEG-chitosan, PHEA-chitosan, POZ-chitosan and 
PVP-chitosan. 
 
The main problem of chitosan is its poor aqueous solubility, especially when the pH is higher 
than its pKa (pKa  is ~ 6.5, depending on factors such as DA and the molecular weight of 
chitosan) (Wang et al., 2006). A turbidimetric technique was used to determine the pH-
solubility profiles of unmodified and modified chitosan. Figure 5.10 shows that unmodified 
chitosan was soluble (illustrated by low turbidity or absorbance) at acidic pH ranges. 
However, it underwent rapid precipitation (indicated by high turbidity or absorbance) at pH 
higher than 7.38.  This result was expected, because at acidic pH, the amino groups of 
chitosan undergo protonation, whereas at near neutral pH, they become deprotonated 
(Rinaudo, 2006).  All the modified chitosan, however, showed full aqueous solubility 
(illustrated by low turbidity) at the studied pH ranges (3-10). This result could be due to the 
grafting of the polymers to the chitosan macromolecules which reduced the crystallinity of 
chitosan by reducing intra- and inter-molecular hydrogen bonding, leading to enhanced 






















Figure 5.10 pH-solubility profiles of unmodified and modified chitosan (mean ± SD, n = 3). 
 
5.3.2 Characterisation of unmodified and modified chitosan nanoparticles 
The improved water-solubility of modified chitosan is a highly important step towards the 
preparation of modified chitosan nanoparticles as solubilisation of chitosan is necessary prior 
to ionic gelation. Chitosan nanoparticles can be prepared via electrostatic attractive 
interactions between positively charged chitosan and negatively charged TPP (Figure 5.11). 
Although several studies have reported the formation of chitosan nanoparticles using TPP, 
the variation in the source of chitosan which in turn leads to the variation in the molecular 
weight, the DA, the viscosity and other properties requires a full optimisation study to 
prepare chitosan nanoparticles. Some studies reported that there is no clear correlation 
between the mass ratio of chitosan/TPP and the size of chitosan nanoparticles (Zhang et al., 
2018). Thus, several attempts have been tried to obtain nanoparticles aiming to determine 
the smallest size with acceptable polydispersity index (PDI) (Table 5.2). This was achieved 
by changing the concentration of chitosan solution, weight ratio of chitosan/TPP, 
concentration of acetic acid, temperature of crosslinking and pH of chitosan and TPP 
solutions. CS16 (Table 5.2) was selected as the optimum formula of unmodified chitosan 
nanoparticles. The same condition was used to prepare modified chitosan nanoparticles. The 





130-152 nm with a PDI of 0.24-0.29 ( Table 5.3 and Figure 5.12). However, the ξ-potential 
of each of the unlabelled modified chitosan nanoparticles was lower than the unmodified 
chitosan nanoparticles (Table 5.3). This may be attributed to the decrease in the number of 
protonated amino groups upon modification or the presence of a polymeric shell in modified 
chitosan nanoparticles which can mask the positive charges of chitosan. The ξ-potential of 
all the chitosan nanoparticles are generally low (< 30 mV), but taking into account the effect 





























Table 5.2 Optimisation of preparation of unmodified chitosan nanoparticles. The size of 
chitosan coils in solution without addition of TPP was also measured. The 
nanoparticles were prepared at room temperature. 





















CS solution 1 0 - 1 3  - 956 ± 124 0.197 ± 0.233 
CS solution b 1 0 - 1 3  - 361 ± 332 0.846 ± 0.263 
CS1 2 1 3:1 1 4.9 9  554 ± 191 
 
0.600 ± 0.109 
 
CS2 2 1 5:1 1 4.9 9 577 ± 68 
 
0.427 ± 0.030 
 
CS3 2 1 6:1 1 4.9 9 602 ± 46 
 
0.260 ± 0.048 
 
CS4 2 1 7:1 1 4.9 9 601 ± 23  0.447 ± 0.061 
 
CS5 1.5 1 6:1 1 4.9 9 758 ± 501 
 
0.612 ± 0.336 
 
CS6 1 1 1:1 1 4.9 9 225 ± 16 
 
 0.339 ± 0.089 
 
CS7 1 1 2:1 1 4.9 9 169 ± 8  0.384 ± 0.014 
 
CS8 1 1 3:1 1 4.9 9  256 ± 11 0.380 ± 0.028 
 
CS9 1 1 6:1 1 4.9 9 893 ± 857 
 
 0.614 ± 0.334 
 
CS10 c 2 1 5:1 1 4.9 9 397 ± 38  
 
0.587± 0.138 
CS11 1 1 2:1 0.175 4.9 9 266 ± 15 
 
0.366 ± 0.047 
CS12 1 1 2:1 0.175 4.15 9 205 ± 42 0.298 ± 0.013 
CS13 1 1 2:1 1 3.6  2  187 ± 48 
 
0.315 ± 0.083 
CS14 1 1 2:1 1 3.6 5 162 ± 21  0.442 ± 0.046 
 
CS15 1 1 2:1 1 4.5 9  214 ± 9  
 
0.387 ±  0.049 
 
CS16 1 1 2:1 1 5.5 9 152 ±  13  0.242 ± 0.016 
 
CS17 1 1 2:1 1 6 9 151 ± 13 
 
0.255 ± 0.031 
 
CS18 1 1 1:1 1 5.5 9 367 ± 4 
 
0.323 ± 0.016 
 
CS19 0.5 1 2:1 1 5.5 9 125 ± 8 0.317 ± 0.022 
 
a CS: chitosan 
b chitosan solution filtered through 0.2 µm syringe filter 







Figure 5.12 DLS size distribution of different unlabelled chitosan nanoparticles.  
   
Initial TEM analysis was performed without staining and also with staining using uranyl 
acetate dihydrate solution (1% w/v in distilled water) and this resulted in images with poor 
contrast (data not shown). However, using phosphotungstic acid hydrate solution (2% w/v 
in deionised water) the particles were clearly visible (Figure 5.13). The size of all unmodified 
and modified chitosan nanoparticles measured by TEM was smaller than the size measured 
by DLS. This discrepancy can be due to the presence of a hydration shell around the 
nanoparticles, as in DLS, particles are measured in the aqueous suspension form. The 
thickness of this shell can be significantly decreased during TEM sample preparation upon 
drying. The discrepancy in the size using DLS and TEM has also been discussed in other 
studies on silica nanoparticles (Mun et al., 2014; Mansfield et al., 2018). However, the 
difference observed in this study is greater (Table 5.3) than the previous publications (Mun 
et al., 2014; Mansfield et al., 2018)  which could be due to the highly hydrophilic nature and 



























                                    
 
 




a For size measurement by TEM, 20 values from 20 individual nanoparticles from 3 different 
TEM images were used. Note: only individual particles were measured and fused particles 
were excluded. 
Types of nanoparticles Z-average (nm) PDI ξ-potential (mV) Size (nm, TEM)a 
Unmodified chitosan 152 ±  13 0.242 ± 0.016 25.54 ± 1.25 43 ± 15 
PEG-chitosan 137 ± 23 0.253 ± 0.028 13.38 ± 0.08 55 ± 15 
PHEA-chitosan 142 ± 11 0.292 ± 0.035 13.66 ± 0.13 41 ± 9 
POZ-chitosan 145 ± 21 0.277 ± 0.017 15.01 ± 0.28 31 ± 9 
PVP-chitosan 130 ± 19 0.280 ± 0.037 12.29 ± 1.62 33 ± 10 







To prepare fluorescent chitosan nanoparticles, unmodified and modified chitosan 
were first fluorescently labelled using Alexa Fluor™ 546 according to Figure 5.14-A. 
The fluorescence labelling is essential for the later diffusion study in BSM solution and 
penetration through nasal mucosa. The freeze dried Alexa Fluor™ 546-labelled 
unmodified and modified chitosan had a bright pink colour. Analysis of the dialysis 
media showed that there was no free Alexa Fluor™ 546 in the labelled polymers 
(Figure 5.15). The calibration curve which was used to calculate the Alexa Fluor™ 
546 content of chitosan is shown in Figure 5.16. Unmodified and modified chitosan 
showed similar Alexa Fluor™ 546 content (Table 5.4). However, the fluorescence 
intensity of the Alexa Fluor™ 546-labelled unmodified chitosan nanoparticles was 
less than modified chitosan nanoparticles (Figure 5.14-B and Table 5.4), which could 
be due to the stronger interaction between the amino groups of the unmodified 
chitosan and TPP resulting in a partial fluorescence quenching. In case of modified 
chitosan, this interaction could be decreased as a significant number of amino groups 
have been replaced by the correspondent polymers resulting in a higher fluorescence 
intensity of modified chitosan nanoparticles compared to unmodified chitosan 



















Figure 5.14 (A) Scheme of fluorescent labelling of chitosan with Alexa Fluor™ 546 and (B) 
fluorescence emission spectra of the unmodified and modified chitosan 
nanoparticles, with 0.5% w/v bovine submaxillary mucin (BSM) solution as 
background control at 554 nm. The nanoparticles were diluted (1:50) with ultrapure 














Figure 5.15 Washing after dialysis for Alexa Fluor™ 546-labelling of unmodified and 





Figure 5.16 A calibration curve used to calculate the degree of Alexa Fluor™ 546-labelling 

































































Table 5.4 Characterisation of Alexa Fluor™ 546 labelled polymers and nanoparticles (mean 
± SD, n = 3). 
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It was possible to measure the size of the Alexa Fluor™ 546-labelled chitosan nanoparticles 
using DLS. This was because the excitation wavelength (absorption maxima, 554 nm) of 
Alexa Fluor™ 546-labelled chitosan nanoparticles is significantly lower than the wavelength 
used by the Zetasizer (633 nm, red laser) and thus no interference in light scattering would 
be expected. This hypothesis is also supported by Geißler et al. (2015) who showed that 
fluorescent-labelling does not have a significant impact on the size data of the polymeric 
nanoparticles from DLS and small angle X-ray scattering especially when absorption 
maxima of the nanoparticles are different from the wavelength of the laser used and the 
degree of fluorescent-labelling is not extremely high. Nevertheless our data showed that the 
Alexa Fluor™ 546-labelled chitosan nanoparticles have a slightly lower PDI than the 
unlabelled nanoparticles (Table 5.3 and Table 5.4).   
NTA can be used to measure the size, the concentration (particles/mL) and also the diffusion 





to DLS, it is a more accurate technique for the measurement of the size of the polydispersed 
nanoparticles (Filipe et al., 2010; Gross et al., 2016). The NTA analysis of size was in 
agreement with the DLS data (Table 5.4). The particle size distribution measured by NTA 
(Figure 5.17) indicated that the prepared unmodified and modified chitosan nanoparticles 
were relatively monodispersed. This was also evident from the relatively low standard 
deviation measured by NTA (99 ± 13, 85 ± 12, 81 ± 16, 78 ± 10 and 106 ± 4 nm for 
unmodified, PEG-, PHEA-, POZ- and PVP-chitosan nanoparticles, respectively). 
 
 
Figure 5.17 Size distribution of Alexa Fluor™ 546-labelled unmodified and modified 









































5.3.3 Chitosan nanoparticles’ diffusion in BSM solution and penetration into sheep 
nasal mucosa  
 NTA can be used to measure the mean diffusion of nanoparticles in polymeric solutions 
(Mun et al., 2014) and mucin dispersion (Mansfield et al., 2015). To conduct diffusion 
studies, NanoSight should be under the fluorescent mode instead of light scattering mode 
enabling the visualisation of only the fluorescent nanoparticles. BSM solution (2% w/v, in 
pH 5 phosphate buffer solution) has previously been used to study mucoadhesive properties 
of polymeric microparticles (L. Achar & Peppas, 1994). As BSM solution has intrinsic 
fluorescence properties, a preliminary study was required to find the optimum concentration 
of BSM solution that gives minimal interference. It was found that 0.5% w/v BSM solution 
had negligible interference with the visualisation of the nanoparticles compared to 1% w/v 
BSM solution, and therefore 1% w/v BSM solution was excluded. We preferred 0.5% w/v 
BSM solution over each of 0.1 or 0.25% w/v BSM solution as the higher concentration may 
provide a higher opportunities of the interaction of the particles with the mucin 
macromolecules. It is worth mentioning that the concentration of mucin solution in this study 
is lower than the nasal mucosa (2% w/v) (Mistry et al., 2009), however, it is significantly 
higher than the concentration used in some studies involving polymers- and nanoparticles-
mucin interactions (0.1% w/v and even 0.001% w/v) (Fefelova et al., 2007; Chuah et al., 
2014; Albarkah et al., 2015). Additionally it is not recommended to use 2% w/v mucin 
solution as its high viscosity could limit the NanoSight’s application range which work 
optimally when the viscosity of the media is between 0 to 10 cP (Mansfield, 2016). The 
viscosity of 0.5% w/v BSM solution used in this study was 3.05 ± 0.37 cP at 25 °C. This 
value was calculated using the trendline equation of the temperature-viscosity plot (Figure 
5.18). The reason for using BSM and not PGM was mainly related to the stronger auto 
fluorescence and the higher viscosity of PGM compared to BSM which hindered the precise 
detection of the nanoparticles. Our diffusion study was conducted at pH 5.5 which is in the 
range of human nasal mucosa pH (5.3–7.0) (England et al., 1999; Ireson et al., 2001; 
Aderibigbe, 2018). The NTA analysis revealed that the modified chitosan nanoparticles 
diffuse significantly faster in BSM solution (p < 0.001) compared to unmodified chitosan 
nanoparticles (Figure 5.19). This was evident from the higher normalised mean diffusion 
coefficient of the modified chitosan nanoparticles in 0.5% w/v BSM solution compared to 
unmodified chitosan nanoparticles. In addition to the mean diffusion coefficient, the 





determined (Figure 5.20), which also indicated higher diffusivity of the modified chitosan 
nanoparticles compared to unmodified chitosan nanoparticles.  
 
 
Figure 5.18 Temperature versus viscosity profile of 0.5% w/v bovine submaxillary mucin 
(BSM) solution, the calculated value of viscosity of BSM solution was 3.05 ± 0.37 






















































Figure 5.19 Normalised experimentally determined mean diffusion coefficient of Alexa 
Fluor™ 546-labelled unmodified and modified chitosan nanoparticles in 0.5% w/v 
BSM solution. One way ANOVA between chitosan and each of modified chitosan 
nanoparticles, and also between PEG- and each of PHEA, POZ- and PVP-chitosan 
nanoparticles was performed; there is no significant difference (p = 0.063) between 















Figure 5.20 Distribution of diffusion coefficient for Alexa Fluor™ 546-labelled unmodified 
and modified chitosan nanoparticles in 0.5% w/v BSM solution measured at 25 °C 
using NTA (mean, n = 9). 
 
 
The enhanced diffusivity of the modified chitosan nanoparticles can be related to the 
presence of PEG, PHEA, POZ or PVP in the modified chitosan nanoparticles. Lai et al. 
(2007) showed that PEG coating of the polystyrene nanoparticles facilitates their penetration 
in fresh undiluted human cervicovaginal mucus. We also showed that PEGylation and 
POZylation of thiolated silica nanoparticles enhanced their diffusivity in PGM dispersion 
and through porcine gastric mucosa (Mansfield et al., 2015) and also reduced their 
mucoadhesiveness with regard to rat intestinal mucosa (M. Ways et al., 2018b). Casettari et 
al. (2010) showed that PEGylated chitosan does not significantly enhance the permeability 
of fluorescein isothiocyanate-dextran macromolecules across Calu-3 cell monolayer at pH 
7.4, whereas they observed a dramatic permeability enhancement when the polymer was 
tested at pH 6. Casettari et al. (2010) did not report any possible reasons for the difference 
in the permeability at these two different pH. However, they claimed that the enhancement 
could be due to the higher equivalent concentration of chitosan in PEGylated chitosan 
compared to unmodified chitosan and also the enhanced diffusivity of the PEGylated 
chitosan compared to unmodified chitosan. The latter reason was also indirectly supported 







































with 1% degree of PEGylation had significantly less hypocalcaemic effect than those with 
0.5% degree of PEGylation when orally administered to rats. They postulated that an 
increase in the degree of PEGylation might result in a decrease in the mucoadhesive 
properties of chitosan. Thus, a weak interaction between PEGylated chitosan nanocapusles 
(with 1% degree of PEGylation) and the negatively charged components of the 
gastrointestinal mucosa was expected. Zhang et al. (2018) claimed that they were the first 
research group who reported the ability of PEGylated chitosan/DNA nanocomplexes to 
enhance the transport of DNA through artificial mucus using a Transwell mucus permeation 
assay. However, to our knowledge no studies on the diffusion of PEGylated chitosan 
nanoparticles in mucin solution using NTA have been reported. 
The NTA data showed the rank of diffusivity in BSM solution as PEG-=PVP->POZ-
>PHEA-chitosan>unmodified chitosan nanoparticles (Figure 5.19). To compare the NTA 
analysis to nasal mucosal tissues, a penetration study was conducted using sheep nasal 
mucosa. Sheep model was selected mainly due to its large nares and anatomical similarity 
of the nasal cavity with human nose (Illum, 1996; Tas et al., 2009; Barrios et al., 2014; 
Macias-Valle et al., 2018). The chitosan nanoparticles showed different degrees of 
penetration into sheep nasal mucosa (Figure 5.21 and Figure 5.22). After 5 minutes of 
incubation, modified chitosan penetrated significantly (p < 0.001) deeper into the nasal 
mucosa compared to unmodified chitosan. From Figure 5.21 and Figure 5.22, it is clear that 
all nanoparticles gradually diffused thorough the nasal mucosa. After 15 minutes incubation, 
modified chitosan nanoparticles still penetrated deeper than the unmodified nanoparticles 
significantly. However, at 30 minutes no statistical significant difference (p = 0.08) was 
found between unmodified and PEGylated chitosan nanoparticles. On the contrary, PHEA-, 
POZ- and PVP-chitosan nanoparticles showed significantly greater penetration compared to 
unmodified chitosan. The distance between the nanoparticles and the nasal epithelial cells 
are shown in Figure 5.23 and Figure 5.24.  It is clear that an agreement exists between the 
diffusion study using NTA and sheep nasal mucosa, where generally, modified chitosan 
showed a greater diffusivity than the unmodified chitosan nanoparticles. However, the 
potential differences in the barrier properties, the pH and the biochemical composition of the 
media in the NTA study using BSM solution compared to ex vivo penetration study with 
sheep nasal mucosa could explain the lack of difference between the penetration depth of 
unmodified chitosan and PEG-chitosan nanoparticles at the longer incubation time (30 





the pH of sheep nasal mucosa, nevertheless studies suggested the presence of acidic and 













Figure 5.21 Exemplary fluorescent images showing penetration of Alexa Fluor™ 546-
labelled (yellow)  unmodified and modified chitosan nanoparticles into sheep nasal 

































Figure 5.22 Comparison of penetration depth of unmodified and modified chitosan 
nanoparticles into the freshly excised sheep nasal mucosa after 5, 15 and 30 minutes 
of incubation. Values represent the mean penetration across 10 separate tissue 













Figure 5.23 Exemplary fluorescent images showing penetration of Alexa Fluor™ 546-
labelled (yellow)  unmodified and modified chitosan nanoparticles into sheep nasal 
mucosa after 5, 15 and 30 minutes of incubation at 10x magnification (except for 
PVP-chitosan 5 minutes and POZ-chitosan 30 minutes, which are at 5x 
magnification). The nuclei of the epithelial cells were stained (blue) with DAPI 











Figure 5.24 Exemplary fluorescent images showing the penetration of Alexa Fluor™ 546-
labelled (yellow) PVP-chitosan nanoparticles into sheep nasal mucosa after 30 
minutes of incubation with sheep nasal mucosa at 20x magnification. The nuclei of 







The nasal mucosa of both human and sheep is mainly divided into olfactory and respiratory 
regions. The olfactory mucosa is a small area of the caudal roof of the nasal cavity which 
covers ethmoturbinates and the caudal parts of the dorsal and middle nasal conchae. It 
consists of the olfactory mucosa and the underlying connective tissue lamina propria. The 
olfactory mucosa consists of specialised ciliated cells which their main function is the 
detection of smell (Ugwoke et al., 2005; Ibrahim et al., 2014). This layer has a direct access 
to the central nervous system (Ugwoke et al., 2005). The respiratory mucosa composed of 
respiratory epithelium and the connective tissue laminar propria. The respiratory epithelium 
is a pseudostratified ciliated and non-ciliated columnar type cells distributed alongside with 
basal cells, ciliated cells, goblet cells and the opening of the seromucus glands (Ugwoke et 
al., 2005; Ibrahim et al., 2014). The goblet cells consist of an apical part which contains 
mucin polysaccharides (Ibrahim et al., 2014) which swell in the nasal fluid as a component 
of the mucus layer  (Ugwoke et al., 2005). Although, due to technical limitations, we have 
used the respiratory mucosa, studies reported some similarities in the mucin expression 
between the olfactory and the respiratory mucosa (Ibrahim et al., 2014). Nevertheless, in 
contrast to respiratory mucosa, cilia in olfactory region are non-motile as they lack dynein 
arms which contain the Mg2+-ATPase required to generate the force for the ciliary movement 
(Mistry et al., 2009). Thus, there is no mucociliary clearance mechanism in the olfactory 
mucosa. However, mucus can still be cleared due to  gravity when the human head is at 
upright position (Charlton et al., 2007). Therefore, mucus penetrating nanoparticles may 
have a great potential applications in nasal drug delivery via both respiratory and olfactory 
mucosa. 
PHEA is a polymer with hydroxyl side groups which has been used in drug delivery due to 
its hydrophilicity and biocompatibility (Arun & Reddy, 2005; Khutoryanskaya et al., 2008; 
Steinhauer et al., 2010; Lin et al., 2012). PHEA has FDA approval for indirect additives used 
in food contact substances as an adhesive and a component of coatings (FDA, 2018). 
Polymers with hydroxyl side groups including poly-N-2-hydroxypropyl methacrylamide 
(PHPMA) were found to have stealth properties (Talelli et al., 2010; Du et al., 2016). 
PHPMA is even superior to PEG in decreasing the accelerated blood clearance phenomenon 
of poly-D,L-lactic acid-PHPMA nanoparticles (Du et al., 2016). In contrast to poly-2-
hydroxyethylmethacrylate (PHEMA) (the closest analogue to PHEA), PHEA is completely 





(Khutoryanskiy, 2018). To the best of our knowledge, no studies have reported the use of 
PHEA in designing the mucus-penetrating nanoparticles.  
Peppas and colleagues (1995 ; 1996) showed the mucoadhesive capacity of PHEMA 
microparticles in Sprague Dawley rat jejunum and found that the presence of free short chain 
PEG (1 kDa) in the PHEMA microparticles significantly increased their mucoadhesive 
capacity. However, longer chain PEG (100 kDa) had a detrimental effect on the 
mucoadhesive capacity. In the light of Peppas et al. study (1995 )  and as mentioned earlier 
that PHEA is more water soluble than PHEMA, we can hypothesise that PHEA is less 
mucoadhesive than  PHEMA. An outcome which we indirectly showed by the enhanced 
mucus penetrating capacity of PHEA-chitosan nanoparticles compared to unmodified 
chitosan nanoparticles.  
POZ belongs to polyoxazolines which are a class of polymers with polypeptide isomeric 
structures. They have recently attracted a considerable attention in biomedical applications 
(Gaertner et al., 2007; Hoogenboom, 2009; Sedlacek et al., 2012). They were found to have 
some similar properties to PEG in terms of blood circulation time, their uptake by liver and 
spleen (Adams & Schubert, 2007), the biodegradability (Ulbricht et al., 2014; Hoogenboom 
& Schlaad, 2017), the biocompatibility and non-toxicity (Lava et al., 2015). Nevertheless, 
polyoxazolines have some advantages over PEG and these include the possibility in the 
variation of the monomer composition and the versatility of the side chain functionalities. 
This feature can result in polymers with various physicochemical properties and a broad 
range of applications (Hoogenboom, 2009; Tim R Dargaville et al., 2014; Hoogenboom & 
Schlaad, 2017). POZ currently lacks FDA approval, however, SER-214 (rotigotine-POZ 
conjugate) is currently under clinical trial for the treatment of Parkinsonism as an injectable 
formulation administered subcutaneously once a week (ClinicalTrials.gov Identifier: 
NCT02579473). Our current study clearly demonstrates the mucus-penetrating capacity of 
POZ-chitosan nanoparticles.  
PVP has a wide range of applications as a biomaterial in various medical areas such as 
dosage forms design including tablets, granules, soft shell capsules and injectables as well 
as non-medicals including optical, electric, ceramics, papers, coating and inks (Teodorescu 
& Bercea, 2015). This is due to its solubility in water and several organic solvents, 
biocompatibility, lack of toxicity, wetting and binding properties (Teodorescu & Bercea, 





(Benahmed et al., 2001; Hadjesfandiari & Parambath, 2018), but again no literature on the 
mucus penetration ability of PVP exists. However, several publications indicated that PVP 
has poor mucoadhesive properties (J. D. Smart et al., 1984; Solomonidou et al., 2001; Mishra 
& Mishra, 2012; Russo et al., 2016). Indeed, Smart et al. (1984) found that PVP (44 kDa) 
and PEG (6 kDa) were less mucoadhesive compared to other studied materials (75P sodium 
carboxy methylcellulose, Carbopol 934, tragacanth, Gantrez® AN, sodium alginate (high 
viscosity), hydroxypropylmethyl cellulose (medium viscosity), gelatin and pectin) with 
regard to partially purified mucus obtained from guinea-pig intestine. Additionally, Ivarsson 
& Wahlgren (2012) reported that PVP has poor or no mucoadhesive properties when studied 
using ellipsometry, tensile strength and rheological methods in respect to PGM. These 
observations indirectly indicate the mucus-penetrating ability of PVP and PEG and is in 
agreement with our results. Another possible explanation for the better mucus penetration 
ability of PVP could be due to its amphiphilic properties (having both polar and apolar 
groups) (Benahmed et al., 2001), which allows easier diffusion through mucus gel via 
hydrogen bonding and interacting with the lipophilic cellular surfaces via hydrophobic 
interactions.   
5.4 Conclusions 
We synthesised four derivatives of chitosan using EDAC/NHS chemistry by reacting 
carboxyl-terminated PEG, PHEA, POZ and PVP with unmodified chitosan. The modified 
chitosan showed full solubility at any pH whereas unmodified chitosan precipitated at pH 
7.3. This improvement in the solubility can dramatically broaden the range of chitosan 
applications. Methods to prepare, characterise and evaluate different unmodified and 
modified chitosan nanoparticles were developed. The modified chitosan nanoparticles 
showed an enhanced diffusivity in BSM solution compared to unmodified chitosan 
nanoparticles. They also penetrated deeper into the sheep nasal mucosa compared to 
unmodified chitosan nanoparticles. The modified chitosan nanoparticles have potential 
applications in the nasal drug delivery for the treatment of various local and systemic 
diseases including central nervous system disorders.  
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Chapter 6: Haloperidol- and phenobarbital-loaded 
unmodified chitosan and PVP-chitosan nanoparticles for 




Study in the area of nasal drug delivery is becoming one of the focal points of pharmaceutics 
research groups in both academia and industry. This is due to the several advantages of the 
nasal route of drug administration including the avoidance of pre-systemic metabolism, 
rapidity of onset of action, its non-invasive nature and the possibility of a direct access to 
the central nervous system. Chitosan-based formulations have been used to enhance the 
efficacy of nasal formulations. However, this effect can be further enhanced using 
formulations based on hydrophilically modified chitosan. In this study, we have formulated 
haloperidol unmodified chitosan-sodium tripolyphosphate (TPP) nanoparticles and 
phenobarbital unmodified and polyvinyl pyrrolidone (PVP)-chitosan-TPP nanoparticles. 
These two drugs were selected to allow future in vivo experiment of the nanoformulations 
using behavioural studies. With haloperidol loaded unmodified chitosan nanoparticles, a 
relatively low drug loading capacity was found. On the other hand, phenobarbital loaded 
unmodified and PVP-chitosan nanoparticles demonstrated a high drug loading capacity and 
a sustained drug release. Our findings provide an important insight into some of the aspects 













The nasal route of drug administration has attracted a lot of attention due to avoidance of 
first pass metabolism, the presence of highly vascularised nasal mucosa with large surface 
area and its non-invasive nature (Ugwoke et al., 2005). It has been extensively used for 
systemic delivery of various peptide-based drugs and indeed a number of products including 
Synarel™ and Miacalcic™ (for nasal administration of nafarelin and calcitonin, 
respectively) are currently available (Rohrer et al., 2018). However, the barrier properties of 
mucus, the mucociliary clearance, the tight junctions and degradation of drugs by the nasal 
mucosal enzymes often resulted in low bioavailability of hydrophilic peptide-based drugs 
larger than 1 kDa (Rohrer et al., 2018). The nasal route has showed some potential for direct 
transport of drugs (mainly hydrophilic) to the central nervous system (CNS) in animals and 
humans, due to the presence of olfactory epithelium and trigeminal nerves in the olfactory 
and respiratory epithelia. However, evident from animal studies, the CNS bioavailability of 
drugs directly via the nasal route is often very low (< 0.12% of the administered dose) (Illum, 
2000, 2004; Wang et al., 2008; Mistry et al., 2015). 
The use of mucoadhesive polymers, permeation enhancers, enzyme inhibitors and 
nanoparticles are considered as potential strategies to enhance the systemic and CNS 
bioavailability of drugs (Mistry et al., 2009; Rohrer et al., 2018). In this regard, chitosan has 
been frequently used due to its mucoadhesive, permeation enhancing effect and nontoxicity 
(Bernkop-Schnürch & Dunnhaupt, 2012; Casettari & Illum, 2014; M. Ways et al., 2018). 
We previously showed that modification of chitosan with hydrophilic polymers including 
polyethylene glycol (PEG), polyhydroxyethyl acrylate (PHEA), poly-2-ethyl-2-oxazoline 
(POZ) and polyvinyl pyrrolidone (PVP) enhanced the diffusion of modified chitosan 
nanoparticles in  mucin solution and their nasal mucosa penetration capacity compared to 
unmodified chitosan nanoparticles (Chapter 5). In the current study, we explored the 
possibilities of incorporating two CNS active drugs (haloperidol and phenobarbital sodium) 
into unmodified and modified chitosan nanoparticles. Haloperidol is a dopamine D2 receptor 
antagonist which is prescribed for the treatment of nausea and vomiting, schizophrenia, 
bipolar disorder and some other CNS disorders (Joint Formulary Committee, 2018). Its 
administration to rats results in catalepsy and such behavioural responses can be used to test 
certain formulations (Piazza et al., 2014). Phenobarbital is a barbiturate and is used in the 
treatment of all forms of epilepsy except typical absence seizures (Joint Formulary 





by clinical observation of the subjects. Figure 6.1 shows the chemical structure of both 




Figure 6.1 (A) Chemical structure of haloperidol and (B) phenobarbital. 
 
There are a small number of studies that looked at the nasal route for delivering haloperidol 
(El-Setouhy et al., 2016) and phenobarbital (Czapp et al., 2008) using nanoemulsions and 
gels, respectively, to enhance the drug efficacy and to reduce systemic side effects. Chitosan-
sodium tripolyphosphate (TPP) nanoparticles are promising drug carriers and they can be 
prepared via ionic interaction between cationic chitosan and anionic TPP. This method 
requires only a few excipients and does not need a high temperature, allowing the 
incorporation of temperature-sensitive drugs (Calvo et al., 1997). Unmodified chitosan-TPP 
nanoparticles enhanced the systemic bioavailability of insulin in rabbits (Fernández-
Urrusuno et al., 1999) and leuprolide in rats (Shahnaz et al., 2012) via nasal route. However, 
to our knowledge, no unmodified- and PVP-chitosan-TPP nanoparticles were studied as a 
potential nasal delivery system for both haloperidol and phenobarbital. The main aim of this 
study is to develop unmodified and PVP-chitosan-TPP nanoparticles as a potential nasal 
drug delivery for haloperidol and phenobarbital. 
6.2 Materials and methods 
6.2.1 Materials 
Medium molecular weight chitosan (degree of deacetylation 75-85%), 1-ethyl-3-3-
dimethylaminopropyl-carbodiimide hydrochloride (EDAC), N-hydroxysuccinimide (NHS), 
sodium tripolyphosphate (TPP), phenobarbital sodium, methoxy-PEG-COOH and D-(+)-
trehalose dihydrate were purchased from Sigma-Aldrich (Gillingham, UK). Glacial acetic 





dihydrate (NaH2PO4.2H2O), sodium phosphate dibasic anhydrous (Na2HPO4) were 
purchased from Fisher Scientific (UK). Haloperidol was purchased from Alfa Aesar 
(Lancashire, UK). PVP-COOH was synthesised by Prof Richard Hoogenboom research 
group at University of Ghent, Belgium as described in Chapter 5. Dialysis membrane with 
molecular cut-off 12–14 kDa was purchased from Medicell International Ltd., UK. All other 
chemicals were of analytical grade and were used as received.  
6.2.2 Synthesis of PEG- and PVP-CO-NH-chitosan 
PEG-CO-NH chitosan and PVP-CO-NH-chitosan were synthesised according to the method 
described in Chapter 5. Briefly, 11.5 mL acetic acid (1% v/v) was added to 80 mg medium 
molecular weight chitosan. The mixture was continuously stirred for 20 hours at room 
temperature. The pH of the chitosan solutions was increased to 6 using 5 M NaOH solution. 
117 mg of methoxy-PEG-COOH or 100 mg of PVP-COOH was added to the chitosan 
solution. Then after 5 minutes stirring, NHS (13.5 mg) was added and stirred for 30 minutes. 
EDC (22.4 mg) was then added and stirred for 24 hours. The products were dialysed against 
deionised water (4 L, 8 total changes, 12-14 kDa) at room temperature for 3 days. The 
products were recovered by lyophilisation using Heto Power Dry LL 3000 freeze-drier 
(Thermo Electron Corporation) and characterised as described in Chapter 5. 
6.2.3 Preparation of haloperidol loaded unmodified chitosan-TPP nanoparticles 
Haloperidol loaded unmodified chitosan-TPP nanoparticles (hereinafter referred to 
haloperidol-chitosan nanoparticles) were prepared using an ionic gelation method. Chitosan 
solution (1 mg/mL in 1% v/v acetic acid) was prepared and the pH was adjusted to 5.5 using 
5 M NaOH solution. TPP (1 mg/mL in deionised water) and the chitosan solutions were 
filtered through 0.2 µm syringe filter. 1 mL Haloperidol solution (initial conc. 5 mg/mL in 
1% v/v acetic acid) was added to 4 mL of the filtered chitosan solution.  Then, 2 mL TPP 
solution was added dropwise to 5 mL of chitosan-haloperidol mixture over 5 minutes. The 
nanoparticles suspension (pH 5.06) were stirred for another 30 minutes at room temperature. 
The nanoparticle suspension were then centrifuged using Amicon Ultra™ centrifugal filter 
unit (0.5 mL capacity, 3 kDa MWCO, Millipore, UK Limited) for 90 minutes at 10000 rpm 
(Sanyo, Micro Centaur, UK). The retentates were reverse spun at 1000 rpm for 2 minutes 
and the nanoparticles were re-suspended with 200 µL ultrapure water. The pH of the 
nanoparticle suspension was 5.06. The particles were freeze dried using Heto Power Dry LL 





each step of preparation (before and after centrifugation and after freeze drying), the particles 
size was measured using dynamic light scattering (DLS).  
6.2.4 Preparation of phenobarbital loaded unmodified, PEG- and PVP-chitosan-TPP 
nanoparticles 
Unmodified, PEG-CO-NH- and PVP-CO-NH-chitosan solutions (1 mg/mL in 1% v/v acetic 
acid) were prepared and the pH was adjusted to 5.5 using 5 M NaOH solution. Phenobarbital 
sodium (at the final concentration of 4 or 2 mg/mL) was added to TPP solution (1 mg/mL in 
deionised water). Both TPP-phenobarbital mixture and chitosan solutions were filtered 
through 0.2 µm syringe filter. Then, TPP-phenobarbital mixture was added dropwise to 
chitosan solution (1:2) over 5 minutes. The suspensions were stirred for another 30 minutes 
at room temperature. Based on the size analysis by DLS, the optimised nanoparticle types 
were selected and were lyophilised using Heto Power Dry LL 3000 freeze-drier (Thermo 
Electron Corporation) after addition of trehalose (5% w/v) to produce the phenobarbital 
loaded unmodified, PEG-CO-NH- and PVP-CO-NH-chitosan-TPP nanoparticles 
(hereinafter referred to phenobarbital-unmodified chitosan, PEG-chitosan and PVP-chitosan 
nanoparticles, respectively). 
6.2.5 Characterisation of the nanoparticles 
The size, polydispersity index (PDI) and ξ-potential of the nanoparticles were measured 
using a Zetasizer Nano-ZS (Model: ZEN3600, Malvern, UK). For the size measurement, the 
samples were diluted (1:20) with ultrapure water before analysis. A refractive index of 1.59 
and an absorbance of 0.01 were used for all measurements. Viscosity (0.8872 cP) and 
refractive index (1.33) of water were used as dispersant parameters. The samples were 
incubated for 60 seconds and the measurements were conducted in triplicate for 10 seconds 
per run, with 12 runs per reading at 25 °C. The measurement angle was set to 173° 
backscatter. For the data processing, the normal resolution analysis model was selected. In 
case of the freeze dried nanoparticles, the nanoparticles were first redispersed in ultrapure 
water (at a concentration of 108.5 and 100 mg/mL of haloperidol- and phenobarbital-
chitosan nanoparticles, respectively) and then diluted (1:20) with ultrapure water. ξ-potential 
values were measured using DTS-1070 folded capillary tube cuvettes (Malvern, UK). 
Samples were diluted (1:10) with ultrapure water before analysis. Samples were measured 





mode analysis model. At least 3 samples were measured and processed using the 
Smoluchowski model (Fκa = 1.50).  
6.2.6 High performance liquid chromatography (HPLC) analysis of haloperidol 
The HPLC analysis of haloperidol was carried out using an Agilent 1100 Series automated 
system. Chemstation software was used for the acquisition and processing of the data. The 
HPLC instrument was coupled with a binary pump and a VWD UV detector. 
Chromatographic separations were carried out using a Phenomenex® HPLC column (5 µm 
C18 (2), 100 Å, 250 × 4.6 mm, P/NO: 00G-4252-E0). The mobile phase consisted of 0.05 M 
NaH2PO4.2H2O solution: acetonitrile (70:30, pH 5) with flow rate set at 1 mL/minute in 
isocratic mode, injection volume of 100 μL and detection at 254 nm with each run lasted 30 
minutes at 25 °C. Freshly prepared mobile phase was used and degassed for 20 minutes prior 
to HPLC experiments. The calibration curve was constructed from serial solutions of 
haloperidol in the mobile phase in the concentration range of 5-30 µg/mL.  
6.2.7 HPLC analysis of phenobarbital 
For phenobarbital, the HPLC system and method were performed as section 6.2.6 with some 
modifications. Briefly, the mobile phase consisted of 0.05 M NaH2PO4.2H2O solution: 
acetonitrile (65:35, pH 5.2). The detection was at the wavelength of 220 nm and each run 
lasted 20 minutes. The calibration curve was constructed from serial solutions of 
phenobarbital in the mobile phase in the concentration range of 1.25-160 µg/mL.  
6.2.8 Drug loading capacity of haloperidol-chitosan nanoparticles 
The freeze dried haloperidol-chitosan nanoparticles were redispersed in DMSO (1 mg/mL). 
The mixture was stirred overnight at room temperature to extract the haloperidol content. 
The samples were filtered through 0.22 µm syringe filter prior to HPLC analysis. The 
haloperidol association efficiency and loading capacity were calculated according to 
Equation 6.1 and Equation 6.2, respectively. 
Association efficiency = 
Amount of associated haloperidol in freeze dried nanoparticles
Total amount of haloperidol 
×100     Equation 6.1 
 
Drug loading capacity = 
Amount of associated  haloperidol  
Weight of freeze dried nanoparticles 





6.2.9 Determination of association efficiency of phenobarbital-unmodified and PVP-
chitosan nanoparticles 
The filtration and extraction methods were used in calculating association efficiency of 
phenobarbital-unmodified and PVP-chitosan nanoparticles. First, nanoparticles suspension 
(12 × 0.5 mL) was centrifuged at 10000 rpm for 1 hour. For the filtration method, the filtrate 
was collected and the volume was measured. Then, 0.25 mL filtrate was diluted with 4.75 
mL mobile phase and phenobarbital content was quantified by HPLC.  For the extraction 
method, retentate was recovered by reverse spinning at 1000 rpm for 2 minutes. Then, 9 mL 
of 50% v/v ethanol in deionised water was added to the retentate (1 mL) to extract 
phenobarbital from the nanoparticles and stirred for 20 hours at room temperature. Then 2.5 
mL extract was diluted with 2.5 mL of the mobile phase. The solutions were filtered through 
0.22 µm syringe filter before HPLC analysis. The phenobarbital calibration curve was 
plotted in the concentration range of 1.25 to 160 µg/mL using stock solution (5 mg/mL in 
the mobile phase stirred for 18 hours at room temperature). The mobile phase was used as 
blank. The phenobarbital association efficiency was calculated according to Equation 6.3 . 
 
Association efficiency =
Amount of associated phenobarbital in nanoparticles retentate
Total amount of phenobarbital
×100       Equation 6.3 
 
6.2.10 Drug loading capacity of phenobarbital-unmodified and PVP-chitosan 
nanoparticles 
50 mg of freeze dried phenobarbital-unmodified and PVP-chitosan nanoparticles were 
redispersed in 10 mL of 50% v/v ethanol in deionised water and stirred at room temperature 
for 20 hours. Then, 2.5 mL extract was diluted with 2.5 mL of the mobile phase, filtered 
through 0.22 µm syringe and analysed by HPLC as described in section 6.2.9. The drug 
loading capacity of phenobarbital-unmodified and PVP-chitosan nanoparticles was 
calculated using  Equation 6.4.  
  
Drug loading capacity=
Total amount of phenobarbital (associated+free) in freeze dried nanoparticles
 Weight of freeze dried nanoparticles







6.2.11 Phenobarbital drug release 
78 and 81 mg of freeze-dried phenobarbital-unmodified and PVP-chitosan nanoparticles 
(equivalent to 1 mg phenobarbital sodium) were redispersed in 1 mL 0.05 M phosphate 
buffer solution pH 6.4 (PBS). A Spectra-Por® Float-A-Lyzer® (G2 black, 1 mL, MWCO 3.5-
5 kDa) was rinsed 3 times with deionised water and equilibrated with 2 mL deionised water 
at room temperature for 10 minutes. Then, it was conditioned with 2 mL PBS twice. The 
Float-A-Lyzer® submerged in 20 mL PBS and was placed in a 50 mL centrifuge tube. 1 mL 
aliquot was taken and this was considered as time zero sample. Then, 1 mL redispersed 
nanoparticle suspensions was placed in the Float-A-Lyzer® and the system was returned to 
the centrifuge tube. At pre-determined time intervals, 1 mL aliquot was taken and the 
phenobarbital content was quantified by HPLC. Phenobarbital sodium solution (1 mg/mL in 
PBS) was used as a control. The experiment was performed at 32 °C. The data were 
expressed as mean ± SD of three independent experiments. Duplicate injections were 
performed for both samples and the standard at each time and concentration point.  The 
phenobarbital calibration curve was established in the concentration range of 1.25 to 160 
µg/mL from 3 independent 1 mg/mL stock solutions in PBS prepared at room temperature. 
6.2.12 Statistical analysis 
Unless otherwise stated, all measurements were collected in triplicate and the data are 
expressed as mean ± standard deviation (SD). The data were analysed using the SPSS 
Statistics 21 program (IBM, US). The statistical significance of any difference between 
groups was determined using one-way analysis of variance (ANOVA) with the least 
significant difference (LSD) post-hoc test. Differences were considered statistically 
significant at p ˂ 0.05.  
6.3 Results and discussion 
Incorporation of drugs (especially lipophilic drugs) into chitosan nanoparticles has always 
been challenging due to the hydrophilic nature of chitosan and the lack of drug-chitosan 
interactions (De Campos et al., 2001). In this study, the poor aqueous solubility of 
haloperidol provided an additional formulation challenge. Haloperidol is only soluble in 
organic solvents and dilute acids. Thus, haloperidol was dissolved in 1% v/v acetic acid and 
added dropwise to the acidic chitosan solution to prevent precipitation. The pH of chitosan 
solution was adjusted to 5.5 which favours the formation of nanoparticles with small particle 





the formation of nanoparticle suspensions due to the electrostatic interactions between the 
positively charged chitosan macromolecules and the negatively charged TPP molecules 
(Calvo et al., 1997). As shown in Table 6.1, the haloperidol-chitosan nanoparticles had size 
of 117 ± 1 nm and low PDI (0.198 ± 0.018). Centrifugation was used as a method for the 
analysis of association efficiency to separate the free drug from the drug-loaded 
nanoparticles. The nanoparticles were centrifuged and their size and PDI before and after 
centrifugation was compared. As shown in Table 6.1, at the optimised centrifugation 
condition, it was possible to retain the size of the nanoparticles close to their original size. 
The pH of the nanoparticles suspensions before and also after centrifugation was 5.06 at 
which haloperidol is still soluble. The use of trehalose (5% w/v) resulted in the preservation 
of the nanoparticles size and PDI after freeze drying (Table 6.1 and Figure 6.2). 
 
Table 6.1 DLS data of haloperidol-chitosan nanoparticles at different stages of preparation 
(mean ± SD, n = 3). 
Conditions Z-average (nm, DLS) PDI 
Before centrifugation 117 ± 1 0.198 ± 0.018 
After centrifugation  95 ± 2 0.289 ± 0.029 
After redispersion of the freeze dried 
nanoparticles 









Figure 6.2 DLS size distribution of haloperidol-chitosan nanoparticles after redispersion of 
freeze dried nanoparticles (108.5 mg/mL ultrapure water), n=3.  
 
Figure 6.3 and Figure 6.4 shows the HPLC chromatogram of haloperidol and the calibration 
curve used to calculate the haloperidol content, respectively. The loading capacity and the 
association efficiency of haloperidol-chitosan nanoparticles were 0.204 ± 0.001% w/w and 
4.78 ± 0.039% w/w, respectively. The haloperidol content was quantified using HPLC. 
These values are relatively low, which could be due to the lipophilic nature of haloperidol 
and the hydrophilic nature of chitosan. This resulted in the poor affinity of haloperidol to the 

























Figure 6.3 An example of chromatogram of 30 µg/mL haloperidol solution in the mobile 
phase; the peak at retention time of 13.07 minutes is related to haloperidol. The 












Figure 6.4 An HPLC calibration curve of haloperidol in the mobile phase. The mobile phase 
composed of 0.05 M NaH2PO4.2H2O solution: acetonitrile (70:30, pH 5). 
 
Phenobarbital-unmodified chitosan nanoparticles were prepared using an incorporation 
technique prior to the ionic gelation. As phenobarbital is soluble at basic pH, it was first 
added to the basic TPP solution (pH 9) prior to the addition to chitosan solution. At 4 mg/mL 
phenobarbital, it was possible to produce unmodified chitosan nanoparticles (Table 6.2 and 
Figure 6.5), however, these nanoparticles could not be redispersed (Table 6.3). On the other 
hand, at 2 mg/mL, it could be redispersed readily in ultrapure water and PBS (Table 6.2, 
Table 6.3, Figure 6.5 and Figure 6.6).  
To explore the possibilities of incorporating phenobarbital into modified chitosan 
nanoparticles, initially, PEG-chitosan was investigated as a model example of modified 
chitosan. At 4 mg/mL phenobarbital sodium solution, large aggregates of PEG-chitosan were 
observed. DLS study of the supernatant of these aggregates revealed the presence of 
nanoparticles with size of 106 ± 2 nm. However, due to the presence of excessive amount of 
visible large aggregates, further experiments on these particles were not performed. At 2 
mg/mL phenobarbital sodium solution, PEG-chitosan nanoparticles produced can be readily 
redispersed in both ultrapure water and PBS. Thus, 2 mg/mL phenobarbital sodium solution 
was also used to prepare PVP-chitosan nanoparticles (Table 6.2, Table 6.3, Figure 6.5 and 
Figure 6.6). The final pH (before freeze drying) of 2 mg/mL phenobarbital-unmodified and 
PVP-chitosan nanoparticles suspensions was 5.57 and 5.58, respectively.  
 





















Table 6.2 DLS data of phenobarbital-chitosan nanoparticles suspensions before freeze 
drying (mean ± SD, n = 3). 
 
 
*samples from supernatant portion were taken for analysis as large aggregates was observed. 
 
Figure 6.5 DLS size distribution of phenobarbital-chitosan nanoparticles suspensions before 


























4 mg/mL phenobarbital-unmodified chitosan




Types of nanoparticles Initial conc. of 




PDI Zeta potential 
(mV) 
Unmodified chitosan  4 159 ± 5 0.264 ±  0.005 17.11 ± 0.05 
Unmodified chitosan  2 173 ± 4 0.265 ±  0.029 16.65 ±  0.97 
PEG-chitosan  4 106 ± 2* 0.128 ± 0.023 8.04 ± 0.85* 
PEG-chitosan 2 99 ± 4 0.115 ± 0.021 11.41 ± 0.84 





Table 6.3 Properties of phenobarbital-chitosan nanoparticles suspensions after redispersion 
of the freeze dried products with ultrapure water and PBS. 
Types of 
nanoparticles 
Initial conc. of 
phenobarbital 







4 After redispersion with ultrapure water, 
transparent solution with large 
aggregates were observed which did not 
disintegrate after overnight stirring at 
room temperature 
814 ± 211 
 
 




2 Redispersed rapidly in deionised water 
and PBS 
193 ± 9 0.311 ± 0.017 
PEG-chitosan  2 Small white particles observed after 
redispersion but easily dissolved upon 
further dilution with water 
147 ± 3 
 
0.190 ± 0.037 
 
PVP-chitosan 2  Redispered fully in deionised water and 
PBS 









Figure 6.6 DLS size distribution of phenobarbital loaded nanoparticles suspensions after 
redispersion of the freeze dried products, n=3. 
 
Phenobarbital- PEG- and PVP-chitosan nanoparticles had a lower zeta potential than their 
unmodified chitosan counterparts (Table 6.2). This could be due to the presence of PEG and 
PVP shells in the structure of phenobarbital- PEG- and PVP-chitosan nanoparticles.  
Figure 6.7 and Figure 6.8 show the HPLC chromatogram of phenobarbital and the calibration 
curve used to calculate the phenobarbital content of the chitosan nanoparticles, respectively. 
Using filtration method, it was found that phenobarbital-unmodified and PVP-chitosan 
nanoparticles displayed an association efficiency of 25.13 ± 0.04 and 26.00 ± 0.05% w/w, 
respectively. The association efficiency of phenobarbital-unmodified and PVP-chitosan 
nanoparticles found by extraction method was 36.73 ± 0.03 and 32.01 ± 0.03% w/w, 
respectively. Although phenobarbital is poorly water soluble (Jelveghari & Nokhodchi, 
2008), both phenobarbital-unmodified and PVP-chitosan nanoparticles had a high 
association efficiency which could be due to the fact that phenobarbital is negatively charged 
(Cheng et al., 2008) and thus it is postulated that phenobarbital can associate with the 
positively charged chitosan via electrostatic interactions. The drug loading capacity of 
phenobarbital-unmodified and PVP-chitosan nanoparticles found by HPLC was 1.2718 ± 




















4 mg/mL phenobarbital-unmodified chitosan









Figure 6.7 An example of chromatogram of 160 µg/mL phenobarbital sodium solution in the 
mobile phase; the peak at retention time of 7.86 minutes is related to phenobarbital. 
The mobile phase composed of 0.05 M NaH2PO4.2H2O solution: acetonitrile 
(65:35, pH 5.2). 
 
 
Figure 6.8 An HPLC calibration curve used for the analysis of phenobarbital loading 
capacity of the unmodified and PVP-chitosan nanoparticles. The mobile phase 
composed 0.05 M NaH2PO4.2H2O solution: acetonitrile (65:35, pH 5.2) (mean ± 
SD, n = 3). 






















As phenobarbital is a negatively charged drug (Cheng et al., 2008), we investigated the 
possibility of any crosslinking between phenobarbital and unmodified chitosan. As shown 
in Table 6.4 and Figure 6.9, no such crosslinking happened at the studied conditions. 
 
Table 6.4 Properties of phenobarbital-unmodified chitosan without addition of TPP solution 
(mean ± SD, n = 3). 





observed and the 
solution was clear 
153 ± 4 
 





Figure 6.9 DLS size distribution of phenobarbital-unmodified chitosan without addition of 
TPP solution. 
 
Trehalose was used as a cryoprotectant as nanoparticles generally do not redisperse readily 
after freeze drying. Some studies reported that PVP itself can be used as a cryoprotectant in 
nanoparticle formulations (Abdelwahed et al., 2006a; Abdelwahed et al., 2006b), however, 
our results showed that without using trehalose, phenobarbital-PVP-chitosan nanoparticles 






















Table 6.5 Properties of phenobarbital-PVP-chitosan after redispersion of the freeze dried 
product without addition of trehalose (mean ± SD, n = 3). 







Formation of thread-like 
gel which could not be 
redispersed easily 
 
720 ± 875 
 






Figure 6.10 DLS size distribution of PVP-chitosan after redispersion of the freeze dried 
product without addition of trehalose. 
 
 
The phenobarbital release study was performed at pH 6.4 to mimic the human nasal mucosa 
pH which shown to be in the range of 5.3–7.0 (England et al., 1999; Ireson et al., 2001; 
Aderibigbe, 2018). Figure 6.11 shows the calibration curve used in the calculation of 
phenobarbital release. The nanoparticles provided a sustained release of the drug (Figure 
6.12). Focusing on the initial release (Figure 6.13), it is clear that both unmodified chitosan 
and PVP-chitosan nanoparticles provided a slower initial drug release compared to the free 























points between 20-60 minutes was significantly lower from the control phenobarbital sodium 
solution (Figure 6.13). This could be due to the association of phenobarbital to the surface 




Figure 6.11 An HPLC calibration curve used for the analysis of phenobarbital in 0.05 M 
PBS (pH 6.4, composed of both NaH2PO4.2H2O and Na2HPO4) for the release study 
of the unmodified and PVP-chitosan nanoparticles. The mobile phase composed 























Figure 6.12 Release profiles of phenobarbital from phenobarbital sodium solution, 
phenobarbital-unmodified chitosan and PVP-chitosan nanoparticles at 32 °C. Data 
represent mean ± SD, n= 3. 
 
 
Figure 6.13 Comparison of the release profiles of phenobarbital from phenobarbital sodium 
solution, phenobarbital-unmodified chitosan and PVP-chitosan nanoparticles at 32 
°C over the first 120 minutes. Data represent mean ± SD, n= 3; * denotes p < 0.05,   





























Although the initial release from unmodified chitosan and PVP-chitosan nanoparticles was 
slower than the control, once released, the release was rapid as higher % release can be seen 
at earlier time (e.g. at 360 minutes) and then reached a plateau at 480 minutes. This could be 
due to the potential enhancement of the water solubility of phenobarbital by chitosan and 
PVP-chitosan present in the structure of both unmodified chitosan and PVP-chitosan 
nanoparticles, respectively. It has been shown that polyamidoamine dendrimers enhanced 
the water solubility of phenobarbital possibly due to the electrostatic interaction between 
positively charged polyamidoamine and negatively charged phenobarbital (Cheng et al., 
2008).  Also, Portero et al. (1998) revealed that chitosan enhanced the dissolution rate of 
other poorly water soluble drugs (nifedipine) when used in nifedipine-chitosan co-ground 
and/or solid dispersion.  They related this to a decrease in the drug’s crystallinity (changed 
from a crystalline form to a more water soluble amorphous form) and an increase in the drug 
wettability. Similarly, in the current study, chitosan and PVP-chitosan could enhance the 
dissolution rate of phenobarbital, which eventually led to a higher % phenobarbital release 
at earlier time (e.g. at 360 minutes) from unmodified and PVP-chitosan nanoparticles 
compared to the control.  On the other hand, the control provided a relatively constant release 
throughout the time frame.  
6.4 Conclusion 
In this study, we have demonstrated a method of incorporating a drug, haloperidol, into 
unmodified chitosan nanoparticles and phenobarbital into unmodified and PVP-chitosan 
nanoparticles. Both phenobarbital- unmodified and PVP-chitosan nanoparticles showed a 
relatively high drug loading capacity and a sustained drug release. The in vivo performance 
of these nanoparticles can be explored using behavioural studies in rats following their nasal 
administration. 
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7.1 Conclusion and future studies 
Mucosal drug delivery refers to drug administration via the mucosal membranes such as oral, 
nasal, pulmonary, ocular and vaginal mucosa. The oral and nasal routes of drugs 
administration offer several advantages including the ease of administration and the presence 
of large absorptive surface area. For oral route, the presence of gastric acid, the digestive 
enzymes as well as the mucus layer potentially may lead to poor drug bioavailability. For 
the nasal route, in addition to the presence of metabolising enzymes in the human nasal 
mucosa (Rohrer et al., 2018), the mucociliary clearance can entrap drug molecules, prevent 
their penetration into the mucus and significantly decrease their absorption via the nasal 
mucosa. The pore size of mucus gel, its viscosity, pH, ionic strength, binding capacity, and 
turnover rate are some of the factors which determine the barrier properties of the mucus 
(Leal et al., 2017; Murgia et al., 2018). These properties vary depending on the type of 
mucosal tissues. Nanoparticles can overcome the mucosal barriers due to their unique 
properties including small size, large surface area, providing protection for drugs, the 
possibilities of functionalisation and targeted drug delivery. Among various nanoparticles, 
organosilica nanoparticles are interesting candidates as a drug delivery system due to the 
relatively simple method for their preparation and the possibility of their surface 
functionalisation with fluorescent dyes (for facile detection and analysis in biological 
tissues) and various polymers (to make them either mucoadhesive or mucus-penetrating, 
depending on the type of the polymers). Polymeric nanoparticles (such as chitosan 
nanoparticles) are also desirable due to their biocompatibility, biodegradability and a 
relatively high drug loading capacity. Nanoparticles with an ability to adhere to (trapped in) 
or penetrate into (diffuse rapidly in) the mucus layer are known as mucoadhesive or mucus-
penetrating nanoparticles, respectively. In this thesis, both types of nanoparticles were 
considered. Several key parameters govern whether the nanoparticles are mucoadhesive or 
mucus-penetrating and these include the particle size, hydrophilicity, chemical structure and 
charges (Lai et al., 2007; Mansfield et al., 2015; Menzel et al., 2016). However, so far, no 
simple relationship between these parameters and the resultant nature of the nanoparticles’-
mucus interactions exists, and rather sophisticated phenomena are involved (Lai et al., 2007; 
Nordgård and Draget, 2018).  
The aim of this thesis was to prepare and characterise silica and chitosan nanoparticles for 
oral and nasal mucosal drug delivery, respectively. The studies presented in this thesis, 





polymers resulted in a dramatic change in their physicochemical properties. Studies were 
then conducted to understand how these changes affect the mucoadhesive and mucus-
penetration abilities of the prepared nanoparticles with regards to intestinal and nasal 
mucosa.  
In the first instance, additional physicochemical characterisation was performed in order to 
fully understand the behaviour of thiolated, PEGylated and POZylated silica nanoparticles 
at various pH. It was demonstrated that the size of both thiolated and POZylated silica 
nanoparticles significantly increased at pH ≤ 2, whereas no size change was observed at 
pH 2.5–9 for these two types of nanoparticles. On the other hand, the size of PEGylated silica 
nanoparticles did not change over the pH range of 1.5–9. These indicate that all three types 
of silica nanoparticles can be used in studies involving mucosal surfaces with pH ranging 
2.5–9. However, care should be taken when thiolated and POZylated silica nanoparticles are 
used in studies involving mucosal surfaces with highly acidic pH (pH ≤ 2 e.g. adhesion to 
gastric mucosa). Despite this, it is possible to protect both thiolated and POZylated silica 
nanoparticles using enteric coated capsules and study their in vivo performances (Chapter 
3). 
The retention of thiolated silica nanoparticles in rat intestinal mucosa was significantly 
greater compared to both PEGylated and POZylated nanoparticles (Chapter 3). This could 
be due to the greater thiol content of thiolated silica nanoparticles compared to both the 
PEGylated and POZylated counterparts. The poor retention of PEGylated and POZylated 
silica nanoparticles could also be due to the stealth properties of both PEG and POZ. This 
could minimise the entrapment of PEGylated and POZylated silica nanoparticles in the 
mucus gel layer of rat intestinal mucosa and therefore they only adhered to the superficial 
layer of the mucus gel which could be washed off relatively easily with the bio-relevant 
media. 
In the second instance, a novel method to prepare PEG- and POZ-chitosan (using thiol-ene 
and thiol-yne click chemistry, respectively) from thiolated chitosan was shown in Chapter 
4. However, both PEG- and POZ-chitosan showed poor aqueous solubility possibly due to 
the formation of disulfide bonds which could be originated from the precursor thiolated 
chitosan. Further attempts to improve the solubility of thiolated chitosan (via minimising the 
oxidation of thiol groups or reduction in the number of immobilised thiol groups) may 





alternative approach to synthesise not only PEG- and POZ-chitosan but also two other 
hydrophilic chitosans namely PHEA- and PVP-chitosan using EDAC/NHS chemistry. These 
modified chitosans exhibited a complete solubility at a broad range of pH (3-10). This 
finding will widen the potential applications of chitosan in mucosal drug delivery as those 
formulations often encounter pH changes after their administration into the human body and 
yet should not affect its solubility.   
Until the current studies were carried out, very little was known about the penetration ability 
of chitosan nanoparticles in mucus gel. Methods were developed to prepare and characterise 
unlabelled and fluorescently labelled chitosan nanoparticles with different functionalities, 
and study their diffusion in mucus model. Nanoparticle tracking analysis was used to study 
the diffusive properties of the chitosan nanoparticles in bovine submaxillary mucin solution. 
It was revealed that modified chitosan nanoparticles diffused significantly faster than 
unmodified chitosan nanoparticles in mucin solution. Fluorescence microscopy was used to 
study the penetration of the chitosan nanoparticles into sheep nasal mucosa and showed that 
modified chitosan nanoparticles generally penetrated deeper into the nasal mucosa (Chapter 
5).  
Finally, the possibilities of loading unmodified and PVP-chitosan nanoparticles with two 
psychoactive drugs (haloperidol and phenobarbital) was investigated in Chapter 6. It was 
possible to load haloperidol into unmodified chitosan nanoparticles, however, the loading 
capacity was 0.2% w/w, which is considered to be relatively low taking into account the 
dose of this drug necessary for in vivo studies in rats. On the other hand, both phenobarbital- 
unmodified and PVP-chitosan nanoparticles, had relatively high loading capacities (1.271 
and 1.229 %w/w, respectively), which is highly promising for in vivo studies of these novel 
nanoparticles.  
Throughout this thesis, we showed that using non-ionic hydrophilic polymers, it is possible 
to reduce the mucoadhesive properties of thiolated silica nanoparticles in rat intestinal 
mucosa and enhance the diffusive properties of chitosan nanoparticles in mucus gel either in 
mucin solution or sheep nasal mucosa. Other types of silica nanoparticles are generally 
synthesised using TEOS as a silica source. However, the resultant TEOS-silica nanoparticles 
do not contain reactive functional groups and thus an additional step (e.g. covalent 
attachment of 3-aminopropytriethoxysilane) is often needed before their functionalisation 





of free thiol groups on the surface of our thiolated silica nanoparticles (synthesised from 
MPTS, Chapter 3), they can be easily functionalised with fluorescent dyes or polymers using 
common click chemistry approaches e.g. thiol-ene reactions. One of the disadvantages of 
our thiolated silica nanoparticles is their nonporous nature (and thus potentially low drug 
loading capacity), which limits their applications in drug delivery. However, they are 
considered as an excellent model to study mucoadhesion and mucus-penetration. 
Alternatively, using surfactants, it is possible to synthesise mesoporous thiolated silica 
nanoparticles with potentially high drug loading capacity (Mun, 2014). The use of 
cetyltrimethylammonium bromide as a cationic surfactant during the synthesis has resulted 
in the formation of large, porous and hollow thiolated silica particles. These particles were 
also polydisperse and had a relatively low yield (Mun, 2014). Therefore, optimisation studies 
are needed to maintain the size of the thiolated silica nanoparticles as small as possible while 
imparting some degree of porosity to the thiolated silica nanoparticles. For example, these 
could be achieved by using different types and concentrations of surfactants during the 
synthesis of the nanoparticles.  
Chitosan nanoparticles can be relatively easily prepared by cross-linking cationic chitosan 
with anionic molecules such as TPP using an ionic gelation method (Calvo et al., 1997). 
Chitosan-TPP nanoparticles are advantageous as no heat and organic solvents are needed for 
their preparation. Consequently, it is possible to load labile drugs including peptides into 
chitosan-TPP nanoparticles (Rampino et al., 2013). Due to the highly hydrophilic nature, 
swelling capacity, potentially porous nature, biocompatibility and biodegradability of 
chitosan and each of PEG, PHEA, POZ and PVP, the developed chitosan nanoparticles are 
interesting candidates for mucosal drug delivery. The behavioural study of phenobarbital-
loaded unmodified and PVP-chitosan nanoparticles in rats would be an interesting approach 
to investigate their performances in vivo. It is also possible to orally load these nanoparticles 
with various small and large molecular weight drugs (especially peptide-based drugs such 
as insulin) and study their pharmacokinetics parameters as an indirect method of their 
performances. Alternatively, Alexa-labelled chitosan nanoparticles can be administered 
nasally or orally in vivo and fluorescence microscopy imaging can be used to study the 






7.2 Future perspective 
The challenges associated with the transmucosal routes of drug administration include the 
presence of the harsh environments in the mucosal lumen, the mucus layer and the epithelial 
barriers. The use of mucoadhesive materials has already been proved as an effective strategy 
to improve the mucosal drug delivery. This can be due to the abilities of the mucoadhesive 
polymers to protect the labile drugs against degradation in the mucosal lumen and the 
enhancement of the retention of drugs on the mucosal surfaces. Recently, the use of mucus-
penetrating nanoparticles has become an alternative approach to minimise the barriers 
associated with transmucosal drug delivery. In this case, mucus-inert materials are used to 
modify the surface chemistry of the nanoparticles and thus they decrease the nanoparticles-
mucus interactions. So far, only few polymers (namely PEG and POZ) have shown their 
abilities to enhance the penetration of nanoparticles into the mucus (Khutoryanskiy, 2018). 
In addition to PEG and POZ, in this thesis, we also showed that PHEA and PVP could 
enhance the penetration of chitosan nanoparticles into the mucus. There are conflicting data 
on the abilities of other materials to enhance the nanoparticles’ penetration into the mucus 
gel. This could be related to the differences in the evaluation methods of mucoadhesion and 
mucus-penetration of these systems. This means that there is an urgent need to develop a 
standard method for evaluation of mucoadhesion and mucus-penetration. Due to the 
differences in the properties of mucus in various mucosal surfaces, it is conceivable that a 
method developed to evaluate the mucoadhesion and mucus-penetration in a particular type 
of mucosa may not be used in another type of mucosa. Care should be taken to mimic several 
factors including pH, ionic strength, mucus turnover rate, and the mucin concentration. The 
more resemblance of a method to the in vivo situation, the better in vitro/in vivo correlation 
can be achieved. Considering the reduction in the number of animals in mucoadhesive 
evaluation, several attempts have been made to mimic the mucosal surfaces using polymeric 
materials (Khutoryanskiy, 2011). However, as mucus is a complex biological gel, further 
studies is needed to mimic its biochemical properties.  The next step will be the development 
of novel materials with either mucoadhesive or mucus-penetrating properties, which can be 
used in the formulation of nanoparticles for mucosal drug delivery. Theoretically, cationic 
high molecular weight polymers and those with abilities to form covalent and hydrogen 
bonds with mucus can be mucoadhesive. However, non-ionic or zwitterionic low molecular 
weight hydrophilic polymers can be mucus-penetrating (Khutoryanskiy, 2018). The toxicity 





Mucoadhesive and/or mucus-penetrating nanoparticles are highly promising drug delivery 
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